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ABSTRACT
A series of novel and known heterocyclic pyro­phosphate analogues have been synthesised and screened for activity against herpesvirus DNA polymerases, influenza A RNA transcriptase and calf thymus DNA 
polymerase a.
A direct correlation between the compounds1 abilities to form complexes with zinc ions, as determined by a gel filtration method, and their effectiveness as inhibitors of the RNA transcriptase activity of influenza A virus and in some cases herpesvirus DNA polymerase, has been found. Introduction of 'soft' ligands such as nitrogen and sulphur into pyrophosphate and its analogues has resulted in improved antiviral activities, in particular, replacement of a phosphoryl group with a thiophosphoryl group has resulted in the discovery of some potent inhibitors of influenza A RNA transcriptase activity. 31P n.m.r. measurements have indicated that these compounds bind to zinc through sulphur, which could account for their increased antiviral activity if they bind in the same way to the essential zinc ion in viral polymerases. The most active of the heterocyclic pyrophosphate analogues, 5-(thiophosphonomethyl)-1(H)- tetrazole, showed improved efficacy against both influenza A RNA transcriptase activity and HSV-1 DNA polymerase activity over its non-thio analogue, 5-(phosphonomethyl)- 1(H)-tetrazole.
Some nucleoside-51 esters of 5-(phosphonomethyl)- 1(H)-tetrazole were synthesised. These compounds were ineffective inhibitors of the RNA transcriptase activity of influenza and the DNA polymerase activity of herpes­viruses, they did, however, exhibit some activity in tissue culture systems. These compounds may therefore act via a mechanism other than inactivation of viral polymerases, or be hydrolysed by cellular enzymes to give the free phosphonate.
A strain dependence has been observed for the inhibition of influenza A virus in tissue culture by plaque reduction assay. Influenza A/WS was found to be the most sensitive of a series of strains tested.Some variation was also observed in the inhibition of different herpesvirus DNA polymerases with the compounds studied.
The uptake of radiolabelled phosphonoacetate and 5-(phosphonomethyl)-1 (H)-tetrazole into herpesvirus infected cells has been studied, and a virally-mediated increase in cell permeability to the compounds found to occur maximally 6-7 hours after infection. 5-(Phos- phonomethyl)-1(H)-tetrazole shows a small increase in uptake over PAA into infected cells.
1CHAPTER 1 
INTRODUCTION
1.0 THE DISCOVERY OF VIRUSES ANDTHE PROBLEM OF VIRAL CHEMOTHERAPY
In the early 1890's Ivanovsky, and later 
Beijerinck reported the existence of submicroscopic 
infectious particles in the bacteria-free filtrates 
of the sap of mosaic-diseased tobacco plants, which 
were capable of inducing disease in healthy plants.
It was Beijerinck who named these pathogenic principles 
as "oontagium vivum fluidum", a living infectious liquid 
which he called a "virus". In 1898 Loeffler and Frosch 
were able to transmit foot-and-mouth disease to calves 
by inoculation with bacteria-free filtrates of lymph of 
animals infected with the disease. Thus, the existence 
of mammalian viruses was established.
At the same time the principle of selective 
toxicity of chemotherapeutic agents for their target 
organisms was beginning to be considered, culminating 
with Gultman and Ehrlich's first successful human trial 
of a chemotherapeutic drug, methylene blue, against 
the intracellular parasite Plasmodium vivax. In 1892 
Romanovsky demonstrated the selective toxicity of 
quinine against the same organism.
However, their submicroscopic size and the 
fact that viruses required the introduction into living
2cells for replication created vast problems for early 
researchers into possible chemotherapy, and not 
surprisingly work in this area moved towards the 
less elusive pathogens such as protozoa and bacteria.
The independent nature of bacteria and the 
existence of unique enzymes and substrates makes anti­
bacterial drugs a relatively easy proposition when one 
considers the obligate intracellular nature of viruses, 
which only multiply within living cells able to provide 
the necessary organelles, metabolic pathways and enzymes 
or cofactors which they lack. The problem of selective 
antiviral therapy was therefore, in the early years at 
least, considered by many to be one that would not be 
solved by the chemist since chemical agents having any 
effect on virus multiplication would have a deleterious 
effect on the host cell.
Since the early 1960's however, considerable 
advances in the field of viral chemotherapy have been 
made, with the discovery, usually serendipitously, of 
a number of truly selective antiviral agents.
Advances in modern virology at the molecular level has 
also meant that many virus-specific processes are now 
known in detail and a number of virus specific enzymes 
well characterised, as well as other proteins and specific 
components of viral replication which specific chemically 
synthesised blocking agents can be targeted against. 
Examples of such targets are DNA-dependent DNA polymerases 
of herpesviruses and RNA-dependent RNA polymerases of
3myxo- and paramyxoviruses. Other targets are discussed 
in Section 1.3.
1.1 VIRUS STRUCTURE AND REPLICATION
The viral genome consists of either DNA or 
RNA, the latter case being unique in that no other 
organism employs RNA as its genetic material. Viral 
nucleic acid may be single- or double-stranded, and 
may be linear or circular. It may be a polycistronic 
molecule or the molecules may be separate distinct 
segmented genomes. Single-stranded viral nucleic 
acid may also be of positive (viral RNA acts as 
messenger RNA) or negative (complementary RNA) polarity 
which must be transcribed to give mRNA by a viral 
transcriptase (Bishop, 1977). The nucleic acid is 
enclosed and protected within a protein coat (capsid) 
to hold the viral nucleic acid in the correct conforma­
tion with respect to its transcriptase and to repress 
the transcription of certain "early genes". The capsid 
consists of a number of identical subunits (capsomeres) 
usually arranged with helical or icosahedral symmetry.
The host virally-induced immunological 
response is largely directed at the protein coat, which 
may be enclosed within an outer lipid membrane containing 
viral proteins which are often responsible for specific 
absorption to susceptible cells.

5The viral replicative process varies with 
virus type at most stages and since the work described 
in this thesis is concerned in the main with influenza 
viruses and herpesviruses, the structure and replication 
of these viruses will be concentrated upon.
1.1.1 Influenza Viruses
The influenza viruses (orthomyxoviruses) are 
a large group of viruses, three types of which (A, B, C) 
are recognised, and all of which cause respiratory tract 
infections. The first isolation of a virus responsible 
for human epidemic influenza (Smith, et al., 1933) was 
the result of years of work on the cause of the 1918-19 
influenza pandemic which resulted in 20 million deaths, 
and has remained the most serious unconquered threat to 
worldwide human health (Grist, 1979). Epidemics and 
pandemics arise due to antigenic variation of the 
haemagglutinin (H) and neuraminidase (N) surface 
antigens, which can be a result of mutation and 
immunological selection (antigenic drift) or by 
replacement of the entire gene coding for the H or N 
with that of another strain (antigenic shift) .
Antigenic drift is associated with new epidemics, 
and antigenic shift can result in a pandemic.
Genetic reassortment is possible because 
of the unusual virus genome, which is in eight distinct 
single-stranded RNA pieces. It is thought that this 
leads to reassortment between human and other strains
6of influenza, particularly those infecting birds, 
resulting in "hybrid" viruses showing antigenic shift 
(Webster, et al., 1982) and causing pandemics as a 
result of new surface N and H antigens to which 
populations have no immunity.
1.1.2 The Influenza Virion
The influenza virus exhibits particles of 
varying size and morphology but are in general spherical 
or filamentous (diameter 100 nm) and surrounded by a 
host cell-derived outer lipid membrane into which the 
two glycoprotein surface antigens are inserted. The 
haemagglutinin (H)* occurs as three-sided (14 x 4 nm) 
rods, and the neuraminidase (N) as four mushroom-type 
spheres on a rod (Varghese, et al. , 1983).
The influenza genome RNA segments are 
closely associated with a basic nucleoprotein (NP), 
the antigenicity of which is used to define the three 
types of influenza (A, B and C). The ribonucleoprotein 
is surrounded by a shell of hydrophobic matrix protein, 
within which, and associated in some way with the 
genome RNA, are three high molecular weight P proteins 
(PA, PBj^ , PB2) which form the RNA-dependent RNA 
polymerase complex, which transcribes complementary 
mRNA molecules from the genome RNA template.
The influenza virus genome consists of eight 
single-stranded RNA molecules of negative polarity (i.e., 
viral mRNA is complementary to the genome or virion 
*  Wilson et al _ 1981
6of influenza, particularly those infecting birds, 
resulting in "hybrid" viruses showing antigenic shift 
(Webster, et al. , 1982) and causing pandemics as a 
result of new surface N and H antigens to which 
populations have no immunity.
1.1.2 The Influenza Virion
The influenza virus exhibits particles of 
varying size and morphology but are in general spherical 
or filamentous (diameter 100 run) and surrounded by a 
host cell-derived outer lipid membrane into which the 
two glycoprotein surface antigens are inserted. The 
haemagglutinin (H)* occurs as three-sided (14 x 4 nm) 
rods, and the neuraminidase (N) as four mushroom-type 
spheres on a rod (Varghese, et al., 1983).
The influenza genome RNA segments are 
closely associated with a basic nucleoprotein (NP), 
the antigenicity of which is used to define the three 
types of influenza (A, B and C). The ribonucleoprotein 
is surrounded by a shell of hydrophobic matrix protein, 
within which, and associated in some way with the 
genome RNA, are three high molecular weight P proteins 
(PA, PBj, PB2) which form the RNA-dependent RNA 
polymerase complex, which transcribes complementary 
mRNA molecules from the genome RNA template.
The influenza virus genome consists of eight 
single-stranded RNA molecules of negative polarity (i.e., 
viral mRNA is complementary to the genome or virion 
* Wilson et al , 1981
7Fig. 1.1.2 The structure of the influenza virion.
(not to scale)
RNA (vRNA)). Each segment then acts as a monocistronic 
message for a virus polypeptide (McGeoch, et al. , 1976) .
1.1.3 Influenza Virus Replication
Influenza viruses are known to bind to cells 
by interacting with membrane receptors containing sialic 
acid via the viral haemagglutinin on the viral membrane. 
Changes in receptor binding specificity as a consequence 
of amino acid substitutions in viral haemagglutinins
8Table 113 Lamb and Choppin, 1983
Influenza virus genome RNA segments a n d  coding assignments
— . . .
Nascent Approx,  no.
Length mRNA length En co d ed poly pep tide molecu les
Segment (nucleotides) (nucleotides) po lypep t ide length (aa) per virion Remarks
1 2,341 2,320 PB2 759 3 0 - 6 0 Host-cell RNA cap binding: com ponen t  o f  RNA
transcriptase
2 2,341 2,320 PB 1 757 3 0 - 6 0 Initia tion ot transcription : possibly endonuclease
activity: co m ponen t  o f  RNA transcriptase
3 2,233 2,211 PA 716 3 0 - 6 0 Elongat ion o t  mRNA chains?: com ponen t  ot
RNA transcriptase
4 1,778 1,757 HA 566 5 0 0 Surface glycoprote in , trimer; major  antigenic
determinan t
5 1,565 1,540 NP 498 1,000 Associated with RNA segments to form ribonuc-
leoprotein: structura l com ponen t o f  RNA tran-
scriptase
6 1,413 1,392 NA 454 100 Surface glycoprotein: neuraminidase activity.
Tetramer
7 1,027 1,005 M, 252 3,0 00 Major prote in co m ponen t  o f  virus: underlies lipid
bilayer
316 M 2 96 Spliced mRNA, nonstructural  prote in:  funct ion
u nknow n
276 ? ?9 Spliced mRNA, pept ide predicted by  nucleotide
sequence only
8 890 868 NS. 230 Nons t ructural  prote in:  funct ion unknow n
395 n s 2 121 Spliced mRNA, nonstructural  protein: funct ion
unknow n
Total 13,588
suggest that the sialic acid binding site is a surface 
pocket at the distal end of the H molecule (Wilson, 
et al. , 1981). Further analysis of H structures and 
their binding specificities and of H-sialyllactose 
complexes, could lead to specific inhibition of 
virus adsorption (Skehel and Wiley, 1983).
The next step in the replicative cycle is 
membrane fusion and penetration. Binding of virus 
particles to their receptors is followed by endocytosis 
and fusion of the viral and endosomal membranes. It
9appears that haemagglutinin is involved and that the 
pH optimum of 5.0 (the pH of endosomes) is important 
in that the H structure is modified at this pH, thus 
enabling it to interact with the endosomal membranes 
(Brand, et al., 1980; Huang, et al., 1981).
Changes in endosomal pH may occur on treatment 
with basic compounds such as amantadine (see Section 
1.3.2.1) or by inhibiting the pH maintaining H+ pump 
(Galloway, et al., 1983).
1.1.4 RNA Synthesis
After viral entry into the cell and its 
uncoating, the transcriptase complex must carry out 
two functions. The eight negatively-sensed monocistronic 
segments of vRNA must be transcribed into positively- 
polarised early virus mRNAs required for viral replication, 
and also complementary full-length transcripts must be 
produced to serve as templates for the replication of 
the virus genome RNAs. Because viral mRNAs contain 
host derived sequences at their 5'-ends and lack 
sequences complementary to the last 17-22 nucleotides 
at the 5'-ends of vRNA segments, the viral mRNAs are 
not suitable templates for replication.
The formation of virus mRNA, mediated by the 
viral transcription complex (PA, PBj, PBj, NP, MP and the 
eight RNA molecules) is thought to occur in three 
discrete steps (Lamb and Choppin, 1983; McCauley 
and Mahy, 1983) as shown in Fig. 1.1.4.
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CLEAVAGE
m7GpppXmY
m7GpppXmY
10-13
nucleotides
endonucleolytic cleavage 
AjpZ.....
G ^ Z ......
INITIATION
UpÇpGpUpUpUpUpCp. 
m7GpppXmY. A ^^pG
ELONGATION
UpÇpGpl^pUpypVpÇp 
m7GpppXmV ÀpGpCpÀpApÀpÀpGp
Fig. 1.1.4 Priming and synthesis of influenzalviral mRNA (from Krug, 1983).
(i) A virally-coded endonuclease cleaves from
cellular mRNA a capped oligonucleotide which serves 
as a primer for initiation. It consists of 10-13 
nucleotides in the form of a cleaved 5'-terminal 
fragment from newly synthesised capped (m^GpppNm- 
containing) cellular RNAs in the nucleus.
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(ii) Initiation of the mRNA synthesis then occurs 
by the incorporation of a GMP residue complementary to 
the second base at the 3'end of the viral genome.
(iii) In the elongation reaction it has been shown 
that the two basic viral proteins PB^ and PB2 are 
required for the cleavage of the host cell mRNA and 
incorporation of the first nucleotide (Plotch, et al.,
1981; Ulmanen, et al. , 1983; Blaas, et al. , 1982).
The PB.^  protein is also implicated in elongation (Braam, 
et al., 1983; Romanos and Hay, 1984). A highly conserved 
uridine-free sequence occurs in all influenza mRNA after 
the host cell-derived sequences (Skehel and Hay, 1978) 
followed by message-specific sequences.
Viral mRNA contains 3'-terminal poly(A) sequences. 
Experiments in which hybrids between vRNA segments and 
poly(A)-containing viral mRNAs were digested with single­
strand specific nucleases indicate that the viral mRNAs lack 
the sequence complementary to the 5'-terminal 20-30 
nucleotides of the vRNAs (Plotch and Krug, 1978; Hay, 
et al. , 1977).
Regulation of mRNA synthesis during infection 
has been studied in chick embryo fibroblasts (Hay, et al., 
1977) (Table 1.1.4) .
The relative rates of synthesis of the 
various viral mRNAs at different times of infection 
correlates closely with the relative rates of synthesis 
of the proteins encoded by these mRNAs (Hay, et al.,
1977; Inglis and Mahy, 1979). This indicates a regulation
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of viral gene expression largely at the transcriptional 
level. The virus-specific products synthesised after 
infection have been implicated in the regulation of 
viral mRNA synthesis during infection, but the 
mechanism of this regulation is unknown. It has been 
suggested that the NS protein plays a role, since in 
temperature—sensitive mutants defective in the NS genome, 
the shift from early to late viral protein synthesis 
(and hence viral mRNA synthesis) is inhibited in infected 
cells at the nonpermissive temperature (Koennecke, 
et al. , 1981; Wolstenholme, et al. , 1980).
Full-length transcripts of vRNA segments without 
host primer sequences probably act as templates for 
vRNA replication. Indeed, full-length transcripts are 
not associated with polyribosomes but are in the form 
of nucleocapsids (Hay, et al., 1977). The full-length 
RNA transcripts are also able to form duplex "panhandle" 
structures by virtue of the presence of the complements 
of the vRNA 5'-ends. These structures could serve as 
recognition signals to form nucleocapsids and be copied 
by the polymerase P proteins (Krug, 1983).
Little is known about the replicative synthesis of 
vRNA although it has been suggested that since equimolar 
amounts of the full-length transcripts are made through­
out infection, whereas the vRNAs can vary in rate of 
synthesis (the three P vRNAs in particular), then copying 
of various templates probably occurs at various specified 
times after infection (Hay, et al. , 1977).
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Following viral polypeptide synthesis on 
cellular polysomes, the newly synthesised polypeptides 
are transfered across the rough and smooth endoplasmic 
reticula where t*he haemagglutinin and neuraminidase 
are glycosylated prior to insertion into the cell 
membrane. At the plasma membrane both glycoproteins 
are involved in the formation of infectious virus 
particles. The haemagglutinin precursor glycoprotein 
is cleaved to form the HA^ and HA2 components which 
are linked by a disulphide bond (Waterfield, et al.,
1981). The neuraminidase has a specific role in the 
formation and release of the virus particles from the 
infected cell, in which sialic acid residues are removed 
from viral and cellular glycoproteins and glycolipids, 
thus removing H receptors from the cell membrane and 
allowing release of virus particles. This step is a 
possible target for antiviral drugs since the three 
dimensional structure of the neuraminidase enzyme has 
been determined and knowledge of the active site is 
accumulating (Varghese, et al., 1983; Colman, et al., 
1983).
1.1.5 Herpesviruses
The herpesviruses are large icosahedral 
enveloped DNA viruses noted for their tendency to 
establish persistent and latent infections and to be 
reactivated by immunosuppression. There are four 
human herpesviruses (1) Herpes Simplex (HSV); type 1
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causing primary pharyngitis and recurrent "cold sores", 
also kerato-conjunctivitis and meningo-encephalitis; 
type 2 causing herpes genitalis and neonatal herpes, (2) 
Varicella-zoster (VZV); causing primary chickenpox 
and recurrent herpes zoster ("shingles"), (3) Cytomegalo­
virus (CMV); which can cause severe congenital abnormalities 
in the newborn, lethal pneumonitis and hepatitis in the 
immunocompromised, (4) Epstein-Barr virus (EBV); causing 
infectious mononucleosis (glandular fever) in adolescents 
and persists in B lymphocytes. In addition, there are 
over eighty viruses which infect vertebrates and 
invertebrates, many of which are species specific.
The HSV-1 and HSV-2 genomes are linear double- 
stranded molecules of about 100 x 10  ^molecular weight 
(Kieff, et al., 1971), and have several characteristic 
features, (i) terminal repetitions that allow circular 
genomes to form, (ii) discontinuities in the sugar- 
phosphate backbone of each strand of the duplex DNA and 
(iii) internal repeated sequences (Roizman, 1979).
About 50 HSV-infected cell polypeptides (ICPs) 
have so far been identified, with molecular weights 
ranging from 12 000 to 220 000 (Honess and Roizman,
1973; Powell and Courtney, 1975). Three groups have 
been classed as a (immediate-early), B(early) and y(late).
The a polypeptides reach maximal levels 2-4 hours 
after infection and are subsequently phosphorylated 
and transported to the infected cell nucleus (Wilcox, 
et al., 1980). B Polypeptides are synthesised maximally
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from 5-7 hours post-infection and include enzymes 
involved in viral DNA synthesis such as DNA polymerase 
and thymidine kinase. B Polypeptides require functional 
a polypeptides via activation of 8 gene transcription.
At least one functional 8 polypeptide is then required 
to terminate the synthesis of a polypeptides and 
activate y gene expression (12-17 hours after infection) 
to produce y virion structural polypeptides (Honess 
and Roizman, 1974).
Host cell DNA and protein synthesis are shut 
off during infection at the same time as the synthesis 
of virus-specific components involved in progeny virus 
synthesis. Once viral DNA and late protein synthesis 
are in progress the assembly of infectious progeny 
virus is initiated.
The completed HSV virion contains the DNA and 
numerous structural polypeptides, the genome being wound 
on a protein structure comprised of basic histones and 
located in the icosahedral nucleocapsid of diameter 
100 nm, composed of 162 capsomeres (Wildy, et at., 1960) . 
Also contained in the virion are glycosylated proteins, 
lipids, polyamines and various enzyme activities. The 
enveloping lipid skeleton is derived from the infected 
cell inner nuclear membrane by budding (Roizman and 
Furlong, 1974). The viral surface enzyme glycoproteins 
(gA-gF and gy) are involved in virus attachment, and 
penetration (gB), as well as the immune response to 
infection (gC).
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Fig. 1.1.5 Schematic representation of HSVreplication in a permissive cell.
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The productive replicative cycle eventually 
leads to cell death, however, the herpesviruses can 
also survive in a noninfectious or latent form in the 
nervous system and other tissues of asymptomatic 
individuals. This strategy of infection enables the 
virus to avoid elimination by host-mediated influences 
and despite the development of immunity can persist in 
the host for long periods. The virus may then become 
reactivated and after lying in a latent state in the 
dorsal root ganglia (VZV and HSV) or B-lymphocytes 
(EBV), pass along nerve trunks to the initial site of 
infection and cause recurrent infections.
1.2 THE CONTROL OF VIRAL INFECTION
Significant advances towards the control of 
infectious diseases have been made in recent years, 
from the simplest methods such as sanitation and personal 
hygiene improvements, to the development of antibiotics, 
vaccines and antiviral agents. Such progress has 
resulted in the erradication of smallpox through the use 
of vaccinia virus immunisation, and the control of such 
viral diseases as polio, measles, rabies and mumps, 
through effective vaccines. New problems will always 
arise however, such as non-A, non-B hepatitis and 
acquired immuno-deficiency syndrome (AIDS).
Despite such headway made in the control of 
viral infection, the principal viral diseases of
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our time are still largely unconquered - herpes simplex 
and zoster, influenza virus, hepatitis, cytomegalovirus 
and rhinoviruses (common cold), although recent progress 
has been promising in the herpes area.
1.2.1 Stimulation of the Immune Response -Herpesviruses
The added complication of recurrent exacerbations 
make a herpesvirus vaccine a valuable target. However, 
a vaccine would only be able to prevent primary infections, 
and thereby recurrences after latent infection has been 
established, since even naturally acquired immunity 
fails to prevent recurrence.
One of the major problems associated with 
herpesvirus vaccines has been, with the exception of 
HSV, the fact that the virus remains cell-associated in 
tissue cultures resulting in only small numbers of virions 
in the supernatant and thus making large scale inactivated 
vaccine manufacture very difficult. Live vaccines may be 
more accessible, however the possible complications in 
their use must be considered. They may, for example, be 
able to establish latent infections, which could manifest 
itself, perhaps harmfully, years after apparently 
successful trials may have been completed. Surprisingly, 
attention has been focussed only recently on the control 
of herpes simplex virus, responsible for the greatest 
morbidity of the group, and the only human herpesvirus 
which grows to high titre in tissue culture. The near 
epidemic proportions of HSV-2 in some areas is in need
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of urgent attention, also worth preventing is perinatal 
herpes and rare but lethal encephalitis. Subunit type 
vaccines are the most promising (Skinner, et at. , 1982) 
with an acetone-derived subunit vaccine derived from 
HSV-1 also being active against the type 2 virus.
As well as conventional approaches, biotech­
nology may provide a route to a vaccine. An immuno- 
logically active chimaeric protein containing a 
glycoprotein from HSV-1 has been produced, the gene 
coding for the protein is expressed in Escherichia coti 
(Weis, et at. , 1983).
The activation of human T-lymphocytes to 
synthetic peptides of herpes simplex virus glycoprotein 
D(gD) has recently been reported (De Freitas, et at., 
1985). The major viral glycoproteins are, therefore, 
implicated as HSV-specific antigens and immunostimulants 
and are good targets for synthetic peptide programmes.
1.2.2 Influenza Viruses
Influenza virus disease illustrates perfectly 
the immense problems that can arise in the control of 
viral infection by immunisation. Influenza is the best 
known virus capable of antigenic shift and drift, 
although similar properties are exhibited by human 
rhinoviruses and foot-and-mouth disease virus. This 
type of behaviour can render a once effective vaccine 
obsolete.
Vaccines to date have been egg-grown, formalin-
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or B-propiolactone-inactivated and incorporate up to 
25 ug of the latest known haemagglutinins. Protection 
has been lower than seventy percent, particularly for the 
elderly, one major problem being anamnestic recall of 
antibody against earlier strains as an immune response 
to vaccination (Hoskins, et al. , 1979). Improvement 
of response by increased dosage necessitates higher 
costs and increased side-effects.
Recent developments include the possible use 
of liposomes (or virosomes), constituted from influenzal 
H and N. DNA copies of the RNA gene for H have now 
been cloned in mammalian (Simian) cells using SV40 DNA 
as vector (Gething and Sambrook, 1981; Sveda and Lai,
1981) . This gene has also been incorporated into the 
vaccinia viral genome by recombination resulting in a 
potentially useful type of vaccine (Panicali, et al.,
1983). The actual de novo synthesis of antigenic sites 
has now become possible by virtue of the rapid determination 
of H sequences of different influenza strains and a 
knowledge of the important antigenic sites on the 
molecule (Green, et al., 1982; Jackson, et al. , 1982; 
Mtiller, et al., 1982). Peptides have been conjugated 
with tetanus toxoid for immunisation, however the 
resulting protection depends upon obtaining the correct 
length of peptides and correct folding to mimic native 
structures (Shapira, et al. , 1984).
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1.2.3 Viral Chemotherapy
Even with promising advances in the area of 
vaccines in recent years, it is apparent that active 
stimulation of the immune response does not solve all 
of the problems encountered in the control of viral 
infection and can even complicate therapy.
The risk of complications caused by administra­
tion of vaccines is in general so greatly outweighed by 
its preventative potential that vaccines are considered 
totally acceptable. This does not, however, prevent 
some hesitation when there is an awareness of possible 
complications after such immunisations as vaccinia.
There is therefore a general reluctance for immunisation 
against diseases considered by many to be of remote 
threat, particularly the use of live vaccines, when 
there may be fear of reversion to a pathogenic form or 
incorporation of the genome into host DNA.
When an effective and undeniably safe vaccine 
is developed, trials are often very time-consuming when 
compared to other drug trials, a disadvantage when 
new viral diseases such as AIDS appear. A previously 
developed broad-spectrum antiviral compound could 
well prove to be active in such circumstances - enabling 
the disease to be tackled immediately, long before vaccine 
development can get under way.
The purely preventative nature of vaccination 
also gives us little hope of controlling viral infection 
once it has been contracted. This, together with the
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now widespread use of cancer chemotherapy and organ 
transplantation resulting in a higher incidence of 
immunocompromised patients, means that ideally a 
range of antiviral chemotherapeutic agents will be 
available for use in combination with prophylactic 
measures, or when such measures cannot be relied 
upon.
1.3 ANTIVIRAL AGENTS AND THEIR TARGETS
1.3.1 Viral Adsorption and Cell Penetration
A recent approach to the inhibition of viral 
penetration into host cells has utilised suppression 
of the activity of a viral protein rather than a viral 
enzyme (Choppin, et at. , 1984) . Myxo- and paramyxo­
viruses have been inhibited by oligopeptides with 
similar sequences to an essential polypeptide (F or 
fusion protein) involved in viral penetration. The 
protein involved has membrane-fusing activity upon 
activation by a host cell protease to give the F protein 
a new N-terminus which is highly conserved in the 
virus. The synthetic oligopeptides with similar 
hydrophobic sequences inhibit the F protein activity, 
the most active being carbobenzoxy-D-Phe-L-Phe-Gly- 
D-Ala-D-Val-D-Ile-Gly (50% inhibition at 0.02 yM 
against measles virus) and carbobenzoxy-D-Phe-L-Phe-Gly 
(50% inhibition at 0.2 yM). Research in this area 
will at least enable a better understanding of viral
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interaction with host cellular membrane receptors and 
may lead to compounds active in vivo.
Fig. 1.3.2.1 Structure of adamantane derivatives.
(I, R = NH2) has been rather under-used clinically, 
despite being the only therapeutic or prophylactic 
treatment for influenza A infections in recent years. 
Amantadine acts, without being metabolised, at some 
point within the process of virus uncoating after 
the virus has entered the cell, although the exact 
point of attack remains to be unequivocally assigned 
(Skehel, et al. 1978; Oxford and Galbraith, 1980).
The point of action may be on the pH control of cells, 
an acidic pH being required for fusion of the viral 
and vacuole membranes after viropexis (see Section 1.1.3)
1.3.2 Uncoating
1.3.2.1 Adamantane Derivatives
I
1-Amino adamantane (amantadine, symmetrel)
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1-Adamantane-methy lamine (rimantadine; I, R = 
CH(CH3)NH2) has a similar mechanism of action, is 
used clinically in the USSR, and has been reported as 
being more effective (Burlington, et al., 1974) with 
less side-effects on the central nervous system 
(Oxford, 1984). Tromantadine (I, R = NHC0CH20(CH2)2NMe2) 
has some activity against HSV-1 and HSV-2.
resistant mutants has prompted studies with simultaneous 
administration of inactivated HN vaccine and amantadine 
(Webster, et al., 1985). Such combinations could be 
valuable against highly pathogenic influenza outbreaks.
1.3.2.2 21-Deoxyglucose
Fig. 1.3.2.2 2'-Deoxyglucose
HSV-1 infectivity is decreased by 2'-deoxy­
glucose as a result of a reduced ability to penetrate
The occurrence of amantadine and rimantadine
c h 2o h
the cell or in the uncoating process (Spivak, et al.,
1982), cellular attachment is little-affected. In
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the case of influenza virus the target is known to 
be glycosylation of virus proteins in infected cells 
which is inhibited (Blough and Guitolini, 1979) 
altering their functioning and interaction with the 
cell membrane prior to budding and virus release.
1.3.2.3 Arildone and Derivatives
Activity against DNA and RNA viruses is 
exhibited by the B-diketone Arildone (1) (Diana, et al. , 
1977). The mode of action of this class of compounds 
has been elucidated for polio and HSV-2, acting at an 
early stage, likely to be the uncoating of the virus, 
preventing production of virally coded RNA, DNA or 
proteins (McSharry, 1979). Arildone has shown promise 
against human cytomegalovirus replication, blocking 
at a stage after virion uncoating but prior to DNA 
synthesis (Tyms, et al., 1984).
Also reported are the pyrazole analogues (2) 
with antiherpes activity (Diana, et al. , 1981) and 
the phosphonate derivative (3) (Diana, et al. , 1984) 
which was active -in vitro and in vivo against HSV-2.
1.3.3 Intracellular Events
1.3.3.1 Synthetic Oligonucleotides
Current knowledge of the intracellular 
events following virus infection is rapidly increasing 
and this will surely result in new targets for drug 
development.
Specific interference with viral genomes to
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Fig. 1.3.2.3 Arildone and analogues.
affect replication and/or transcription is a 
possibility. Sequence-specific non-polar oligo­
nucleotides (Ts'O, et al., 1983) may overcome problems 
associated with reaching the desired site such as pene­
tration and enzymatic degradation. A decrease in 
polarity may be achieved using phosphotriesters between 
nucleosides rather than diester linkages.
1.3.3.2 The Interferons
After its discovery in 1957 by Isaacs and 
Lindenmann, the antiviral protein interferon was 
thought to show great promise as a clinically useful 
antiviral agent. However, difficulty in the production 
of sufficient quantities for study resulted in 
significant loss in interest until recent years. The
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timely development of recombinant DNA technology and 
monoclonal antibodies has solved these initial problems 
and the different interferon (IFN) types have now 
been cloned and purified .
The three categories comprise IFN-a (leucocyte 
interferon), IFN-B (fibroblast interferon) and IFN-y 
(immune interferon). Binding to specific cell surface 
receptors induces a cascade of cellular events with 
the induction of a number of new enzymes; (2'-5')(A)n 
synthetase, and a 73 K protein kinase which require 
double-stranded RNA for their activation (Kerr and 
Brown, 1978; Marcus, 1982), and this has therefore been 
assumed to be an intermediate or a by-product in all 
DNA and RNA virus replicative cycles. The activated
2-5A synthetase catalyses the synthesis of short-lived 
oligonucleotides (2'-5')pppA(pA) or (2-5)A, which in 
turn activate an endonuclease (RNase L) to destroy 
mRNA and thereby inhibit protein synthesis in virus- 
infected cells treated with interferon (Baglioni, 1983). 
Several (2-5)A analogues have been synthesised and 
their antiviral activities investigated (Torrence, 
et al. , 1984; Lesiak, et al. , 1983; Goswami, et al.,
1982). Compounds of this type are, however, relatively 
impermeable to cell membranes by virtue of their highly 
charged nature, and are also susceptible to hydrolysis 
by phosphodiesterases and dinucleoside polyphosphatases.
The 73 K protein kinase simultaneously 
inactivates the chain initiation factor eIF-2 (Lengyel,
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1982) by phosphorylation. Other biochemical events 
include inhibition of methylation of the 5'-terminal 
guanosine cap of viral mRNA (Baglioni, 1979).
Interferons have the potential to be antiviral 
antibiotics with a broad spectrum of specific activity, 
furthermore no problems of resistance have been reported. 
Human IFN-a and -6 have shown promise when used in high 
dosage early in infection. Interferon's multifaceted 
nature, however, means that its other properties may 
result in deleterious effects. It has antiproliferative 
properties and immune enhancing effects and is thought 
to have a role in some autoimmune diseases, multiple 
sclerosis, and more recently, AIDS.
1.3.3.3 Methylation of mRNA as a Target
Many viral and cellular messenger RNAs 
contain N-7 methylated 5'-terminal cap structures.
The methyl group is derived from S-adenosylmethionine, 
to produce S-adenosylhomocysteine (SAH) as a by-product, 
which is cleaved by S-adenosylhomocysteine hydrolase.
This enzyme is inhibited by 9-B-D-arabinosyladenine 
(ara-A), (S)-9-(2,3-dihydroxypropyl)adenine (Holy,
1982) and 3-deazaadenosine and its carbocyclic derivative 
(De Clercq and Montgomery, 1983). The SAH which 
accumulates is a potent inhibitor of S-adenosylmethionine- 
dependent methylation.
Ribavirin (1-B-D-ribofuranosyl-1,2,4-triazole- 
3~carboxamide) has a similar structure to guanosine 
and inosine. It shows broad spectrum activity against
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Fig. 1.3.3.3(i) Ribavirin
DNA and RNA viruses (Smith and Kirkpatrick, 1980). 
Ribavirin monophosphate inhibits IMP dehydrogenase 
(Streeter, et al. , 1973) and therefore affects GTP 
and dGTP pools. However, the fact that the related 
thiazole analogue inhibits IMP dehydrogenase but has 
minimal antiviral activity seems to rule out this 
route of specific antiviral action (Robins, et al. , 
1982). The triphosphate, however, inhibits mRNA 
guanyltransferase (Goswami, et al., 1979). The 
specific inhibition of influenza RNA polymerase 
(Eriksson, et al. , 1977) may well be due to inhibition 
of the essential 51-cap transfer reaction required 
during influenza mRNA synthesis. Ribavirin analogues 
modified in the azole ring have met with some success, 
a highly potent and selective antiviral agent was
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obtained on introducing selenium (Robins, et al. , 1983) 
(Fig. 1.3.3.3(ii)).
O
ii
Fig. 1.3.3.3(ii)
The precise mechanism of action of 
ribavirin and its analogues is therefore still 
unclear, its broad spectrum activity seems most likely 
to be due to a number of different points of attack. 
Inhibition of protein synthesis cannot be ruled out, 
perhaps occurring by virtue of the similarity to
3-amino-l,2,4-triazole - a mitochondrial ribosome 
protein synthesis inhibitor.
1.3.3.4 Protein Synthesis and Processing asa Target
Apart from the interferons and their inducers, 
there are some other compounds having an effect on 
protein synthesis. Isatin-6-thiosemicarbazide, for 
example, inhibits late protein synthesis in poxvirus 
infected cells (Cooper, et al. , 1979) .
Evidence that virus-infected cell membranes
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have altered permeabilities and allow transport of 
certain compounds not normally taken up (Carrasco and 
Smith, 1900 ) led to investigation of the GTP methylene 
analogue GppCH2p, which selectively inhibits protein 
synthesis in virus-infected cells only (Carrasco, 1978) . 
This "membrane leakiness" is exhibited by a number of 
viruses including herpesviruses and paramyxoviruses, 
however, with the exception of vaccinia virus (Carrasco 
and Esteben, 1982), this is usually late in infection 
which may prove to be a drawback when the potential for 
antiviral exploitation of these membrane permeability 
changes is examined.
The interdependent manner of the sequential 
formation of HSV a, 6 and y proteins (Honess and 
Roizman, 1974) may be exploitable. Gamma-polypeptides 
are able to shut off the synthesis of 6-proteins 
(including thymidine kinase and DNA polymerase). The 
development of small, stable polypeptides able to 
interact with the y-protein receptors could lead to 
prevention of the synthesis of these viral-specific 
enzymes.
1-3.4 Viral Enzyme Inhibition
Perhaps the best and most widely investigated 
targets for antiviral chemotherapy are the viral-specific 
enzymes. Recent progress has been in the identification 
and characterisation of a number of virus-coded enzymes 
which are either absent from uninfected cells or
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fundamentally different from their normal cellular 
counterparts.
Enzymes with a unique activity include the 
RNA transcriptase of influenza and parainfluenza, and 
the reverse transcriptase of RNA oncogenic viruses. 
Negative sense RNA viruses such as influenza have 
associated with the virion a RNA dependent RNA polymerase 
(transcriptase) required for the synthesis of early 
viral mRNAs.
Virally encoded enzymes are also known which 
catalyse reactions occurring in uninfected cells but 
which have sufficiently different properties to the 
corresponding cellular enzymes to allow selective 
inhibition by chemotherapeutic agents.
Viruses of the herpes group are known to code 
for at least six such enzymes which are required for 
their own biosynthetic pathways; ribonucleotide 
reductase, thymidine kinase, DNase, uracil-DNA- 
glycosylase, dUTPase and DNA polymerase (see Table 1.3.4)
1.3.4.1 Thymidine Kinase
Herpesvirus encoded thymidine kinase is not 
yet a direct target for antiviral agents but is critical 
for the activation of a number of nucleoside analogue 
antiviral compounds which are not substrates for the 
cellular enzyme.
The virus induced thymidine kinase differs 
from the host cell enzyme in molecular weight, 
electrophoretic mobility, isoelectric point and
35
7 > > ’O T
O
r- iT
Fi
g.
 1
.3
.4
.1
 
Nu
cl
eo
si
de
 a
na
lo
gu
e 
su
bs
tr
at
es
 f
or
 h
er
pe
sv
ir
us
 t
hy
mi
di
ne
 
ki
na
se
.
36
immunological properties (Kit, 1979) . The viral enzyme 
has rather poor substrate specificity and is therefore 
a prime target for the selective activation of 
antiviral compounds. The HSV-1 thymidine kinase, for 
example, phosphorylates a number of nucleoside analogues 
as well as thymidine (Fig. 1.3.4.1).
1.3.4.2 Acyclonucleoside Analogues
Interest in a class of antiviral nucleoside 
analogues in which major modification of the sugar 
residue is present was initiated by the discovery of 
9-(2-hydroxyethoxymethyl)guanine (acyclovir) as a 
potent agent against HSV-1 and HSV-2 in vitro 
(Schaeffer, et al. , 1978), active at concentrations 
as low as 0.1 yM with no cytotoxicity up to 20 mM.
Acyclovir has rapidly progressed to clinical use and 
is now available for treatment of HSV-1 occular 
keratitis, genital herpes and varicella zoster lesions.
The drug has been shown to be phosphorylated 
to its monophosphate by the herpesvirus thymidine 
kinase, the monophosphate is then further phosphorylated 
by cellular kinases to the triphosphate (Miller and Miller, 
1982) which preferentially inhibits the viral DNA 
polymerase, and can be incorporated into oligonucleotides 
resulting in chain termination by virtue of the 
availability of only one phosphodiester forming hydroxyl 
group (Furman, et al. , 1979, 1980).
Some close analogues of acyclovir have been 
synthesised and shown to have increased potency and
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similar mechanisms of action. Of these compounds, the 
most promising have been 9-(1,3-dihydroxy-2-propoxy- 
methyl)guanine (2'NDG, DHPG, Fig. 1.3.4.1) (Smith, 
et al., 1981) and (S)-9(2,3-dihydroxy-1-propoxymethyl)- 
guanine (iNDG) (MacCoss, et al., 1985). More recently 
a cyclic GMP analogue, 9-[(2-hydroxy-l,3-2-dioxaphos- 
phorinan-5-yl)oxymethyl]guanine P-oxide, sodium salt 
(2'-nor-cGMP, Fig. 1.3.4.2) has been reported as a 
potent and broad spectrum anti-DNA-viral agent 
(Tolman, et al., 1985). Unlike other acyclonucleosides 
2'-nor-cGMP activity against herpesviruses is not 
dependent on virus-induced thymidine kinase activity, 
although cleavage of the cyclic phosphate intracellularly 
could produce 2'NDG monophosphate, which could be 
converted to the triphosphate by host enzymes.
Intracellular levels of 2'NDG triphosphate are, however, 
insufficient to account for activities observed, 
indicating a mechanism separate from that of the known acyclo­
nucleosides .
0
i
HO
Fig. 1.3.4.2 2'-Nor-cGMP
1.3.4.3 5-Iodo-21-deoxyuridine (Idoxuridine, IDU )
IDU (Fig. 1.3.4.1) is phosphorylated by
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both virus-infected and normal cells and subsequently 
incorporated into DNA (Prusoff and Goz, 1973) whereby 
replication and transcription are affected. Analogues 
are reported as showing selectivity against herpesviruses 
by virtue of selective phosphorylation by the viral 
thymidine kinase (DeClercq, et al., 1978). Since IDU 
and its close analogue trifluorothymidine (TFT) show 
little specificity for incorporation into DNA they 
can only be used where cellular DNA synthesis is 
minimal, as the presence of nucleoside analogues in 
DNA has an effect on transcription and translation 
(Otto, et al. , 1982) .
1.3.4.4 E-5-(2-Bromovinyl)-21-deoxyuridine (BVDU)
BVDU (Fig. 1.3.4.1) is the most effective 
antiviral agent of a number of 5-(2-halogenovinyl)-2'- 
deoxyuridine derivatives (DeClercq, et al., 1979, 1980). 
BVDU is a potent inhibitor of HSV-1 but is less effective 
against HSV-2. The mode of action has been suggested to 
be via specific phosphorylation to the 5'-phosphate in 
HSV-1 and HSV-2 infected cells by the viral thymidine 
kinase (Cheng, et al. , 1981) , followed by further 
phosphorylation to the 5'-pyrophosphate by the dTMP 
kinase activity of HSV-1 thymidine kinase but not by 
the HSV-2 enzyme. Subsequent phosphorylation by 
cellular enzymes to the 5'-triphosphate then occurs 
within HSV-1 infected cells. In HSV-2 infected 
cells, however, the viral kinase phosphorylâtes the 
nucleoside only to the 5'-monophosphate (Descamps and
39
DeClercq, 1981) , which can then be attacked by cellular 
thymidylate kinase, for which BVDU-monophosphate is a 
good substrate, before further phosphorylation by a 
cellular kinase can occur (Barr, et al. , 1983).
The BVDU 51-triphosphate shows marked 
preferential inhibition of HSV DNA polymerase (Allaudeen, 
et al. , 1981), and is also incorporated into viral DNA 
resulting in an increased lability of the DNA as revealed 
by an increased number of single strand breaks observed 
in alkaline sucrose gradients (Mancini, et al., 1983).
The extent of incorporation is related to antiviral 
activity and occurs at much lower concentrations than 
required by cellular DNA. BVDU also appears to interfere 
with the glycosylation of HSV-1 late polypeptides (Siegel, 
et al. , 1984).
The drawbacks with this highly potent 
compound arise from the unusual base structure, which, 
should it become detached from the sugar, perhaps by 
the action of a nucleoside phosphorylase, is likely to 
have unforeseen side-effects on host cellular DNA or 
RNA synthesis.
BVDU and similar compounds are also 
likely to be phosphorylated to some extent in uninfected 
cells and therefore incorporated into cellular DNA.
The presence of the abnormal halogenated base is likely 
to affect the base pairing properties of a growing 
DNA chain with possible mutagenic consequences. Also 
likely to be affected, is the behaviour of enzymes
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in which base recognition is important.
1.3.4.5 2'-Fluoro-5-iodo-l-B-D-arabinofuranosyl- 
cytosine (FIAC)
FIAC (Fig. 1.3.4.1) also relies upon 
specific phosphorylation for its antiviral activity, 
the 5'-triphosphate is able to interfere with the 
viral DNA polymerase or be incorporated into DNA, 
probably resulting in defective mRNA and therefore 
proteins. Inhibition of viral DNA polymerase is also 
likely to be of importance (Larsson and fiberg, 1981) .
1.3.4.6 Ribonucleotide Reductase 
Ribonucleotide reductase is an essential
enzyme for DNA synthesis in all prokaryotic and 
eukaryotic cells, catalysing the synthesis of all 
four deoxyribonucleotides by direct reduction of the 
corresponding ribonucleotides.
Fig. 1.3.4.6 Action of ribonucleotide reductases.
4 1
A number of herpesviruses induce a ribo-
nucleotide reductase activity which differs from 
that of the host cell. These include HSV-1 (Cohen, 
1972), HSV-2 (Cohen, et al., 1974), pseudorabies 
virus (PrV) (Lankinen, et al. , 1982) and EBV (Henry, 
et al. , 1978) . The HSV-1 enzyme is known to be virus- 
coded (Dutia, 1983) and like all other enzymes 
catalyses the reduction of all ribonucleotides.
a-(N)-heterocyclic carboxaldehyde thiosemicarbazones 
has been reported (Moore and Sartorelli, 1984), these 
compounds being very powerful inhibitors of the 
mammalian enzyme, a property leading to potential anti­
viral activity. A good correlation is indeed observed 
between the inhibition of the formation of herpesvirus 
virions and the inhibition of the virus induced 
reductase by compounds of this type (Brockman, et al., 
1970).
linked to a thiosemicarbazide side chain through the 
carbon atom a- to the ring nitrogen (Fig. 1.3.4.6(i)). 
High selectivity against HSV-1 and HSV-2 has been
Inhibition of ribonucleotide reductase by
Active compounds are heteroaromatic rings
Fig. 1.3.4.6U)
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observed for a series of 2-acetylpyridine thiosemi- 
carbazones, with the unusual property of higher activity
against HSV-2 (Shipman, et al., 1981) (Fig. 1.3.4.6(ii).
Ri R2
H H
H 1-Adamantyl
CH3 c h 3
Fig. 1.3.4.6 (ii)
Inhibition of vaccinia and some parainfluenza 
viruses has been observed for analogues of methisazone 
(N-methylisatin— 0-thiosemicarbazone (Fig. 1.3.4.6(iii) 
(Giovanninetti, et al., 1981), the mechanism of action 
is unclear however.
Fig. 1.3.4.6(iii) Methisazone
1.3.4.7 Protein Kinase
An envelope-associated cyclic AMP-independent 
protein kinase has been reported for HSV-1 (Lemaster 
and Roizman, 1980; Blue and Stubbs, 1981). It is 
unclear, however, whether the enzyme is virally
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coded, host cell derived or a virus-induced host cell 
enzyme. The protein kinase could be a valuable target 
for chemotherapy if its role in the sequential synthesis 
of a, 6 and y HSV-polypeptides is confirmed.
1.3.5 Viral Nucleic Acid Polymerase Inhibitors
Almost all viruses have a specific nucleic 
acid polymerase activity (Table 1.3.5), many of which 
are easily assayed in cell-free systems and present 
excellent primary targets for antiviral chemotherapy.
Several of the nucleoside analogues already 
discussed rely upon selective activation by a herpes­
virus thymidine (or deoxycytidine) kinase activity 
before they may act upon the DNA polymerase and other 
targets. The antiviral compound vidarabine (9-6-D- 
arabinofuranosyl(adenine) ara-A) is phosphorylated 
by cellular kinases to the 5'-triphosphate which is a 
preferential inhibitor of HSV DNA polymerase (Drach 
and Shipman, 1977). Ara-A also inhibits ribonucleotide 
reductase, RNA-dependent RNA polymerase and some other 
enzyme systems.
It should also be noted that cytomegalovirus 
does not induce a thymidine kinase activity (Zavada, 
et al. , 1976), and outside the herpesvirus group only 
vaccinia has been shown to code for the enzyme. These 
compounds are therefore not brcai spectrum antiviral 
agents and require metabolism before they become active. 
There is therefore a need for compounds able to act
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V irus E nzym e activ ity
P ic o r n a v ir u s c s
P o liov iru s. E M C , R N A -d e p en d en t R N A  p o ly m e ra se , N D V , m u m p s  v irus, n e u ra m in id a s e , E C  3.2.1
F M D V , rh in o v iru s E C  2.7.7 S endai v iru s
P oliov irus, F M D V en d o n u c lease , E C  3.1.4 N D V a d e n o s in e  tr ip h o sp h a ta s e  (A T P ase),
P o liov irus, E M C , 
F M D V
p ep tid e  h y d ro la se  (p ro te ase ), E C  3.4
R h a b d o v ir u s e s
E C  3.6 .1
R e o v ir u s e s V SV (g u a n in e -7 )-m e th y ltra n sfe ra se ,
R eovirus (g u an in e-7 )-m eth y ltra n sfe ra se , E C  2.1.1 E C  2 .1 .1
R eovirus, ro ta v iru s R N A -d e p en d en t R N A  p o ly m erase . V SV (a d e n in e -2 ) -m e th y ltra n s fe ra s e , EC  2.1.1
E C  2.7.7 V SV , rab ie s  virus p ro te in  k in a se , E C  2.7.1
R eovirus po ly  G  po ly m erase , E C  2.7.7 V SV n u c le o s id e  d ip h o sp h a te  k inase ,
Reovirus po ly  A  po ly m erase , E C  2.7.7 E C  2.7.1
R eovirus m R N A  g u an y ly ltra n sfe ra se , E C  2.7.7 V SV . ra b ie s  virus, R N A -d e p e n d e n t R N A  po ly m erase .
Reovirus nu c leo sid e  tr ip h o sp h a ta se , E C  3.6.1 sa lm o n id  v iruses E C  2 .7 .7
R eovirus p o ly n u c leo tid e  5 '- tr ip h o sp h a ta se , V SV m R N A  g u a n y ly ltra n s fe ra se , E C  2.7.7
E C  3.6.1 V SV po ly  A  p o ly m e ra s e , E C  2.7.7
R eovirus trip h o sp h a te -p y ro p h o sp h a te  exch an g e V SV e n d o n u c le a s e , E C  3.1.4
T o g a v i ru se s V SV n u c le o s id e  tr ip h o sp h a ta s e , E C  3.6.1
Sindbis v iru s, Sem liki p ro te in  k inase , E C  2.7.1 R e tr o v ir u s e s
F orest v irus A SV , M u L V , M TV , p ro te in  k in a se , E C  2.7.1
Sindbis v iru s, Sem liki R N A -d e p en d en t R N A  p o ly m e ra se , R SV , F eL V , A M V
F orest v irus E C  2.7.7 R SV , A M V , etc. R N A -d e p e n d e n t D N A  p o ly m erase ,
S indbis v irus en d o n u c lease , E C  3.1.4 ( re v e rse  tra n sc rip ta s e ) , E C  2.7.7
O r to m y x o v ir u s e s R SV , A M V , etc. D N A -d e p e n d e n t D N A  po ly m erase ,
In fluenza  A  virus p ro te in  k inase, E C  2.7.1 ( re v e rse  tra n sc rip ta s e ) , E C  2.7.7
In fluenza  A virus n u cleoside  d ip h o sp h a te  k inase . A M V , RSV e n d o n u c le a s e , E C  3.1.4
E C  2.7.4 R L V R N ase  H , E C  3.1.4
In fluenza  A , B, C v irus R N A -d e p cn d en t R N A  p o ly m e ra se , R L V p ro te a s e , E C  3.4
E C  2.7.7 A M V n u c le o s id e  tr ip h o sp h a ta se , E C  3.6.1
In fluenza  A . B, virus n eu ram in id ase , E C  3.2.1
In fluenza  A  v irus 
P a r a m y x o v ir u s e s
nu c leo sid e  tr ip h o sp h a ta se , E C  3.6.1 P ich in d e  v irus R N A -d e p e n d e n t R N A  p o ly m erase , 
E C  2 .7 .7
N D V (g u an in e -7 )-m e th y ltra n sfe ra se , B u n y a v ir u s e s
E C  2.1.1 U u k u n iem i virus R N A -d e p e n d e n t R N A  p o ly m erase ,
Sendai v iru s p ro te in  k inase, E C  2.7.1 
N D V , m um ps v irus, R N A -d e p cn d en t R N A  p o ly m e ra se , 
m easles v iru s, E C  2.7.7 
Sendai v iru s , SV5
N D V , S endai v irus. SV5 po ly  A  p o ly m erase , E C  2.7.7 
N D V  m R N A  g u a n y ly ltra n sfe ra se , E C  2.7.7 
Sendai v iru s  en d o n u c lea se , E C  3.1.4
E C  2 .7 .7
A vian m ye lob la sto sis  v iru s , A M V ; av ian  sa rc o m a  v iru s , A SV ; en cep h a lo m y o ca rd itis  
virus. E M C ; feline le u k em ia  v irus, F eL V ; fo o t a n d  m o u th  d isease v iru s , E M D V ; 
m am m ary  tu m o r v iru s , M T V ; m urine  leu k em ia  v iru s, M u L V ; N ew castle  d isease v irus, 
N 'DV; R au c h e r leu k em ia  v irus, R L V ; R o u s sa rc o m a  v iru s , R SV ; s im ian  v irus 5, SV5; 
vesicu lar s tom a titis  v iru s , V SV .
Table 1.3.5 Enzymes induced by RNA viruses.
Helgstrand & Oberg , 1980
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Virus E n z y m e  activ ity
P a r v o \  iru ses
K ilharn  rat virus D N A -d e p e n d e n t D N A  po lym erase , V acc in ia  v irus D N A -d ep en d e n t D N A  po ly m erase .
E C  2.7.7 E C  2.7.7
P a p o v a v ir u s e s V acc in ia  v irus po ly  A  p o ly m erase , F.C 2.7.7
P o lyom a virus p ro te a s e , E C  3.4 V acc in ia  v iru s m R N A  g u an y ly Itran sfe ra se . E C  2.7.7
D N a se , E C  3.1.4
A J e n o v ir u s c s nu c leo sid e  tr ip h o sp h a ta se , E C  3.6.1
A denov irus type 2 p ro te in  kinase, E C  2.7.1 V acc in ia  v irus p o ly n u c leo tid e  5 '* trip h o sp h a tase ,
A denov irus type  2 p ro te a s e , E C  3.4 E C  3.6.1
H e r p e s v ir u s e s V acc in ia  v irus p o ly n u c leo tid e  ligase , E C  6.5.1
H SV -1. H SV -2 rib o n u c le o tid e  red u c ta se . E C  1.17.4
H SV -1, pseudo rab ies p ro te in  kinase, E C  2.7.1 H e p a t i t i s  B  v iru s e s
virus H u m a n  h e p a tit is D N A -d ep en d e n t D N A  po lym erase ,
H SV -1, HSV -2, V ZV , n u c le o s id e  p h o sp h o tran sfe ra se B v iru s , w ood ch u ck E C  2.7.7
EBV, pseudo rab ies ( th y m id in e  k inase), E C  2.7.1 h ep a tit is  B v irus
virus. H V T , EH V -1
HSV-1 th y m id y la te  k inase , E C  2.7.4
HSV -1, H SV -2, V ZV , D N A -d e p e n d e n t D N A  po lym erase ,
H V T , M D V , C M V , E C  2.7.7
EBV , p seudo rab ies
virus, EH V -1
HSV-1, HSV -2, V ZV . D N a se , E C  3.1.4
C M V , EBV
HSV-1 D eo x y cy tid in e  d e a m in a se , EC  3.5.4
I r id o v iru s e s
F rog virus 3 p ro te in  k inase, E C  2.7.1
A SFV D N A -d e p e n d e n t D N A  po lym erase ,
E C  2.7.7
F rog virus 3 D N a se , E C  3.1.4
F rog  virus 3 R N a s e , E C  3.1.4
F rog v irus 3 a d e n o s in e  tr ip h o sp h a ta s e  (A T P ase),
E C  3.6.1
P o x v ir u s e s
V accin ia  virus ig u a n in -7 )-m e th y ltra n sfe ra se ,
E C  2.1.1
V accinia virus m R N A  rib o se -2 '-0 -m e th y ltra n sfe ra se ,
E C  2.1.1
V accin ia  virus p ro te in  k inase, E C  2.7.1
V accin ia  virus n u c le o s id e  p h o sp h o tran s fe ra se
(thymidine kinase), EC 2.7.1
Vaccinia virus, DNA-dependent R N A  polymerase,
rabbit pox virus EC 2.7.7
A frican  swine fever v iru s , A S F V ; cytomegalo virus, C M V ; E p s te in -B a rr  v irus, E B V ; 
equine herpesvirus type 1, E H V -1 ; herpes simplex v iru s type  1, H S V -1 ; h e rp es  s im p lex  
virus type 2, H SV -2; h e rp es-v iru s  o f  tu rk e y s , H V T ; M a re k ’s d isea se  v irus, M D V ; 
varicella-zoster v irus, V Z V .
Table 1.3.5 Enzymes Induced by DNA viruses
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CO
Fig. 1.3.5(i) Ara-A
directly on nucleic acid biosynthesis without being 
metabolised.
Nucleic acid biosynthesis can be regarded 
as essentially a four step process, the elements of 
which are outlined in Fig. 1.3.5(ii).
(i) Template binding; the polymerase enzyme 
recognises a specific template nucleotide sequence and 
binds to it.
(ii) Initiation; a nucleoside 5'-triphosphate or 
oligonucleotide primer binds to the enzyme/template 
complex at a site corresponding to the 51-terminus
of the nucleic acid to be synthesised.
(iii) Elongation; nucleoside 5'-triphosphates 
bind to the active site as determined by the template 
sequence, and react with the free 3'-hydroxyl group
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G
Fig. 1.3.5(11) Stages in nucleic acid synthesis.
of the growing nucleic acid molecule, with the 
elimination of pyrophosphate via a pyrophosphate 
binding site.
(iv) Termination; nucleic acid synthesis ceases
on reaching a specific template sequence and the complex 
of template, polymerase and nascent nucleic acid 
dissociates.
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All four of the processes present a possible 
target for interference by chemotherapeutic agents.
Since the agent must be selective, however, there must 
be differences in the viral and cellular enzyme active 
sites due to different amino acid sequences at essential 
positions. The principal targets for the design of 
antiviral molecules can be regarded not only as the 
substrates (nucleoside analogues) and templates or 
primers, but also the by-products of the reaction. 
Analogues of pyrophosphate are almost unique in that 
they act preferentially against viral polymerases without 
being metabolised in the cell, and in general show a 
broader spectrum of activity than those compounds 
discussed so far.
1.3.6 Pyrophosphate Analogues
It has now been known for some time that 
analogues of inorganic pyrophosphate can exhibit 
antiviral activity. The first compound of this type 
to be evaluated as a chemotherapeutic agent was 
phosphonoacetic acid (PAA, Fig. 1.3.6).
O
HO
O
c c h 2 p
OH
OH
Fig. 1.3.6 Phosphonoacetic acid (PAA) (1).
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PAA was discovered through random screening 
of compounds in herpesvirus-infected WI-38 tissue culture 
cells (Shipkowitz, et at., 1973). Its chemotherapeutic 
potential was at first unexciting, with high concentra­
tions (100 vig/ml) required for consistent activity 
in cell culture, although there were no adverse effects 
on cell growth or division at higher levels, and early 
studies appeared to show that only herpes simplex 
virus was susceptible.
PAA was subsequently shown to suppress repli­
cation of cytomegalovirus (Huang, 1975), Epstein-Barr 
virus (Yajima, et at., 1976), varicella-zoster virus 
(Overby, et at. , 1977) and vaccinia virus in tissue 
culture. Promising results-against ocular, cutaneous 
and encephalitic herpesvirus infections in animals 
have been reported (Gerstein, et at., 1975; Meyer, 
et at., 1976; Shipkowitz, et at., 1973).
These in vivo studies led to further 
investigations on the molecular events in normal and 
HSV-infected human cells treated with PAA. The rates 
of normal cellular RNA, DNA and protein synthesis 
were not significantly affected by PAA (Overby, 
et al. , 1974), whereas in HSV-infected cells synthesis 
of virus-specific DNA was completely inhibited.
Mao, et at., (1975) isolated the virus-induced DNA 
polymerase from infected cells and showed direct 
inhibition by PAA on the partially purified HSV-induced 
enzyme.
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1.3.6.1 DNA Polymerases
In clarifying the antiviral role of PAA it is 
helpful to compare the roles and properties of normal 
mammalian cellular DNA polymerases and the herpesvirus- 
induced enzyme. The cellular polymerases are necessary 
for cell division and DNA repair, while the virus-induced 
enzyme is required forvDNA replication.
Of the three biophysically and biochemically 
distinct cellular DNA polymerases, a, B and y (see 
Table 1.3.6.1), the herpesvirus induced enzyme is most 
similar to DNA polymerase a. Both enzymes are able to 
copy efficiently, double stranded DNase "activated"
DNA as well as the synthetic primer-template (dG)^^^- 
(dc)n (Wagner, et al., 1974; Weissbach, et al., 1973). 
The enzymes can only be separated by phosphocellulose 
chromatography (Weissbach, et al., 1973) . The virally 
induced enzymes are most active at high ionic strengths, 
at which host cell polymerases are totally inactive 
(Weissbach, et al. , 1973). DNA polymerase a is 
inhibited by PAA but at concentrations up to 100 times 
higher than required to inhibit the herpesvirus-induced 
enzymes (Bolden, et al. , 1975; Miller and Rapp, 1976; 
Sabourin, et al. , 1978) , whereas DNA polymerase B and y 
are relatively unaffected by high concentrations of 
PAA.
PAA resistant mutants of herpesvirus strains 
have been isolated and characterised (Honess and 
Watson, 1977; Powell and Purifoy, 1977) and have shown
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unequivocally that PAA inhibits herpesvirus replication 
by direct interaction with and inactivation of the 
viral DNA polymerase.
1.3.6.2 Mechanism of Action and Structure-Activity Relationships
Independent studies by Helgstrand, et al. 
(1978) and Reno, et al. (1978) led to the evaluation
of phosphonoformic acid (PFA) (2) (Fig. 1.3.6.2) as 
an antiviral compound, which was found to inhibit 
herpesvirus DNA polymerase and herpesvirus replication 
in a manner similar to PAA.
h o '  oh
( 2 )
0 *  ? .O R ,  
C P ,
RgO' OR2
(3)
Fig. 1.3.6.2 Phosphonoformic acid (2) andesters (3) .
The activity of PFA revealed that separation 
of the phosphono and carboxyl group negative charges 
is not mandatory for antiherpes activity, and 
subsequently, despite the structure of PAA providing 
little opportunity for chemical modification to 
optimise activity, a number of analogues have been 
synthesised and tested on isolated viral enzymes in 
cell culture and animal models (Table 1.3.6.2).
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A n alo g s  o f  p h o s p h o n o a c e ta te  lested  for a n lih c rp c sv iru s  ac tiv ity
A n alo g A c tiv ity R eference
I. C a rb o x y l es te rs
E th y l; p ro p y l; r-buty l Y es (ethyl) H ekkin  e t a l. (1977)
C y c lo h ex y l; o c ty l; benzyl Y es (octy l) H e r r in  et al. (1977)
II. M o n o p h o sp h a te  esters
M e th y l; p ro p y l; hexyl N o H e r r in  e t al. (1977)
III. T rie s te rs
T rim eth y l N o Lee e t al. (1976)
T rie th y l N o S h ie k o w it z  e t a l. (1973)
IV. M o n o p h o sp h in ic  ac id s
P h e n y l;4 -m e th o x y p h e n y l;  m e th y l N o H e r r in  e t al. (1977)
V. P h o sp h o n o  a n a lo g s
S u lfo ac e ta te N o Le in b a c h  e t a l. (1976)
M a lo n a te N o L e in b a c h  e t a l. (1976)
A rse n o a c e ta te Yes N e w t o n  (1979)
VI. C a rb o x y l an a lo g s
P h o sp h o n o a c e ta ld e h y d e N o Bo e z i (1979)
P h o sp h o n o a c e ta m id e N o Bo e z i (1979)
/V -M eth y lp h o sp h o n o a c e ta m id e N o Bo e z i (1979)
/V -P ropyl-; N -b u ty l- ; A /-cycIohexyl-; Yes v o n  Es c h  (1978)
•/V -am an ty lp h o sp h o n o a c e ta m id e
A cetony l p h o sp h a te N o Bo e z i (1979)
A m in o m e th y lp h o sp h o n a te N o Lee e t al. (1976)
cr-Amino e th y l p h o s p h o n a te N o Lee e t al. (1976)
N -{ p h o sp h o n o ace ty i)-L -a sp a rta te N o Bo e z i (1979)
M eth y len e  d ip h o s p h o n a te N o Lee et al. (1976)
M eth y len e  d ia rso n a te Yes N e w t o n  (1979)
A rso n o m e th y lp h o sp h o n a te Yes N e w t o n  (1979)
V II. M eth y len e  a n a lo g s
P h o sp h o n o fo rm a te Yes R e n o  e t al. (1978)
P h o sp h o n o p ro p io n a te N o S m fK o w rrz  e t al. (1973)
P h o sp h o n o b u ty ra te N o S h ii-k o w it z  e t al. (1973)
a -P h o s p h o n o p ro p io n a te N o Le in b a c h  e t a l. (1976)
a -M e th y l-2 -p h o sp h o n o p ro p io n a tc N o Le in b a c h  e t a l. (1976)
a -P h e n y lp h o sp h o n o a c e ta te N o Le in b a c h  e t a l. (1976)
c r-A m in o p h o sp h o n o ac e ta tc N o Le in b a c h  e t a l. (1976)
V III. O th e r  re la ted  co m p o u n d s
P h o sp h o g ly co la te N o L e in b a c h  e t a l. (1976)
Im id o d ip h o sp h o n a tc N o Bo e z i (1979)
C a rb a m y l p h o sp h a te N o Bo e z i (1979)
2 '-D e o x y rib o th y m id in c -5 - N o Bo e z i (1979)
p h o s p h o ro p h o sp h o n o a c c ta  tc
P u r in e -5 '-m o n o -ca rb o x y m e th y l- Yes H eimer a n d  N ussbaum  (1977)
p h o s p h o n a te
P y r im id in e -5 -m o n o -c a rb o x y m e th y l- Yes H eimer a n d  N ussbaum  (1977)
p h o s p h o n a te
Table 1.3.6.2 PAA analogues and their antiherpes activity. (From Overby, 1982)
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Concentration(//M) giving 50% inhibition
Comoound
HSV-1
DNA-pol
HSV-2
DNA-pol
HCMV
DNA-pol
Influenza
RNA-pol
Cellular
DNA-pol<*
HO OH
> 5 0 0 >5  0  0 >5 0  0 4 5 0 > 5 0 0
HO ?  V ?OH 
HO H OH
> 5 0 0 - > 5 0 0 > 5  0 0 > 5 0 0
HO OH
1 0 2 7 6 2 8 0 100
HO ?  ^  °>0H
'P -C -P .
HO OH
> 5 0 0 > 5 0  0 — 10 3 5 0
HO.? JJ J >> -c -c
HO ^  OH
0-5 0-7 0-4 3 0 0 3 5
HO ?  Çhl O 
>  C-C 
HO )!< OH
1 5 5 5 0 1 8 > 5 0 0 > 5 0 0
HO.? 5
> P -c-c 
EtO h  "OH
> 5 0 0 > 5 0 0 > 5 0 0 > 5 0  0 > 5 0 0
HO ?
> ~ Ç ~ C.HO H OEt
5 0 - - - > 5 0 0
HO.? V /,°  
HO A 'NH,
> 5 0  0 > 5 0  0 — > 5  0  0 > 5 0  0
HO ?  ? *0  
> s - C - C  
HO ^  sOH — 2 70 - — -
HO.? ¡J
0 ^ S S C'OH > 5 0 0 — — — > 5 0 0
H° . t c " °
MO' 'OH
0-3 0-5 0-3 3 0 4 0
HOv?  ?^ .OH 
H O '^ O H
1 5 0 1 2 1 5 0 > 5 0 0 2 5 0
V c ' °
MO "OH
1 1 5 4 0 0 1 3 0 » 5 0 0 > 5 0 0
Structures of some pyrophosphate analogues and their reported inhibitory properties.
Table 1.3.6.3
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Substitution of the phosphono group by 
carboxyl and sulphono groups results in loss of 
activity against the DNA polymerases induced by the 
herpesvirus of turkeys (Leinbach, et at., 1976).
Replacement of the phosphono and/or carboxyl group by 
arseno groups results in comparable activities for 
methylenebisarsonate and arsenoacetic acid in plaque 
reduction assays with HSV-1 (Newton, 1979) but no 
activity is observed in vivo (Mao, et at., 1985). 
Substitution of the carboxyl group by moieties other 
than arseno- or phosphono-generally abolishes antiviral 
activity, with the exception of some amide derivatives 
(Mao, et at. , 1985). Replacement of the carboxyl group 
of PAA by a phosphono-group yields methylenebisphosphonate, 
which, like pyrophosphate, is devoid of significant 
antiherpes activity (Eriksson, et at. , 1980) , 
carbonylbisphosphonate however, shows significant 
inhibition of HSV-1 DNA polymerase (Eriksson, et at.,
1980).
Substitution of the methylene group of PAA 
with various alkyl or aryl groups resulted in a 
reduction in activity against the polymerase enzyme 
and reduced inhibition of HSV-1 plaque formation.
In general esters have proved to be inactive relative 
to PAA and PFA, including aliphatic and aromatic 
mono-, di- and triesters of PFA (Norén, et at. , 1983) .
None showed inhibition of HSV-1 DNA polymerase in vitro. 
Effective antiherpes activity was, however, observed
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for several compounds, probably due to hydrolysis by 
non-specific esterases. More recently, Mao, et al.
(1985) reported that small alkyl esters such as 
methyl, ethyl and propyl, only slightly decrease in 
activity against the HSV-induced DNA polymerase, 
suggesting that, contrary to earlier reports, an 
ionisable carboxylic acid is not an absolute 
requirement for activity. Compounds of this type, 
and bridge substituted PAA, would be expected to 
traverse the cell membrane with more ease than the 
unesterified compound, none were more active than 
the parent compounds however.
1.3.6.3 Mechanism of Action of PAA
PAA inhibits herpesvirus DNA polymerase by 
interacting with the proposed pyrophosphate binding 
site at the enzyme active site (Leinbach, et al., 1976;
Mao and Robishaw, 1975). Non-competitive inhibition is 
exhibited by both PAA and pyrophosphate against the 
virus-induced enzyme with respect to the four deoxyrubo- 
nucleoside triphosphates and non-competitive inhibition 
with respect to DNA at low deoxyribonucleoside 
triphosphate concentrations but almost uncompetitive 
inhibition at high concentrations.
Inhibition studies with pyrophosphate gave 
apparent inhibition constants in the mM range, whereas 
for PAA values of 1-2 yM were obtained. PAA is a 
competitive inhibitor of pyrophosphate in the pyrophosphate- 
deoxyribonucleoside 5'-triphosphate exchange reaction
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and in multiple inhibition analyses pyrophosphate 
and PAA function as mutually exclusive inhibitors 
and hence bind at the same site. Additional 
evidence for the shared binding site of these 
compounds comes from the observation that PAA resistant 
mutants of HSV are also more resistant to PFA and 
pyrophosphate (Eriksson and Oberg, 1979; Hay and 
Subak-Sharpe, 1976; Reno, et al. , 1978).
An alternate product mechanism has been used 
to describe the inhibition patterns observed with PAA 
(Leinbach, et al. , 1976). Pyrophosphate is predicted 
to act as a substrate for the reverse reaction of the 
polymerisation, i.e., pyrophosphate-deoxyribonucleoside 
5'-triphosphate exchange. However, nucleotides 
containing [2-^H]PAA have not been recovered from DNA 
polymerisation reactions containing [2-^H]PAA (Cload,
1983) and, furthermore, nucleotide analogues such as 
dAMP-PAA and dTMP-PAA are neither substrates nor 
inhibitors of HSV DNA polymerase (Cload, 1983;
Boezi, 1979) .
Further insight into the mechanism of action of 
pyrophosphate analogues has come from a consideration 
of their metal-binding abilities. DNA and RNA 
polymerases are zinc-requiring enzymes (Mildvan and 
Leob, 1979) as is reverse-transcriptase (Poesz, et al. , 
1974) which is inhibited by PFA (Sundquist and Oberg, 
1979). The stability constants for some metal complexes 
of PAA and other pyrophosphate analogues have been
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determined (Stünzi and Perrin, 1979; Cload and 
Hutchinson, 1983) and both PAA and PFA found to form 
strong complexes with zinc in particular. It has 
been suggested that these compounds are active by 
virtue of their ability to chelate with an essential 
metal ion in the herpes DNA polymerase (Perrin and 
Stünzi, 1981) .
As shown by the spectrum of activity of PAA 
and PFA (Table 1.3.6.3(i), as well as inhibiting 
herpesvirus DNA polymerase and the reverse transcriptases, 
PFA in particular is also an effective inhibitor of 
influenza virus RNA polymerase activity (Helgstrand, 
et al. , 1978; Stridh, et al. , 1979) .
In h ib itio n  o f  p o ly m erases  by P F A  a n d  P A A
E nzym e C o n c e n tra tio n  g iv ing  50 Vo inh ib ition , 
p M
P F A  P A A
R N A  p o ly m e r a s e s
In flu e n za  v iru s  (M gf+) 20 300
In flu e n za  v iru s  (M n ,+) 0.3 0.9vsv 500 _
R eovirus > 5 0 0 _
C alf th y m u s I > 5 0 0 > 5 0 0
C a lf th y m u s  II > 5 0 0 > 5 0 0
E . c o l i > 5 0 0 > 5 0 0
R e v e r s e  tr a n s c r ip ta s e s
A M V 7 4,000
R M uL V 0.7 600
D N A  p o ly m e r a s e s
HSV-1 (s tra in  C  42) 0.4 0.5
HSV-1 (s tra in  124) 3.5 7.0
H epatitis  B v irus 20 > 5 0 0
C a lf th y m u s  a  (25 U /a s s a y ) 50 75
C a lf th y m u s  a  ( 2.5 U /a ssa y ) 3.5 6.5
C a lf  liver y > 5 0 0 > 5 0 0
M ic r o c o c c u s  lu te u s > 5 0 0 > 5 0 0
E . c o li > 5 0 0 > 5 0 0
Table 1.3.6.3(i) Inhibition of polymerases by PAAand PFA.
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The RNA polymerase activity of influenza 
virus is known to be zinc requiring (Oxford and 
Perrin, 1977) and subsequent studies on the inhibition 
of influenza RNA transcriptase systems has provided 
the best evidence supporting the hypothesis that 
pyrophosphate analogues inhibit these enzyme activities 
by complexing with an essential zinc ion at the active 
site of the enzyme and thus inhibiting, either by 
preventing the binding of incoming nucleoside triphos­
phates or preventing the release of inorganic pyrophos­
phate once the internucleotide bond has been formed 
by the enzyme.
Recent studies on influenza virus have shown 
that PFA does not inhibit the initiation of mRNA 
formation, and in the presence of PFA the primer of 
about thirteen bases can be elongated with about 
twelve bases, but further elongation is inhibited 
(Stridh and Datema, 1984). It was suggested that 
after addition of the conserved nucleotides, changes 
in the viral core proteins may result in an increased 
sensitivity to pyrophosphate analogues by, for example, 
allowing zinc chelation, resulting in enzyme inhibition. 
Alternatively, a different protein such as PA may be 
involved in the synthesis of the message-specific 
sequences and only this enzyme may be PFA sensitive.
A good correlation between the pK^i (-log^g 
dissociation constant of zinc ion-pyrophosphate 
analogue complex)) of pyrophosphate analogues, as
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determined by gel filtration, and their effectiveness 
as inhibitors of the RNA transcriptase activity of 
influenza A has been obtained (Cload and Hutchinson,
1983). PFA and PAA have relatively high pKd , values 
and are inhibitors of the enzyme (Table 1.3.6.3(H) 
and Fig. 1.3.6.3(D) whereas compounds such as 
phosphonopropionic acid (PPA) and esters of PAA have 
lower pK^i values and are ineffective inhibitors.
TABLE
INHIBITORY EFFECT OF PYROPHOSPHATE ANALOGUES ON 
RNA POLYMERASE FROM INFLUENZA VIRUS AND 
CALF THYMUS DNA POLYMERASE a
Compound PKd .*
Concn. (uM) producing 
50% inhibition
'flu RNA
polymerase
DNA polymer­
ase a
(1) r c h2c o o h 5.5 275 45
(2) RCOOH 5.6 35 35
(3) r c h2c h 2c o o h < 4 > 500 > 500
(4) RCHMeCOOH *v 5 > 500 > 500
(5) r c o n h2 < 4 > 500 > 500
(6) (EtO)2P(0)CH2COOH < 4 > 500 > 500
(7) ROR 5.7 125 > 500
(8) RNHR 5.7 50 > 500
(9) r c h2r 5.3 > 500 > 500
(10) RCHO.R > 6 85 > 500
(11) r c ç i2r > 6 75 > 500
(12) RCBr2R > 6 10 350
(13) RCOR 5.4 20 100
whore R - (H0)2P(0)
•Dissociâtion constant of complex formed with zinc 
ions, measured at pH 8.0 as described in text.
Table 1.3.6.3(ii) Inhibitory effect of pyrophosphateanalogues on RNA transcriptase from influenza virus and calf thymus DNA polymerase a. (Cload and Hutchinson, 1983)
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Fig. 1.3.6.3(i) Relationship between pK^i (pH 8) and effectiveness as inhibitors of the RNA transcriptase activity of influenza A. (Taken from Cload and 
Hutchinson, 1983.)
The steric factors determining the type of 
chelate ring formed are likely to be of importance, 
with PFA forming the most stable 5-membered ring.
PAA and PPA would form 6- and 7-membered rings 
respectively (Fig. 1.3.6.3(ii)) and show progressively 
less antiviral activity. Particularly active 
inhibitors were the halogenated methylenebisphosphonates, 
dibromomethylenebisphosphonate being the most active 
(50% inhibitor at 10 uM).
6 2
-1---------c * °
°  ^  o  
?
V
1
1o
A J
(1 ) (2) (3 )
Fig. 1.3.6.3(H) Metal chelates of (1) PFA,(2) PAA, and (3) PPA.
However, with the exception of carbonyl- 
bisphosphonate, these compounds showed no antiherpes 
activity despite forming very stable zinc ion complexes.
It appears therefore that much more stringent structural 
requirements exist for inhibition of HSV DNA polymerase 
than for influenza RNA transcriptase, which is 
presumably due to differences in the pyrophosphate 
binding sites of the two enzymes.
1.3.6.4 Clinical Evaluation
Since PAA exhibits pronounced dermal toxicity 
and is also deposited in the bone, it has not progressed 
significantly beyond animal trials (Boezi, 1979) . PFA, 
however, is much less toxic and is currently undergoing 
clinical trials for topical herpes infections. A 
clinical study on cutaneous herpes using a 3% (w/w)
PFA cream gave some promising results (6berg, 1983).
Although pyrophosphate analogues accumulate 
in bones and teeth it is not known whether this results in 
any deleterious effects (Francis and Centner, 1978).
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The design of pyrophosphate analogues with different 
metal chelating properties should lead to compounds 
with different effects on bones and which have 
antiviral activity. One way in which this may be done 
is to introduce bulky groups into the analogues to 
make them less compatible with the hydroxy apatite 
lattice of bones and teeth, or alternatively introduce 
ligands with a reduced affinity for calcium ions.
1.3.7 Tetrazoles(-CN.H) as Replacements forCarboxylic Acids (-CO.,H)
Chemical modification of the structure of 
PAA has not produced a more effective inhibitor of 
HSV-1 DNA polymerase. However, it has been reported 
that substitution of the carboxylic acid moiety by the 
isosteric tetrazole function to give 5-phosphonomethyl- 
1 (H)-tetrazole (1) (Fig. 1.3.7(D) results in an 
increase in antiviral activity against HSV-2 in tissue 
culture but a decrease in activity against HSV-1 
(Yaouanc, et al., 1980).
Fig. 1.3.7 (i) 5-Phosphonomethyl-1(H)-tetrazole (1).
The close similarity between the pKa of 
5-substituted tetrazoles and their carboxylic acid 
analogues has resulted in the synthesis of various 
biologically active compounds in which this substitution 
has been carried out. The metabolic stability of the 
tetrazole function (Epslin and Woodbury, 1956) has 
also prompted interest in compounds of this type. Of 
those investigated in recent years, a number of 
compounds have exhibited improved biological activity, 
for example in hypocholesterolemic compounds (2)
(Fig. 1.3.7(ii)) (Buchanan and Sprancmanis, 1973) and 
the extended antibacterial activity of the broad- 
spectrum antibiotic 3-(5-tetrazolyl)penam (3)
(Fig. 1.3.7(ii)) (English, et al., 1976). Similar 
biological activities have been observed for tetrazole 
analogues of N-phenylanthranilic acid antiinflammatory 
agents (4) (Fig. 1.3.7 (ii)) (Juby, et al., 1968), 
also pyridyl-substituted 5-(3-pyridyl)tetrazole 
lipolysis inhibitors (5) (Fig. 1.3.7(ii)) (Holland 
and Pereira, 1967) with the tetrazole analogue of 
nicotinic acid (6) being three to four times more 
potent than nicotinic acid in lowering serum 
cholesterol in man (Holland and Pereira, 1967).
1.3.7.1 Tetrazole Structure and Properties
The tetrazole ring is a planar 6w-azapyrole 
type system with two tautomeric forms (a) and (b)
(Fig. 1.3.7.1 (i)).
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Fig. 1.3.7(ii) Some biologically active tetrazoles in which -CN4H replaces -C02H.
N— N N = N
Fig. 1.3.7.l(i)
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System (a) is used to number ring substituents 
throughout this thesis and is known to be the preferred 
form which dominates the annular tautomerism (Butler,
1977). The tetrazole ring differs from other azole 
systems in that it represents the functional group 
for a full series of carbazolic acids (RCN^H) the full 
nitrogen analogues of carboxylic acids (RC02H).
In addition to those compounds discussed in 
Section 1.3.7, tetrazole analogues of amino acids are 
also known and have pKa values that agree closely with 
those of the corresponding amino acids (McManus and 
Herbst, 1959). Furthermore, close similarities between 
the spatial requirements of the tetrazolate and carboxylate 
ions have been noted, with almost identical anionic 
charges in similar locations and with similar dimensions 
(Morley, 1968). Bond lengths are characteristic of an 
aromatic system, a planar resonance hybrid being 
indicated by x-ray crystal structure studies. The bond 
distances and angles of sodium tetrazolate monohydrate 
are shown in Fig. 1.3.7.1(ii), and sodium formate in (iii) .
Fig. 1.3.7.1(ii) (iii)
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Moreover, a wide range of stable metallic
complexes of tetrazole systems are known (Butler, 1977)
including zinc complexes such as (1) (Baenziger and
Schultz, 1971) (Fig. 1.3.7.1 (iii)) and complexes with
"soft" metal ions such as silver (2) and platinum (3).
A distorted tetrahedral complex was reported for
dichlorobis (l-methyltetrazolo)zinc(II) (Zn,
(C2Nij)2Cl2) (1)/ with monodentate tetrazole ligands which
coordinate via a charge-transfer a-bond between the
2+4-N atom and the Zn which was coplanar with the ring. 
Complexes of 5-substituted tetrazoles in which 
tetrazoles behave as monodentate ligands bound at 
one of the ring nitrogen atoms are known (Weiss and 
Beck, 1972) , and therefore it seems likely that compounds 
of this type may form metal ion complexes in a similar 
manner to PAA and other pyrophosphate analogues.
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1.4 OUTLINE OF WORK UNDERTAKEN
5- (Phosphonomethyl)-1(H)-tetrazole has been 
reported as a more effective inhibitor than PAA of 
HSV-2 in tissue culture, however no studies on influenza 
viruses have been reported and its metal chelating 
properties have not been investigated.
Previous studies have shown a correlation
between pyrophosphate analogue - zinc ion binding and
their effectiveness as inhibitors of the RNA transcriptase
(Cload,1983)activity of influenza virus A.a Most close analogues of PAA 
and pyrophosphate reported to date have, however, proved 
to be less active than the parent compounds against 
herpesviruses. This has made studies on the effect of 
variation in pyrophosphate analogue-metal ion chelation 
on these viruses difficult.
The aim of the project was, therefore, the 
synthesis of 5-(phosphonomethyl)-1(H)-tetrazole and the 
investigation of its antiviral properties against 
influenza viruses as well as herpesviruses, and 
investigation of its metal ion chelating properties, in 
particular the zinc ion stability constant. Subsequent 
studies were aimed at the synthesis of some close 
heterocyclic analogues of 5-(phosphonomethyl)-1 (H)- 
tetrazole which would have different abilities to chelate 
metal ions by virtue of alterations in the heterocyclic 
ring structure and its acidity, replacement of 
phosphono- or carboxylic acid groups by the tetrazole
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function and increasing carbon bridge length. Subtle 
alterations in pyrophosphate analogue structure by 
replacing certain ligands with others expected to 
exhibit markedly different behaviour towards certain 
metal ions was a further target of the synthetic 
programme.
It was hoped that the study of such compounds 
would confirm the proposed role of zinc ions in the 
inhibition of viral DNA polymerase enzymes as well as 
in the inhibition of RNA transcriptase systems, and 
could lead to the design of more potent compounds.
It was also of interest to investigate the 
uptake of pyrophosphate analogues into infected cells, 
and determine whether any changes occur during viral 
infection. Differences in the cellular uptake of close 
analogues of PAA were also of interest with a view to the 
design of more effective compounds in tissue culture 
and in vivo .
Although there is evidence of varying sensi­
tivities of herpesvirus DNA polymerases to PAA and 
PFA, there have been no reports on the sensitivities 
of various strains of influenza virus to pyrophosphate 
analogues and therefore an investigation into this was 
proposed.
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CHAPTER 2
SYNTHETIC CHEMISTRY
2.1 HETEROCYCLIC COMPOUNDS
The most widely used route to 5-substituted
tetrazoles (1) (Fig. 2.1(D) is by 1,3-dipolar 
cycloaddition reactions involving addition of azide 
anion to nitriles.
Fig. 2.1(i) Reaction of nitriles and azides to give 5-substituted tetrazoles.
and the solvent used. Reactions using solutions of 
hydrazoic acid in hydrocarbon solvents (benzene, 
toluene or xylene) or sodium azide and acetic acid 
in protic solvents (2-propanol or butanol), require 
high temperature and pressure and reaction times of 
up to 7 days (Mihina and Herbst, 1950; Herbst and 
Wilson, 1957). Dipolar aprotic solvents such as
RC=N + M+N3 i, A  ■ solvent
H
The reaction is, however, highly sensitive 
to the nature of the cation M+, the type of nitrile
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dimethyl sulphoxide (DMSO) and dimethylformamide (DMF) 
have been found to facilitate reaction under much 
milder conditions (Finnegan, et al., 1958) . The 
presence of protic solvents, even in amounts as low as 
5% results in large decreases in yields obtained 
(Finnegan, et al., 1958).
The best sources of anions for reactions in dipolar 
aprotic solvents are lithium and ammonium salts since 
they are highly soluble and more easily handled than 
free hydrazoic acid.
5-Substituted tetrazoles have been prepared 
in excellent yields using aluminium azide (A1(N3>3) in 
refluxing tetrahydrofuran (THF) when NH^N3, LiN^ or 
NaN^ in DMF or methoxyethanol have failed (Arnold and 
Thatcher, 1969). This method is preferred when addition 
or displacement reactions with azide ion may occur at 
groups other than the nitrile, resulting in azido 
intermediates which subsequently decompose. The 
azide group of A1 (N3)3 does not displace groups such 
as chloro- from 3-chloropropionitrile, confirming the 
intramolecular mechanism outlined in Fig. 2.1(ii).
Nitriles bearing electron withdrawing groups 
react at lower temperatures and with shorter reaction 
times, although even aliphatic and aromatic nitriles 
bearing electron-releasing groups undergo 90% or 
better conversion into tetrazoles in 18-24 hours at 
125 C with ammonium or substituted ammonium azides in 
DMF (Kadaba, 1973) . In these conditions Lewis acids
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RC AKNafe. RC
AI(N3)2
nakn3)2
RC N'N--N^
":N = N = N +
N—N
< > -N
AKN3)2
_H£_HCI AI(H20)6CI3 + 2 HN3
Fig. 2.1(H) Reaction mechanism for addition of A1 (N3)3 to nitriles.
such as BF3 have been found to greatly improve yields 
by coordinating with a nitrile nitrogen and generating 
a +o charge on the nitrile carbon to facilitate the 
approach of azide ion.
R C E N  + BF3 -------- - R C = N ;BF3
This route (Fig. 2.1(D) can be used to 
synthesise a series of 5-5'-bistetrazoles (2) and 
tetrazole 5-carboxylic acids (3) (Fig. 2.1(iii)).
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CN(CH2>nCN j, AKNgb/THF Il H3O
N// 2
^ C iC H ^ n C N  i NH4N3 /D M F 
E tO " " NaOH
\ ( C H 2) n (  >  3HO" XNH
Fig. 2.1 (iii) 5-5'-Bistetrazoles (2) and tetrazole 5-carboxylic acids (3).
The synthesis of 5-(phosphonomethyl)- 1(H)- 
tetrazole (4) directly from the corresponding diethyl- 
cyanomethyl phosphonate and Al(Nj)j has been reported 
(Yaouanc, et al., 1980) (Fig. 2.1(iv)).
O
(RO)jPCH2CN ____a | (n3>3
HCI
O1
(RO)2PCH2
N— N
"n/k 4
Fig. 2.1(iv) Synthesis of diethyl 5-(phosphono­methyl) -1(H)-tetrazole (4).
In this study the above reaction was 
unsuccessful when carried out with AlCN^)^ in THF,
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Fig. 2.1 (iii) 5-5'-Bistetrazoles (2) and tetrazole 5-carboxylic acids (3).
The synthesis of 5-(phosphonomethyl)-1(H)- 
tetrazole (4) directly from the corresponding diethyl- 
cyanomethyl phosphonate and AliN^Jj has been reported 
(Yaouanc, et al., 1980) (Fig. 2.1(iv)).
O
(ROljPCHjCN a i <n 3>3
HCI
(RO)2PCH2
N— N
'ni 4
Fig. 2.1(iv) Synthesis of diethyl 5-(phosphono1 methyl)-1(H)-tetrazole (4).
In this study the above reaction was 
unsuccessful when carried out with AliNj)^ in THF,
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and also when NH4N3 in DMF was employed, even in the 
presence of BF3 catalyst. However, in identical 
conditions chloroalkyl nitriles were found to give 
yields of 80-90% of the corresponding 5-(chloroalkyl)
1 (H)-tetrazoles in relatively short reaction times 
(Fig. 2.1(v)).
Fig. 2.1(v) Synthesis of 5-(chloroalkyl)-1 (H) - 
tetrazoles (5).
be converted into the corresponding phosphonates by 
Michaelis-Arbusov or Michaelis-Becker reactions as 
described in Section 2.2.
prepared directly from 1,2,4-triazole (Jones and 
Ainsworth, 1971) (Fig. 2.1(vi)). Compound (6) can 
then be converted into its phosphonate by Arbusov 
or Michaelis-Becker reaction.
CI(CH2)nCN . ' AI(Nj)ai H3cr 5
H
5-(Chloroalkyl)-1(H)-tetrazoles can then
3-(Chloroalkyl)-1,2,4-triazoles can be
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c h 2o h c h 2c i
Fig. 2.1(vi) Route to 3- (chloromethyl)-1,2,4- 
triazole (6).
2.2 SYNTHESIS OF PHOSPHONATES
2.2.1 Pyrophosphate Analogues
Analogues of pyrophosphate such as PAA and 
methylenebisphosphonate have been prepared by both 
Arbusov and Michaelis-Becker reactions (Nylen, 1924; 
Kosolapoff, 1955; Herrin, et al., 1977).
The Michaelis-Arbusov rearrangement or 
Arbusov reaction (Fig. 2.2.1(i)) is the reaction of an 
alkyl halide with a trialkyl phosphite, yielding a 
dialkyl alkylphosphonate (1).
R =alkyl, ary I,e tc ; R '=alkyl, acy l,e tc ; ha l=  C l, Br, I
h a l '
RO
RO-
RO
. ^ R
RO" p: r*a. R O -P -R "RO'
RO.
RO
.P - R ( 1 )
Fig. 2.2.1(i) The Arbusov rearrangement.
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The lone pair of electrons of the phosphite attacks 
the alkyl group of the halide to form the addition 
compound (la), followed by dissociation of an alkyl 
group from (la), which is unstable in the presence of 
nucleophiles, to form a phosphonate and a new alkyl 
halide. The overall result is a conversion of 
trivalent phosphorus into pentavalent while forming 
the stable P = 0 bond.
of the sodium salt of a dialkyl phosphite on an alkyl 
halide to give the phosphonate (1) (Fig. 2.2.1(ii)).
Fig. 2.2.1 (ii) Michaelis-Becker reaction.
In this study the Michaelis-Becker reaction 
has been used in the synthesis of thiophosphonates 
(see Chapter 5), while the Arbusov reaction has been 
used in all other synthetic routes to heterocyclic 
phosphonates.
The use of 5-(chloroalkyl)-1(H)-tetrazoles 
in the Arbusov reaction is complicated by the presence 
of an acidic nitrogen atom on the tetrazole ring.
The Michaelis-Becker reaction involves attack
P ' Na* + R’—  ha I » P— R + Nahal 
RO
(1)
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Reaction of unprotected 5-(chloroalkyl)-1(H)-tetrazoles 
with trialkyl phosphites therefore gives the N-alkylated 
phosphonate (2) (Fig. 2.2.1(iii)).
Fig. 2.2.1(iii) N-Alkylation of 5-diethylphosphono-
spectra of (2) indicates that alkylation occurs 
preferentially at the 2-position of the tetrazole 
ring (see Appendix III).
therefore necessary in this reaction. The most 
satisfactory protecting group has been found to be 
the N-benzyloxymethy1 substituent, which has 
previously been used to successfully protect pyrole 
nitrogen atoms (Anderson and Groves, 1971). It can 
be introduced onto the 5- ( c h l o r o a l k y l)-1(H)-tetrazole 
(I) via the sodium salt to afford (II). The group 
survives the Arbusov reaction conditions and is 
stable to 4 M hydrochloric acid and refluxing 10% 
aqueous ethanolic potassium hydroxide (Anderson
O N = N
2
H
alkyl tetrazoles in the Arbusov reaction.
A negative result in the NOE difference
Protection of the tetrazole ring nitrogen is
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Groves, 1971). Removal is achieved in high yield 
with excess trifluoroacetic acid (TFA) at 20°C 
(Fig. 2.2.1(iv)).
C,CM’V *  85% 90% -■
H
1 II
i N aH/dioxan, 30m in 2 5 'C  , P h C H jO C h ^C I-E tjO  , 12 h 20 C
ii TFA , 72 h 20 C
Fig. 2.2.1(iv) Protection of tetrazole function with the N-benzyloxymethyl group.
The final step in these synthetic routes is 
the dealkylation of the phosphonate ester produced by 
the Arbusov reaction. All reactions were carried out 
with either triethyl phosphite or sodium diethyl 
phosphite and therefore compounds were diethyl
phosphonates. These compounds can be completely de-esterified 
under vigorous conditions such as refluxing concentrated 
HC1. Although the tetrazole ring is stable under such 
conditions isolated yields are generally low.
Bromotrimethylsilane (Me^SiBr, BTMS) cleanly 
and quantitatively converts the diethylphosphonates 
into the corresponding trimethylsilyl phosphonates, 
which are then readily transformed into the phosphonic 
acids by hydrolysis with neutral H2O or methanol
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(Fig. 2.2.1(v)).
E to " 20*C
TM SOv "
TMSO'"'
+ E tB r + M e3SiOH
Fig. 2.2.1(v) Dealkylation of diethyl phosphonate esters with BTMS.
been used to efficiently dealkylate phosphonate esters 
(Blackburn and Ingleson, 1980). This reagent shows 
total selectivity for most phosphonate esters but 
has no effect on aryl phosphate esters or alkyl 
carboxylate esters and so has been used to prepare 
C-alkyl esters of PAA and PFA. In this study, ITMS 
is the preferred reagent for the dealkylation of 
thiophosphonate esters (see Chapter 5).
2.2.2 Nucleoside-5' Esters of Phosphonates
analogues can be synthesised using dicyclohexylcarbodi- 
imide (DCC) as condensing agent, with nucleosides 
protected at the 2' and/or 3' positions (Fig. 2.2.2) 
as reagents.
Iodotrimethylsiliane (Me^Sil, ITMS) has also
Nucleoside-5' esters of pyrophosphate
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Fig. 2.2.2 Nucleoside-5' esters of 5-phos- phonomethyl-1(H)-tetrazole.
The generality and simplicity of this 
method makes it very popular, although side reactions 
may result in poor yields.
Because of the poor solubility of tetrazole 
phosphonates in anhydrous pyridine, the usual solvent 
for carbodiimide reactions (Gilham and Khorana, 1958), 
DMF was employed according to Ralph, et al. (1963).
R'
Ph
CH
jO
CH
g
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Deprotection of the various hydroxyl functions 
then gives the corresponding nucleoside-5' phosphonate.
2.3 MATERIALS AND METHODS
2.3.1 Materials
(i) Unless otherwise stated, compounds were 
commercially available and were used as received (see 
Appendix I).
(ii) All reagents were of analytical grade or were 
purified before use.
2.3.2 General Chemical Procedures
(i) 1H n.m.r. spectra were recorded at 220 MHz
using a Perkin-Elmer R34 spectrometer, and chemical 
shifts are quoted with either tetramethylsilane (TMS)
(in CDClj or dg-DMSO) or sodium 3-(trimethylsilyl)-1- 
propane sulphonate (TSS) (in D20) as standards. 3lP 
n.m.r. spectra were recorded at 36.44 MHz using a 
Bruker WH90 spectrometer and were proton decoupled.
^*P n.m.r. shifts are quoted relative to an external 
standard (85% H^PO^) with downfield shifts positive.
(ii) Chemical ionisation mass spectra were determined
using ammonia as reagent gas as previously described 
(Cload and Hutchinson, 1983) .
(iii) Chromatography was performed by upward 
development for t.l.c. plates and downward development 
for paper, using the solvent systens described in (iv)
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for silica t.l.c., all other systems are described below:
System Plate/Paper Solvent
I Cellulose F254/W3MM Bu0H/Ac0H/H20 (5:2:3)
II Cellulose F254 EtOH/O.5 M NH4OAc (5:2)
III Whatman 3MM Pr0H/NH40H/H20 (7:1:2)
IV Whatman 3MM MeOH/NH4OH/H20 (6:1:3)
Phosphonates and their nucleoside-5' esters were 
visualised on descending paper chromatograms and 
cellulose t.l.c. plates by the method of Ames and 
Bochner (1981) for the detection of phosphate esters 
on chromatograms. Silica t.l.c. spots were visualised 
by fluorescence under 254 nm light and/or iodine 
vapour.
(iv) Triazoles, tetrazoles and their phosphonate 
esters were purified by silica gel column chromatography 
by the method of Still (1978) using the following solvent 
systems :
System Solvent(s)
A Acetone/60-80° petroleum ether (3:7, v/v)
B c h c i3
C Methanol/CHCl3 (1:9, v/v)
D Ethyl acetate
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Phosphonates and their nucleoside-5' esters 
were purified by either DEAE-Sephadex A-25 or DEAE- 
cellulose DE52 ion-exchange columns eluted with 
triethylammonium bicarbonate buffer as described in 
Section 2.4.
(v) Elemental analyses were carried out by
Elemental Micro-Analysis Limited, Okehampton, Devon,
U.K., CHN Limited, Leicester, U.K., and Butterworth 
Laboratories Limited, Teddington, Middlesex, U.K.
2.4 EXPERIMENTAL
2.4.1 5-(Phosphonomethyl)-1(H)-Tetrazole (1)
5-(Chloromethyl)-1(H)-tetrazole was prepared 
by heating chloroacetonitrile (6.4 ml, 0.1 mol) with 
dry sodium azide (29.5 g, 0.44 mol) and anhydrous 
aluminium chloride (13.3 g, 0.1 mol) in dry THF 
(200 ml) under reflux in a nitrogen atmosphere for 
14 hours. The reaction mixture was cooled, acidified 
with 5 M HC1 and then extracted with ethyl acetate 
(3 x 100 ml). The combined THF and ethyl acetate 
extracts were dried (over Na2S04) and the solvent 
removed in vacuo. The residue was recrystallised 
from chloroform to give the chloromethyl tetrazole 
(9.6 g, 81%), m.p. 85°, lit. 85°, *H n.m.r. (dg DMSO)
6 5.1 p.p.m., CIMS m/z 119 [M + H]+, 136 (M + NH41+.
2-(Benzyloxymethyl)-5-(chloromethyl)-tetrazole 
was prepared by adding to the tetrazole obtained above
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(5.0 g, X equiv.) in dry dioxan (60 ml), with stirring, 
sodium hydride (50% suspension in oil, 2.25 g, 1.1 equiv.). 
After 30 minutes, benzyl chloromethyl ether (6.0 g,
1 equiv.) was added and the mixture stirred for 16 hours 
at 25°C. The reaction mixture was then filtered, the 
solvent removed from the filtrate in vacuo and the 
residue purified by silica gel column chromatography 
(solvent A) to give 2-(benzyloxymethyl)-5-(chloromethyl)- 
tetrazole (8.6 g, 85%), 1H n.m.r. (CDClg) 6 4.65 (2H, s), 
4.8 (2H, s), 5.9 (2H, s) and 7.3 p.p.m. (5H, m), CIMS
m/z 239 [M + H]+, 256 [M + NH4]+.
2-(Benzyloxymethyl)-5-(chloromethyl)-tetrazole 
(2.4 g, 0.01 mol) was stirred at 120°C for 14 hours in 
triethyl phosphite (5.0 g, 0.033 mol). After this time, 
excess triethyl phosphite was removed in vacuo and the 
residue purified by silica chromatography (solvent B) 
to give the diethyl ester of 2-(benzyloxymethyl)-5- 
(phosphonomethyl)-tetrazole (2.2 g, 65%), 1H n.m.r.
(CDC13) 6 1.3 (6H, t, J = 6 Hz), 3.55 (2H, d, 2Jp_H =
20 Hz), 4.2 (4H, m), 4.65 (2H, s), 5.9 (2H, s) and
7.3 p.p.m. (5H, m), CIMS m/z 341 [M + H]+, 358 [M + NH4]+.
This diethyl ester was stirred in trifluoro- 
acetic acid (8 ml) for 72 hours at room temperature.
Removal of the solvent in vacuo afforded diethyl 
5-(phosphonomethyl)-1(H)-tetrazole (1.3 g, 90%) after 
purification by silica chromatography (solvent C),
XH n.m.r. (CDC13) 6 1.35 (6H, t, J = 6 Hz), 3.75 
(2H, d, ^Jp_H = 20 Hz) and 4.25 p.p.m. (4H, m,
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J = 7 Hz), CIMS m/z 221 [M + H]+, 238 [M + NH41+.
Diethyl 5-(phosphonomethyl)-1(H)-tetrazole 
(1.1 g, 0.005 mol) was stirred for 2 hours at room 
temperature with bromotrimethylsilane (1.53 g, 0.01 mol). 
Evaporation of the silane gave a residue to which excess 
water was added, the latter was removed by lyophilisation 
and the addition of water and lyophilisation repeated 
several times. The product was purified by ion-exchange 
on DEAE-Sephadex A25 (Et3NH+ form, 1.5 x 45 cm) and 
elution with a gradient of 0.5-1.0 M triethylammonium 
bicarbonate (pH 8.4) to give the triethylammonium salt 
of 5-(phosphonomethyl)-1(H)-tetrazole which was converted 
using a Dowex 50 (H+ form) ion-exchange column, into
the free acid (615 mg, 75%), m.p. 170° (dec.), H n.m.r. 
(D20) 6 3.5 p.p.m. (d, 2Jp_H = 20 Hz), 3lP n.m.r.
(D20) 6 16.9 p.p.m., analysis C, 14.6; H, 3.33;
N, 33.12; P, 18.42%; C2H5N4C>3P requires C, 14.64;
H, 3.07; N, 34.15; P, 18.88%.
2.4.2 5-(2-Phosphonoethyl)-1(H)-tetrazole (2)
5-(2-Chloroethyl)-1(H)-tetrazole was 
prepared as described above, from 3-chloropropionitrile, 
in yield of 70% (m.p. 103°, lit. 103-104°) after 
recrystallisation from water.
5-(2-Chloroethyl)-1(H)-tetrazole was 
N-protected as described above and purified by 
silica chromatography (solvent A) to afford 2-(benzyl- 
oxymethyl)-5-(chloroethyl)-tetrazole (75%), 1H n.m.r.
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(CDC13) 6 3.35 (2H, t, J = 7 Hz) , 3.9 (2H, t, J = 7 Hz),
4.6 (2H, s), 5.85 (2H, s) and 7.3 p.p.m. (5H, m), CIMS
m/z 253 [M + H]+, 270 [M + NH41+.
2-(Benzyloxymethyl)-5-(chloroethyl)-tetrazole 
(2.5 g, 0.01 mol) was stirred at 120°C for 24 hours in 
triethyl phosphite (5.0 g, 0.033 mol). Excess triethyl 
phosphite was removed in vacuo and the residue purified 
by silica chromatography (solvent B) to give the diethyl 
ester of 2-(benzyloxymethyl)-5-(phosphonoethyl)-tetrazole 
(2.1 g, 60%), XH n.m.r. (CDCl-j) 6 1.3 (6H, t, J = 6 Hz),
2.3 (2H, m) , 3.2 (2H, m) , 4.1 (4H, m) , 4.6 (2H, s) ,
5.85 (2H, s), and 7.3 p.p.m. (5H, m), CIMS m/z 355 
[M + H] +.
Deprotection was carried out as described 
above to afford diethyl 5-(phosphonoethyl)-1(H)-tetrazole
(1.2 g, 85%) after purification by silica column (solvent
C), *H n.m.r. (CDC13) 6 1.3 (6H, t, J = 6 Hz) , 2.3 (2H,
m), 3.35 (2H, m) and 4.15 p.p.m. (4H, m), CIMS m/z 235
[M + H]+, 252 [M + NH4]+.
Dealkylation with bromotrimethylsilane as
described, followed by purification on DEAE-cellulose 
DE52 (Et3NH+ form, 2.5 x 45 cm) ion-exchange column 
eluted with 0.5-1.0 M triethylammonium bicarbonate 
(pH 8.4) gave the triethylammonium salt of 5-(phosphono­
ethyl) -1(H)-tetrazole. Conversion into the sodium salt 
by Dowex 50 (Na+ form) column afforded 5-(2-phosphono- 
ethyl)-1(H)-tetrazole as the disodium salt (774 mg,
68%), 1H n.m.r. (D2Q) 6 2.1 (2H, m) , 3.2 p.p.m. (2H, m) ,
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31P n.m.r. (DzO) 6 24.7 p.p.m., analysis C, 15.97;
H, 3.11; N, 26.21; P, 13.88%; C3H5N403PNa2 requires 
C, 16.20; H, 2.3; N, 25.20; P, 13.95%.
2.4.3 2-Ethyl-5-(phosphonomethyl)-tetrazole (3)
5-(Chloromethyl)-1(H)-tetrazole (1.2 g, 0.01 mol) 
was heated in triethyl phosphite (5.0 g, 0.03 mol) at 
120°C for 14 hours. Excess triethyl phosphite was then 
removed in vacuo and the residue purified by silica 
chromatography (solvent A) to give diethyl 2-ethyl-5- 
(phosphonomethyl)-tetrazole (1.9 g, 80%), n.m.r.
(CDC13) 6 1.2 (6H, t, J = 6 Hz), 1.5 (3H, t, J = 6 Hz),
3.4 (2H, d, 2J„ u = 20 Hz), 4.1 (4H, m, J = 7 Hz) and 
4.55 p.p.m. (2H, q, J = 7 Hz), CIMS m/z 249 [M + H]+,
266 [M + NH4]+.
Diethyl 2-ethyl-5-(phosphonomethyl)-tetrazole 
(1.0 g, 0.004 mol) was stirred at room temperature for 
2 hours with bromotrimethylsilane (1.5 g, 0.01 mol). 
Evaporation of the silane in vacuo gave a residue to 
which excess water was added. The latter was removed by 
repeated lyophilisation to leave a product which was 
purified by chromatography on a DEAE-Sephadex A25 column 
(1.5 x 45 cm) and elution with a gradient of 0-0.5 M 
triethylammonium bicarbonate (pH 8.4) to give the 
triethylammonium salt of 2-ethyl-5-(phosphonomethyl)- 
tetrazole which was converted into the free acid 
using a Dowex 50 (H+ form) column, yield 320 mg (41%) , 
n.m.r. (D20) 6 1.45 (3H, t, J = 6 Hz), 3.4 (2H, d,
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o 312J„ = 20 Hz), 4.6 p.p.m. (2H, q, J = 7 Hz), P n.m.r.
P —H
(D20) 5 18.8 p.p.m., analysis C, 23.6; H, 5.02; N, 26.7; 
P, 14.79%; C4H9N403P.H20 requires C, 22.86; H, 5.20;
N, 26.67; P, 14.76%.
2.4.4 3 - (Phosphonomethyl)-1,2,4-triazole (4)
3-(Chloromethyl)-1,2,4-triazole (3.0 g, 0.025 mol) 
which had been prepared as described (Jones and Ainsworth, 
1971), was heated with triethyl phosphite (12.5 g, 0.075 
mol) at 120°C for 12 hours. Excess triethyl phosphite 
was removed in vacuo and the residue purified by silica 
chromatography (solvent C) to afford diethyl 3-(phos­
phonomethyl) -1 , 2 , 4-triazole (2.1 g, 35%), 1H n.m.r.
(CDC13) 6 1.3 (6H , t, J = 6 Hz), 3.55 (2H, d, 2Jp_H =
20 Hz), 4.2 (4H, m, J = 7 Hz), 8.3 p.p.m. (1H, s),
CIMS m/z 220 [M + H]+.
The diethyl ester (1.5 g, 0.007 mol) was 
heated under reflux in concentrated HC1 (10 ml) for 
12 hours, the excess HC1 was then removed in vacuo 
and the residue purified by chromatography on DEAE- 
cellulose DE52 column (2.5 x 50 cm, Et.jNH+ form) with 
elution by a gradient of 0-0.5 M triethylammonium 
bicarbonate (pH 8.4) to give triethylammonium 3-(phosphono­
methyl )-1,2,4-triazole. Using a Dowex 50 (Na+ form) 
column this was converted into the disodium salt 
(700 mg, 44%), *H n.m.r. (D_0) , 6 3.3 (2H, d, 2J,P-H
20 Hz), 8.3 p.p.m. (1H, s), 3lP n.m.r. (D2Q) 6 17.4 p.p.m.,
analysis C, 15.37; H, 4.2; P, 13.5;N, 19.6;
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C3H3N303PNa2.HjO requires C, 16.0; N, 2.67; N, 18.67;
P, 13.8%.
2.4.5 Adenoslne-51 - (5-phosphonomethyl)-1(H)-
Tetrazole (9)
To a solution of the anhydrous pyridinium salt 
of 5-(phosphonomethyl)-1(H)-tetrazole (150 mg, 0.6 mmol) 
and 2',3'-O-isopropylidene adenosine (184 mg, 0.6 mmol) 
in anhydrous DMF (4 ml) was added a solution of 
dicyclohexylcarbodiimide (60 0 mg, 3 mmol) in DMF (3 ml) .
The mixture was stirred at 20°C for 96 hours, water 
(5 ml) was added and the stirring continued for a 
further 24 hours. The reaction mixture was then filtered 
and the filtrate evaporated to dryness in vacuo. The 
residue was then purified by chromatography on a 
DEAE-cellulose (Et3NH+ form, 2.5 x 40 cm) column with 
elution by a gradient of 0-0.5 M triethylammonium 
bicarbonate (pH 8.2), after following the reaction by 
t.l.c. (solvent systems II and III). 2',3'-O-isopropylidene 
adenosine-5'-(5-phosphonomethyl)-1 (H)-tetrazole was 
isolated as the triethylammonium salt (90 rag, 25%) 
after monitoring the eluate by u.v. absorption (254 nm)
(Rf (II) = 0.24, Rf (III) = 0.57), *H n.m.r. (D20),
6 1.3 (18H, t, J := 6.5 Hz), 1.6 (3H, s), 1.8 (3H, s) ,
3.25 (12H, q, J = 7 Hz) , 3.45 (2H, d, 2Jp_H := 20 Hz) ,
4.15 (2H, m), 4.7 (1H, m) , 5.15 (1H, m), 5.3 (1H, m) ,
6.3 (1H, d, J = 4 Hz) , 8.3 (1H, s) , 8.45 p.p .m. (1H,
Removal of the isopropylidene group and
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isolation of the free acid of (5) was achieved by passing
the triethylammonium salt down a Dowex 50 (H+ form, 1.5 x
12 cm) ion-exchange column to give adenosine-5'-(5-
phosphonomethyl)-lH-tetrazole C52 mg, 18%), chromatography,
Rf (II) = 0.1, Rf (III) = 0.37, XH n.m.r. (D20) 6 3.5
(2H, d, 2Jp_H = 20 Hz), 4.3 (2H, m), 4.5 (1H, m), 4.6
(1H, m), 5.1 (1H, m), 6.3 (1H, d, J = 4 Hz), 8.5 (1H,
s), 8.6 p.p.m. (1H, s), UV pH 7.0 259 ran ( e  16 400),
analysis C, 34.9; H, 4.63; N, 27.0; P, 6.8%;
C,.H.,NnO,P.4Ho0 requires C, 32.0; H, 5.7; N, 27.8;1 z 1 b y b ¿.
P, 6.2%.
2.4.6 Thymidine-5'-(5-phosphonomethyl)-1(H)-Tetrazole (10)
The 3'-0-acetyl thymidine-5' ester of 
5-(phosphonomethyl)- 1(H)-tetrazole was prepared in 50% 
yield as the triethylammonium salt from 3'-O-acetyl- 
thymidine and (1) as described above. The acetyl group 
was removed by treating this salt (380 mg, 0.7 mmol) 
with methanol (10 ml) which had been saturated with 
gaseous ammonia. The product of this reaction, after 
removal of excess methanol, was purified by chromatography 
on a DEAE-cellulose column (Et.jNH+ form, 2.5 x 45 cm) 
with elution by gradient of 0-0.5 M triethylammonium 
bicarbonate (pH 8.4) and finally converted into the 
free acid with a Dowex 50 (H+ form, 1.5 x 12 cm) 
column to afford thymidine-5'-(5-phosphonomethyl)-1(H)- 
tetrazole (140 mg, 54%), Rf (III) = 0.42, Rf (IV) 0.63,
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*H n.m.r. (D20 ) , 6 1 . 7 (3 H , s ) , 2.3 (2H, m) , 3.45 (2H
d, 2J p _H = 20 H z ) , 4.1 (3 H , m ) , 4.5 (1H, m) , 6.25 (1H
7.5 p.p.m. (1H, s) , U V max pH 7.0 266 nm (e 12 800), 
analysis C, 35.10; H, 4.45; N, 20.65; P, 8.19%;
C, .H, _N,0-,P .H_0 requires C, 35.47; H, 4.46; N, 20.68; 
P, 7.62%.
2.4.7 5,5'-Methylenebis-1(H)-tetrazole (5)
To a solution of malononitrile (2.2 g, 0.03 mol) 
in dry THF (150 ml) was added dry sodium azide (20.0 g,
0.3 mol) with stirring, followed by dry, powdered 
aluminium trichloride (9.0 g, 0.03 mol). The mixture 
was heated for 14 hours under reflux in a nitrogen 
atmosphere, then cooled and acidified with 5 M HC1.
The solution was extracted with ethyl acetate (3 x 100 ml) , 
the combined extracts dried (Na2SO^) and the solvent 
removed in vacuo. The residue was recrystallised 
from acetonitrile to give 5,5'-methylenebis-1(H)- 
tetrazole (2.3 g, 50%) m.p. 208-210°(dec.), lit. 215°,
1H n.m.r. (D2O), 6 4.7 p.p.m. (2H, s), CIMS m/z 153 
[M + H]+, 170 [M + NH4]+, analysis C, 23.84; H, 2.33;
N, 73.79%; CgH^Ng requires C, 23.70, H, 2.65; N,
73.66%.
2.4.8 5,5'-Ethylenebis-1(H)-tetrazole (6)
5,5 '-Ethylenebis-1(H)-tetrazole was prepared 
in an analogous manner from succinonitrile (8.0 g, 0.1 
mol) to give 9.7 g, (60%) product, m.p. 234°(dec.),
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lit 230° after recrystallisation from water, n.m.r.
(D2O), 6 3.5 p.p.m. (4H, s), CIMS m/z = 167 [M + H]+,
184 [M + NH4]+, analysis C, 28.90; H, 3.22; N, 64.1%; 
C4H6N8 re<3u;i-res c' 28.90; H, 3.64; N, 64.1%.
2.4.9 1(H)-Tetrazole-5—ethanoic Acid (7)
A solution in DMF (100 ml) of ethyl 
cyanoacetate (11.5 g, 0.1 mol), ammonium chloride 
(5.9 g, 0.11 mol) and dry sodium azide (7.15 g, 0.11 mol) 
was heated at 100°C for 16 hours under dry nitrogen.
Excess DMF was removed in vacuo, the residue dissolved in 
water (50 ml) and acidified to pH 2.0 with 5 M HC1.
This mixture was cooled to 5°C whereupon crystals separated 
out which were filtered off and washed with ice-water. 
Recrystallisation from propan-2-ol gave ethyl 1(H)- 
tetrazole-5-ethanoate (7.6 g, 50%), m.p. 128°, lit. 
128-130°.
The ethyl ester (500 mg, 3.2 mmol) was heated 
under reflux in 3 M NaOH solution (20 ml) for 4 hours.
This solution was neutralised with 5 M HC1 and 
evaporated to dryness in vacuo. The residue was 
extracted with hot acetonitrile (10 ml), filtered and 
the acetonitrile evaporated to dryness. The 1(H)- 
tetrazole-5-ethanoic acid obtained was recrystallised 
from acetonitrile, yield 360 mg (93%), m.p. 170°,
*H n.m.r. (D20), 64.1 p.p.m. (2H, s), CIMS m/z 129 
[M + H]+, 146 [M + NH^]"1”, analysis C, 28.17; H, 3.10,
N, 43.83%; C3H4N4C>2 requires C, 28.13; H, 3.15;
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N, 43.74%.
2.4.10 1 (H)-Tetrazole-5-(3*-propionic Acid) (8)
5-(2-Cyanoethyl)-1(H)-tetrazole was a by­
product formed in the synthesis of (6) and was purified 
by silica chromatography (solvent D), m.p. 140-142°, 1H n.m.r. 
(dg-DMSO) 6 3.55 (2H, t, J = 6.5 Hz), 3.8 p.p.m. (2H, t,
J = 6.5 Hz), CIMS m/z 124 [M + H]+.
5-(2-Cyanoethyl)-1(H)-tetrazole (50 mg,
O. 4 mmol) was heated under reflux in solution in 20% 
HCl/glacial acetic acid (2.5 ml, 1:1 v/v) for 12 hours.
Excess acid was removed in vacuo and the residue 
recrystallised from propan-2-ol to give 1(H)-tetrazole- 
5 - (31-propionic acid) (36 mg, 62%) m.p. 218-220°
(dec.), *H n.m.r. (D20), 6 2.8 (2H, t, J = 6.5 Hz),
3.22 p.p.m. (2H, t, J = 6.5 Hz), analysis C, 33.8;
H, 4.20; N, 38.91%; C4H6N4°2 requires C, 33.8;
H, 4.25; N, 39.42%.
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CHAPTER 3 
HERPESVIRUSES
3.1 METHODS
3.1.1 Virus Stocks
The KOS and HFEM strains of HSV-1 and the
3345 strain of HSV-2 were employed, which had been 
maintained in the laboratories of Roche Products Ltd., 
Welwyn Garden City, by low multiplicity passage in 
Vero cells. The PAA resistant strain (PAAr ) was HSV-l 
18 Clone I (Honess and Watson, 1977) originally supplied 
to Roche Products Ltd., by R. Honness, N.I.M.R.,
Mill Hill, London.
3.1.2 Cell Culture and Media
HeLa (BU25) cells were used for the preparation 
of viral DNA polymerase. Infectivity assays were carried 
out using serially propagated African green monkey kidney 
(Vero) cells. HeLa (BU25) cell cultures were grown as 
monolayers in roller bottles (2.5 L) at 37°C in growth 
medium (~ 150 ml of HEPES-buffered Eagle's minimal 
essential medium (EMEM) supplemented with non-essential 
amino acids (NEAA, 1%), foetal calf serum (FCS, 10%), 
L-glutamine (4 mM), penicillin (100 units/ml) and 
streptomycin (100 ug/ml). The concentration of FCS 
was reduced to 1% for maintenance of cells. Vero cells
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were grown as monolayer cultures in flat culture 
bottles (175 ml) at 37°C in medium (~ 100 ml) of 
HEPES-buffered Dulbecco's modification of Eagle's 
medium supplemented with newborn calf serum (NCS, 10%), 
L-glutamine (4 mM), penicillin (100 units/ml) and 
streptomycin (100 yg/ml). For maintenance of cells 
1% NCS was employed. In all cases cells were passaged 
using a trypsin (0.05%), EDTA (0.02%) HEPES-buffered 
balanced salt solution.
3.1.3 Plaque Reduction Assay
Confluent 175 ml flat culture bottles of 
Vero cells were used, trypsinised and resuspended in 
growth medium (5 ml) and pooled together for a viable 
cell count. Cells were diluted to 2 x 10^ cells/ml 
medium and 24-well plates inoculated with cell 
suspension (1 ml per well). Growth medium was 
removed after 24 hours at 37°C when the cells were 
confluent monolayers and the cells infected with 
freshly diluted virus in maintenance medium (50 p.f.u. 
in 0.2 ml). After virus absorption (1 hour, 4°C) cells 
were overlaid with 0.7 ml of maintenance medium containing 
1% carboxymethyl cellulose (CMC) followed by drug 
dilutions (0.1 ml, in maintenance medium) in triplicate 
wells. Cells were incubated for 3-4 days at 37°C in 
a humidified atmosphere of carbon dioxide (5%) in air. 
Cells were then fixed with formal saline solution (FSS)
(~ 3 ml, 4% (v/v) formaldehyde in phosphate buffered
98
saline (PBS)/well) for 15-30 minutes. FSS was removed 
and plates stained with Giemsa, washed with water and 
dried. Plaques were counted and mean results used to 
plot semi-logarithmic dose-response curves, from which 
the drug concentrations required to reduce the virus 
control figure by 50% (ID5Q) were determined. Drug 
control wells, containing no virus, were used to 
observe any drug-induced cellular cytotoxicity.
3.1.4 Induction of DNA Polymerase Activityin HSV-Infected Cells
The procedure used was a modification of 
that of Powell and Purifoy (1977) and Cload (1983) . 
Confluent monolayers of HeLa (BU25) cells in roller
Obottles (approx. 10 cells/roller bottle) were infected 
with HSV-1 (KOS) at a m.o.i. of 2-10 p.f.u./cell in 
maintenance medium (10 ml, EMEM plus supplements) and 
incubated for 90 minutes at 37°C. At the end of the 
period of absorption fresh medium was added (1% FCS, 50 ml) 
and the previous medium and unabsorbed virus discarded.
The cell monolayers were incubated for 16 hours at 37°C, 
when cytopathic effect was beginning to be observed. 
Monolayers were then scraped into the medium and pelleted 
by low speed centrifugation (2000 r.p.m./15 minutes/4°C). 
Cells were resuspended in cold PBS (40 mis) and centri­
fuged (2000 r.p.m./15 minutes/4°C), the supernatant 
discarded and the process repeated twice. Cells were 
resuspended in cold buffer (10 mM tvis-HCl, pH 7.5,
3 mM 2-mercaptoethanol) at a concentration of 10^
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cells/ml. The cells were then sonicated (1 minute/ 
full power, MSE soniprobe). An equal volume of high 
salt buffer (3.4 M NaCl, 10 mM tris-HC1, 3 mM 2-mercapto- 
ethanol, pH 7.5) was then added and the suspension 
left for 40 minutes at 4°C.DNA and protein precipitates 
were removed by centrifugation (30 000 g/20 minutes), and 
the supernatant dialysed for 3 hours against buffer 
(500 ml, 10 mM tris-HC1, pH 7.5, 3 mM 2-mercaptoethanol, 
10% (v/v) glycerol). The dialysate was then centrifuged
again at 30 000 g/15 minutes before dialysing for 3 hours 
(500 ml buffer) followed by overnight dialysis (1 L 
buffer). The dialysate was clarified by centrifugation 
(100 000 g/1 hour) and stored in 1.5 ml aliquots at 
-70°C and thawed once prior to use.
3.1.5 DNA Polymerase Assays
HSV DNA polymerase activity was assayed in 
a 200 yl reaction mixture containing 50 mM tris-HC1 
buffer (pH 7.8), 5 mM MgCl2, 20 mM KC1, 110 mM (NH4)2S04, 
200 pM EDTA, 6 mM 2-mercaptoethanol, 25 pM each of 
dATP, dCTP, dGTP, 6 pM [methyl-3H]-TTP (1000-2000 
cpm/pmol), and 37 5 pg/ml DNase I treated salmon sperm 
DNA (prepared by the method of Cload (1983)) and 
DNA polymerase (20 pi of enzyme incorporated about 
25 pmol dTMP per 200 pi reaction mixture in 30 minutes).
Calf thymus DNA polymerase activity was 
assayed in a 200 pi reaction mixture containing 50 mM 
tris-HCl buffer (pH 7.0), 1 mM dithiothreitol, 500 pg/ml
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BSA, 10 mM MgCl2, 20 mM KCl, 200 pg/ml DNase I 
treated salmon sperm DNA, 20 pM [^ H]-dTTP (400-1000 cpm/ 
pmol), 100 pM each of dATP, dCTP, dGTP and enzyme (0.01 
unit).
Reaction mixes were kept at 0°C until addition 
of enzyme, and were then incubated at 37°C for 30 minutes 
(HSV-DNA polymerases) or 60 minutes (calf thymus DNA 
polymerase a) during which time a linear increase in 
incorporation of radioactivity into acid-precipitable 
material was obtained. Reactions were stopped by the 
addition of 200 pi TCA (20%, w/v) and the mixtures kept 
on ice for 12 hours. Acid-insoluble material was 
collected by suction filtration onto GF/C discs (Whatman) 
wetted with cold TCA (10%, w/v), on a Millipore 1225 
sampling manifold. Discs were washed with 1 x 10 ml 
cold 10% (w/v) TCA, 2 x 10 ml cold 5% (w/v) TCA,
1 x 10 ml ethanol and then oven dried for 15 minutes at 
80°C before counting in a toluene based scintillant. 
Zero-time control tubes were obtained by adding 200 pi 
10% (w/v) TCA before addition of polymerase. ID5q 
values were obtained from dose-response curves for 
each compound tested.
3.1.6 Determination of Heterocyclic PyrophosphateAnalogue - Zinc Ion Stability Constants
The zinc ion stability constants for each 
compound were determined by the method of Hummel and 
Dreyer (1962) by a gel-filtration method using a
1 0 1
column of Sephadex G-10 (1.6 x 92 cm) equilibrated 
with zinc chloride (10 yM, Sepctroscopic grade) in 
buffer (0.1 M triethanolamine-HCl, pH 8.0). The 
pyrophosphate analogues (150 or 200 nmoles) were 
added in buffer (1.5 ml) and the column eluted with 
the same buffer at a flow rate of 0.4 ml/minute. The 
zinc content of 2.5 ml fractions was determined by 
atomic absorption spectrometry and the stability 
constants determined as described by Hummel and Dreyer 
(1962). Stability constants are represented by the 
term pK^,, defined here as -loglQ (dissociation 
constant of zinc ion-pyrophosphate analogue complex).
A description of the calculation of 
values is given in Appendix II (reprint of N. Yoza,
J. Chem. Ed., 54, 247 (1977).
3.1.7 Uptake of Phosphonoacetic Acid and5-(Phosphonomethyl)-1(H)-tetrazole (i) by HSV-Infected and Uninfected Cells
3.1.7.1 [2- H]-Phosphonoacetic Acid and[2—3h ]-5-(Phosphonomethyl)-1(H)-tetrazole
To anhydrous PAA or (1) (10 mg) dissolved in
carrier free ^HjO (50 yl) was added concentrated
HC1 (2 yl) and the mixture heated at 70°C for 5 hours.
Excess ^HjO was removed in vacuo followed by repeated
addition and removal of unlabelled water and lyophilisation.
3[2- H]—PAA thus obtained had a specific activity of
9.2 yCi/ymole, [2-^H]-(l) had a specific activity 
of 7.2 yCi/ymole, both compounds co-chromatographed
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with unlabelled materials in solvent I.
3.1.7.2 Uptake of [2-3H]-PAA and (1) intoHSV-Infected and Uninfected Vero Cells
Vero cells were grown to confluency in 35 mm 
culture dishes (106 cells/dish). The medium was 
removed and the cell monolayers infected with 107 p.f.u./ 
dish (5 p.f.u./cell) of freshly diluted virus (HSV-1 
18 Cl, PAAr) in medium (200 yl) or mock infected 
with 200 yl medium. After 1 hour at 4°C medium was 
removed and cell monolayers washed once with maintenance 
medium (1.5 ml) before a known activity and concentration 
of [2-^H]-PAA or [2-^H]-(l) was added, this was 5 yCi/ml 
in 1.0 ml medium per plate in experiments A and B, and 
0.5 ymol in experiment C .
Dishes were incubated at 37°C in an atmosphere 
of CC>2 (5%) in air for times of up to 24 hours. After 
the desired incubation period the medium was decanted 
and the cell monolayers washed with 3 x 1  ml PBS, 
followed by solubilisation with 3 M KOH (300 yl, 
incubated at 37°C for 1 hour). Solubilised cells were 
neutralised with 6 N HC1 before counting 350 yl aliquots 
in 10 mis scintillant. Early cytopathic effect was 
observed microscopically after 24 hours when using 
virus infected at 5 p.f.u./cell, at higher multiplicities 
of infection cells were lost at this stage resulting in 
low counts.
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3.2 EXPERIMENTAL AND RESULTS
3.2.1 Effect of Heterocyclic PyrophosphateAnalogues on HSV-Induced DNA Polymerases
Table 3.2.1 shows the heterocyclic compounds 
studied and lists the ID,-0 values (yM) obtained against 
HSV-1 KOS strain DNA polymerase and HSV-2 3345 strain 
DNA polymerase. Compounds (1) — (4) and PAA were also 
tested against the DNA polymerase of the HFEM strain 
of HSV-1.
As shown by Table 3.2.1, most of the compounds 
are the nitrogen heterocyclic analogues of PAA or 
malonic acid, compounds (1) , (4) and (3) showing a 
progressive decrease in their respective heterocyclic 
ring nitrogen acidities. Of these compounds the 1(H)- 
tetrazole analogue of PAA, 5-(phosphonomethyl)-1(H)- 
tetrazole (1) was most active against HSV-1 and HSV-2 
DNA polymerases although at considerably higher 
concentrations than required for PAA. The corresponding 
less acidic triazole analogue (4) exhibited some activity 
against both enzymes (see Fig. 3.2.1) whereas blocking 
the acidic nitrogen function as in (3) virtually 
abolishes antiviral activity. The tetrazole analogue 
of 3-phosphonopropionic acid (2) was inactive, as were 
the bistetrazoles and tetrazole carboxylic acids 
(5) - (8).
The nucleoside-5' esters of (1) show weak 
activity in tissue culture but no significant inhibition
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Fig. 3.2.1 A typical dose response curve showing the difference in the activities of 5-(phosphonomethyl)-1(H)-tetrazole (o) and 3- (phosphonomethyl) -1,2,4-triazole 
(•) -
of the DNA polymerases is exhibited.
Also shown in Table 3.2.1 are the pyrophos­
phate analogue - zinc ion stability constants which 
were determined. The most effective zinc chelating 
compound of the phosphonates was (1) which had a pK^, 
value of 5.6 (PAA had a pKd, of 5.5 under the same
conditions).
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3.2.2 Effect of Compounds on HSV Plaque Formation
Of the heterocyclic phosphonates only
5- (phosphonomethyl)-1(H)-tetrazole (1) and 3-(phos- 
phonomethyl)-1,2,4-triazole (4) had any effect on 
HSV-1 or HSV—2 plaque formation, (1) being the most 
effective with an ID5Q of 0.35 mg/ml (1.5 mM) against 
HSV—2.
The nucleoside-5' esters exhibit weak 
activity against HSV-1 and HSV-2 plaque formation, the 
most effective, thymidine-5'-(5-phosphonomethyl)-1(H)- 
tetrazole (10) inhibited HSV-1 plaque formation by 50% 
at 0.7 mg/ml (1.81 mM).
3.2.3 Effect of HSV-1 Infection on the CellularUptake of Pyrophosphate Analogues
As shown by Fig. 3.2.3 A and Fig. 3.2.3 B, 
infection of Vero cells with HSV-1 18 Cl (PAAr) results 
in an increase in the uptake of both PAA and 5-(phosphono­
methyl) -1 (H) -tetrazole (1) relative to uninfected cells. 
The level of uptake, as indicated by label recovered in 
solubilised cells, reaches a maximum 6-7 hours after 
infection, when up to 1.5 x 10® nmoles/10® cells was 
recovered.
A direct comparison of the two compounds studied 
(Fig. 3.2.3 C) indicates similar levels of uptake Into 
infected cells, a slight increase being observed far 
5-(phosphonomethyl)-1(H)-tetrazole over PAA in the same 
conditions.
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3.3 DISCUSSION
Contrary to a previous report (Yaouanc, et al., 
1980), 5- (phosphonomethyl)-1 (H)-tetrazole (1) was found 
to be inferior to PAA as an inhibitor of both HSV-1 
and HSV-2 induced DNA polymerases and of HSV-1 and 
HSV-2 plaque formation. The rigid structural requirements 
for activity of pyrophosphate analogues against HSV-induced 
DNA polymerases previously reported (Eriksson, et al.,
1980; Mao, et al. , 1985) are thus also confirmed for 
the series of heterocyclic pyrophosphate analogues 
studied. The close similarities in the properties of 
tetrazoles and carboxylic acids, their similar spatial 
requirements, and moreover the very similar zinc 
chelating abilities of PAA (pK^, = 5.5) and 5-(phosphono­
methyl) -1 (H) -tetrazole (pK^ i = 5.6), are therefore 
insufficient to result in similar levels of antiherpes 
activity.
The heterocyclic phosphonate-zinc ion stability 
constants determined show that only the compounds which 
form reasonably stable complexes (pK^ , = 4.5-6) are 
active against the herpesvirus-induced DNA polymerases. 
Replacement of the phosphonate function by the tetrazole 
moiety or carboxylic acid group results in a dramatic 
decrease in zinc binding and these compounds are devoid of 
antiviral activity. These results suggest that these 
compounds could act against the HSV-induced enzyme by 
virtue of coordination with an essential metal ion
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(probably zinc) in the polymerase, which has not been 
established in previous studies in which good zinc 
chelating compounds have only been active against 
influenza RNA transcriptase activity.
nitrogen atom is important for activity. Replacement 
of the tetrazole ring in 5-(phosphonomethyl)-1(H)- 
tetrazole by the similar but less acidic triazole ring 
in 3-(phosphonomethyl)-1,2,4-triazole (4) or alkylation 
of the tetrazole ring in 2-ethyl-5-(phosphonomethyl)- 
tetrazole (3) results in a progressive decrease in 
their respective activities. Both compounds (3) and
(4) also show a decrease in pK^, value, however, both 
are still able to complex with zinc ions, perhaps by 
coordination through the available non-acidic nitrogen 
atoms to form six-membered chelate rings (Fig. 3.3).
Fig. 3.3 Possible zinc chelates of 3-(phosphono-
The presence of an acidic heterocyclic ring
N=N 0
Zn Zn
methyl)-1,2,4-triazole (4) and 2-ethyl-5- (phosphonomethyl)-tetrazole (3).
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5-(Phosphonoethyl)-1(H)-tetrazole (2) is 
able to form zinc complexes and has a similar pK^, to (4) 
but is less active against the HSV-induced DNA poly­
merases. A decrease in antiviral activity on increasing 
the distance between the tetrazole and phosphono groups 
is in agreement with previous reports that elongation 
of the carbon chain between carboxylic acid and 
phosphono groups results in loss of activity (Leinbach, 
et at., 1976; Eriksson, et at., 1980).
None of the compounds studied had any effect on 
calf thymus DNA polymerase a, the active compounds there­
fore retained specific antiviral activity despite higher 
concentrations being required than for PAA to exhibit 
antiherpesvirus activity.
The highly charged nature of the phosphonates 
studied probably accounts for the much higher concentra­
tions required for antiviral activity in tissue culture, 
it was therefore of interest to synthesise compounds 
which might show an improved uptake into cells and 
therefore higher antiviral activity in cells or in vivo.
With this in mind, and considering the 
reported antiviral activity of nucleoside esters of 
PAA (Heimer and Nussbaum, 1977), the adenosine-5' and 
thymidine-51 esters of (1) were prepared. These 
compounds were inactive as inhibitors of HSV-induced 
DNA polymerase but did show weak activity in tissue 
culture tests at comparable concentrations to (1) in 
the same assay system. These results suggest that
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the nucleoside-5' esters could inhibit virus replication 
via a mechanism other than DNA polymerase inactivation. 
Alternatively, hydrolysis by enzymes inside infected 
cells to give the free phosphonate may result in the 
observed activity in cell culture systems. The esters 
are stable in the DNA polymerase assay conditions as 
demonstrated by t.l.c., however no studies on their 
stability to cellular enzymes and conditions have been 
undertaken.
Since synergism of mixtures of nucleoside 
antiviral agents and pyrophosphate analogues is known 
(Smith, et al. , 1982) , compounds in which the two 
types of molecule are linked by a chemical bond as in 
nucleoside-51 esters, in which the nucleoside itself 
is an antiviral agent, for example 5'-esters of BVDU, 
may prove effective, particularly with regard to 
combating resistance. Nucleoside-51 esters of PFA 
have recently been investigated as possible reverse 
transcriptase inhibitors which might show greater 
specificity than PFA or PAA (Robins, 1984).
An investigation into the uptake of PAA and 
5-(phosphonomethyl)-1(H)-tetrazole into infected and 
uninfected cells was undertaken in order to examine 
any differences in transport across cellular membranes 
between the tetrazole analogue and PAA and at the same 
time to determine whether any differences in the 
cellular uptake of phosphonates occur after viral 
infection. It was found that modification of
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membrane permeability to both PAA and (1) appears to 
occur during infection with HSV-1, reaching a 
maximum 6 to 7 hours after infection.
The initial problem in this study was the 
choice of HSV strain. Initial experiments on HSV-1 
(KOS) infected cells showed little difference in 
PAA uptake compared to uninfected cells. However, the 
concentration of PAA required to give sufficient 
radioactivity in cells to be accurately counted was 
at antiviral levels and therefore the possibility 
of virus inhibition and therefore inhibition of any 
virally-induced cell-permeabilisation could not be ruled 
out. The use of a PAA resistant strain, HSV-1 18CI, 
enables the use of higher dosage and therefore higher 
counts of [2-3H]-PAA and (1) and allows the measure­
ment of membrane permeability changes to pyrophosphate 
analogues during the normal course of infection.
Virally mediated changes in membrane 
permeability to small molecules is a widespread 
phenomenon (Carrasco and Smith, 1980) and has been 
reported for a number of viruses including 
paramyxoviruses (Benedetto, et at. , 1980) and 
herpesviruses (Fritz and Nahmias, 1967; Benedetto, 
et al., 1980), also picornavirus, rhabdoviruses and 
togaviruses, taking place early as well as late in 
infection.
Some "impermeant" inhibitors of protein 
synthesis such as the GTP analogue guanylyl (6,y-
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methylene-)-diphosphonate (GppCH2p) are said to inhibit 
protein synthesis in virally-infected cells but 
not uninfected cells due to an increased permeability 
across their plasma membrane (Carrasco, 1978;
Carrasco and Lacal, 1983). This has, however, been 
disputed in another report (Gray and Pasternak, 1984) 
in which the uptake of sugars and amino acids as 
well as [3H]GppCH2p was reported to be unaffected by 
infection with a variety of viruses.
In this study the uptake of [2-^H]PAA and (1) 
increased soon after infection and reached a maximum 
(20% higher) late in infection. It appears, therefore, 
that some sort of modification of the plasma membrane 
does occur after infection. No conclusions can be 
drawn as to whether there occurs an effect on an uptake 
mechanism or merely an increase in the permeability 
of cells. Generalised membrane leakage would result 
in a gradual redistribution of ions and small molecules 
in the cells and the medium, with certain molecules 
being retained in the cell due to interactions with 
cellular or viral components, which would include the 
DNA polymerase. Both the initial and final steps in 
viral infection involve interactions with the cell 
surface. If the initial adsorption and entry of the 
virus alters the membrane permanently, this would 
account for an immediate difference in the uptake of 
small molecules which would proceed until the 
onset of cytopathic effect, after which cells leak in
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general manner before lysis.
The bulk of herpesvirus DNA is made 3 to 6 
hours post-infection (Roizman, 1969) and therefore the 
observed increase in permeability seems to occur too 
late to be exploited by DNA polymerase inhibitors.
Both PAA and (1) are taken up to similar 
extents in HSV-1 infected cells, (1) being taken up 
slightly more readily than PAA, thus confirming that 
the difference in the activities of these two compounds 
is a consequence of differences in HSV-induced DNA 
polymerase inhibition alone, rather than due to 
differences in their cellular uptake. Indeed, the 
uptake of (1) compares favourably with PAA, possibly 
due to the tetrazole group's similarity to some 
nucleoside bases or perhaps histidine, for which there 
may be other transport mechanisms.
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CHAPTER 4 
INFLUENZA VIRUSES
4.1 METHODS
4.1.1 Virus Stocks
Influenza A/X49 (H3N2) , recombinant; [A/England/ 
864/75 X A/PR/8/34] was a gift from Dr. N. J. Dimmock, 
et al., Department of Biological Sciences, University of 
Warwick, Coventry, U.K. Influenza A/X31 (H3N2),
recombinant; [A/PR/8/34 (H1N1) X A/Hong Kong/1/68
(H3N2)], influenza A/RI5 (H2N2) [A/RI/5+/57] and
influenza A/WS (H1N2) [A/WS/33] were gifts from
Dr. K. Katrak, Roche Products Limited, Welwyn Garden 
City, U.K.
Abbreviations: PR = Puerto Rico, WS = Wilson Smith.
4.1.2 Preparation of RNA Transcriptase Assay 
Virus Stocks
The influenza A/X49 strain was used for the 
preparation of the enzyme assay stocks and was grown 
in the allantoic sacs of fertile hen's eggs essentially 
as described by Kelly and Dimmock (1974) . Eleven-day 
old embryonated hen's eggs were inoculated with 
infected allantoic fluid (0.1 ml of a 10-3 dilution in 
PBS). The eggs were incubated (33°C/48 hours) and then 
chilled (~20°C/2 hours). The allantoic fluid was
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collected and centrifuged (3000 r.p.m./20 minutes) to 
remove unwanted egg membranes; from this point onwards 
all procedures were carried out at 0-4°C. The 
supernatant was removed and the virus was pelleted by 
centrifugation (21 000 r.p.m./90 minutes, 6 x 300 ml 
rotor). The supernatant was discarded and the virus 
pellet allowed to soak overnight in PBS. The virus pellet 
was then resuspended in PBS (10 ml) and centrifuged 
(2500 r.p.m./lO minutes) before application onto a 
velocity gradient of 15-45% (w/v) sucrose in buffer 
(60 ml, 10 mM Tris-HC1, 150 mM NaCl, pH 7.4) and 
centrifuged (22 000 r.p.m./l hour, 3 x 65 ml swing-out 
rotor). The diffuse virus band was collected by 
bottom puncture and the sucrose diluted with PBS and 
layered onto an equilibrium gradient of 30-70% (w/v) 
sucrose in buffer (60 ml, 10 mM Tris-HC1, 150 mM NaCl, 
pH 7.4) and centrifuged (20 000 r.p.m./overnight,
3 x 65 ml swing-out rotor). The virus band was 
collected, diluted with PBS and the virus pelleted by 
centrifugation (30 000 r.p.m./2 hours, 8 x 50 ml rotor). 
The supernatant was discarded and the pellet allowed to 
soak overnight in PBS before resuspending the virus in 
buffer (3 ml, 400 wM Tris-HC1, pH 8.0) and frozen as 
aliquots at -70°C and thawed once prior to use.
4-!-3 Influenza RNA Transcriptase Assay
RNA dependent RNA polymerase (transcriptase) 
activity was assayed in a 200 yl reaction mixture
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containing 50 mM Tris-HC1, pH 8.0, 5 mM Mg(CH3C02)2,
150 mM KCl, 5 mM dithiothreitol, 0.4 mM ApG, 0.25%
(v/v) Nonidet P-40, 0.4 mM each of ATP, CTP, GTP 
and [3H]-UTP (5 pCi) and purified virus (10 pi).
Mixtures were kept at 4°C until addition of virus, 
which was followed by incubation for 1 hour at 30°C. 
Reactions were stopped by the addition of 200 pi of 
saturated sodium pyrophosphate solution followed by 
cold TCA (2 ml, 10% w/v) and the mixtures kept on ice 
for 2 hours after thorough agitation. Precipitated 
material was collected on Whatman GF/C discs which 
were wetted with cold 10% (w/v) TCA, washed with
2 x 10 ml cold 10% (w/v) TCA, 1 x 10 ml ethanol,
1 x 5 ml ether and oven dried before counting in a 
toluene-based scintillant. Semi-logarithmic dose- 
response curves were drawn for each compound and ID^g 
values determined.
4.1.4 Plaque Reduction Assay
Madin-Darby canine kidney (MDCK) cells were 
seeded onto 5 cm plastic culture dishes (in duplicate) 
at 3 x 10® cells/plate. Cells were grown at 37°C in 
a humidified atmosphere of 5% C02 in air until 
confluent in maintenance medium (DMEM supplemented with 
10% NCS, 4 mM L-glutamine, and penicillin/streptomycin 
(50 units/ml). The confluent monolayers were washed with 
PBS and aspirated to dryness. Virus suspension 
(100 pi, 60 p.f.u.) was added to the cell sheets and
Compound
Influenza RNApol pKd Z n ^ pK^ Mg2* Plaque reduction(%) 
_______'O s o l/M __________________________ at 500 j jM
P AA
°* ? ,0 H  
CCHj K
mo °H
350 5-5 4 8 8
1
?,OH
Y c ^ p ' oh 275 5 6 4 4 25
2
r \  ? ,0H
550 4 6 <4 0
3
N=N O
/ \ ¡¡.oh
C H a C H ^ ^ C H a P .OH >1000 '4 <4 -
4
t — N Q
\  ° - oh
h n . / ch . ^ 0h 580 4 7 - 5
5 >1000 <4 - -
6
N— N N— N 
H H
>1000 <4 - -
7
0 CH’ < oh >1000 <4 - -
8 ^ > ch3ch3c:° h >1000 <4 - -
9
N— N 0
^CHjP-O-Adenosinea >1000 - - 30
j t ~ \  °10 f i  -O-Th,midin« 
H 0 «
>1000 - - -
Table 4.2.1 Structures of heterocyclic compounds and ID^q , pK^, values obtained.
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left for 15 minutes at room temperature, followed by 
the addition of drug dilution in PBS (300 yl) and the 
cell sheets left for a further 45 minutes at room tem­
perature. Cells were then overlaid with an agar medium 
(3.6 ml) containing 0.1% BSA, 2.5 yg/ml crystalline 
trypsin and 0.1% DEAE Dextran. The plates were 
incubated at 33°C for 4-6 days, stained with neutral 
red and the plaques counted. The percentage of 
plaque inhibition relative to the infected control (no 
drug) plates was determined for each drug concentration 
and the 50% inhibitory concentration (ID^q) values were 
calculated from dose response curves.
4.2 EXPERIMENTAL AND RESULTS
4.2.1 Effect of Heterocyclic PyrophosphateAnalogues on Influenza RNA TranscriptaseActivity
Table 4.2.1 shows the ID,-q values of compounds 
tested and their zinc ion stability constants. Of the 
heterocyclic phosphonates tested, 5-(phosphonomethyl)- 
1 (H)-tetrazole (1) was the most active with an ID^q of 
275 yM, under the same assay conditions PAA has an 
ID50 ^50 uM* 5-(Phosphonoethyl)-1 (H)-tetrazole (2) 
and 3-(phosphonomethyl)-1,2,4-triazole (4) were weaker 
inhibitors of the transcriptase.
The nucleoside-5' esters of (1) were inactive 
as inhibitors of influenza RNA transcriptase, as were 
all compounds with low zinc ion stability constants
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(pKd , s 4) .
4.2.2 Effect of Heterocyclic Phosphonates on InfluenzaA/X49 Replication
Compounds (1), (2), (4), (9) and PAA were
evaluated for antiviral activity in MDCK cells by a 
simple plaque reduction assay, the results of which are 
presented in Table 4.2.2(i).
Compound•
% Plaque Number
1000 yM 500 yM 250 yM
PAA 67 92 100
(1) 55 75 84
(2) 100 100 100
(4) 89 95 100
(9) 57 70 81
Table 4.2.2(i) Plaque reduction by heterocyclic phosphonates against influenza A/X49 in MDCK cells
Compounds which were active were so at 
concentrations at least five times greater than 
required for inhibition of the RNA transcriptase, 
again reflecting the poor uptake of these compounds, 
also observed in studies with herpesviruses in Vero 
cells (Chapter 3). Adenosine-5(5-phosphonomethyl)- 
1 (H)-tetrazole (9) however, was more active in tissue 
culture than against the transcriptase enzyme.
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4.2.2 Effect of Heterocyclic Phosphonates on InfluenzaA/X49 Replication
Compounds (1), (2), (4), (9) and PAA were
evaluated for antiviral activity in MDCK cells by a 
simple plaque reduction assay, the results of which are 
presented in Table 4.2.2(i).
Compound - % Plaque Number1000 viM 500 pM 250 pM
PAA 67 92 100
(1) 55 75 84
(2) 100 100 100
(4) 89 95 100
(9) 57 70 81
Table 4.2.2(i) Plaque reduction by heterocyclic phosphonates against influenza A/X49 in MDCK cells
Compounds which were active were so at 
concentrations at least five times greater than 
required for inhibition of the RNA transcriptase, 
again reflecting the poor uptake of these compounds, 
also observed in studies with herpesviruses in Vero 
cells (Chapter 3). Adenosine-5 1-(5-phosphonomethyl)- 
1 (H)-tetrazole (9) however, was more active in tissue 
culture than against the transcriptase enzyme.
Inhibitor concentration ( / j M )
Fig. 4.2.3(i) Inhibition of plaque formation bystrains of influenza virus A in MDCK cells by PFA, A/X49 (A), A/X31 (X),A/R15 (•), A/WS (o).
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Inhibitor concentration (>uM)
Fig. 4 . 2 . 3 ( H )  Inhibition of plaque formation by strains of influenza virus A  by
5 - (phosphonomethyl)- 1 ( H )-tetrazole, 
A / X 4 9  ( A ) , A/X31 ( X ) , A / R 1 5  ( e ) ,
A / W S  (o).
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The toxicity of these compounds to MDCK cells 
was tested at concentrations up to 8 mM for 3 days and 
any observable cytotoxicity noted. Results are presented 
in Table 4.2.2(ii).
Compound
Concentration (pM)
8000 pM 4000 pM 2000 pM 500 pM 250 pM
PAA + ( + ) - - -
(1) ( + ) - - - -
(2) ( + ) - - - -
(4) - - - - -
(9) - - - - -
PFA + ( + ) - - -
Table 4.2.2(ii) Cellular toxicity of pyrophosphateanalogues, - no observable cytotoxitity, (+) slight cell damage observable,+ cellular cytotoxicity apparent.
4 • 2.3 Effect of PFA and 5-(Phosphonomethyl)-1 (H)-tetrazole (1) on the Replication of Various Strains of Influenza A Virus in MDCK Cells by Plaque Reduction Assay
Figures 4.2.3(i) and 4.2.3(ii) show the dose 
response curves obtained when PFA and (1) were 
evaluated for antiviral activity against a number of 
different strains of influenza A virus in MDCK cells. 
The values obtained are presented below (Table
4.2.3) .
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Influenza Virus Strain PFA
ID50(yM)
(1)
A/X49 380 > 1000
A/X31 340 440
A/RI5 270 600
A/WS 85 560
Table 4.2.3 Inhibition of influenza A strains in MDCK cells by PFA and (1).
4.3 DISCUSSION
The assay system used in this study utilised 
detergent-disrupted virus preparations. Virus treated 
in this manner makes available an RNA transcriptase 
activity which can be assayed in the presence of 
adenylyl-(3'-5 ' ) -guanosine (ApG) as primer and using 
endogenous RNA as template. The reactions carried out by 
this transcriptase complex, containing PA, PB^ , PB2 and 
other components, has not yet been fully characterised 
and the enzyme kinetics found to be complex (Cload, 1983). 
For the purposes of this study, ID^q values are 
regarded as concentrations required to inhibit the 
whole transcriptase complex by 50% and cannot be 
related to specific stages in the polymerisation reaction.
5-(Phosphonomethyl)-1(H)-tetrazole (1) was the 
most effective of the compounds studied, inhibiting 
influenza A/X49 RNA transcriptase activity by 50%
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at a concentration of 275 yM. Under the same conditions 
PAA inhibited the RNA transcriptase by 50% at 350 pM.
The increased activity of (1) against this enzyme 
appears to be related to its zinc ion binding ability, 
a small increase in pKj, being exhibited by (1) (pKd ,= 
5.6) over PAA (pK^, = 5.5). Furthermore, the observed 
IDgg values for compounds (1) — (8) are close to those 
that could be predicted from Fig. 1.3.6.3(i), again 
implicating zinc as having an essential role in these 
enzymes.
Although magnesium ions are essential for 
the RNA transcriptase activity, these compounds do not 
exert their inhibition by complexing with magnesium 
ions and removing them from solution, since the 
concentration of these ions in the polymerisation 
reactions is 5 mM, while compounds are active at 
concentrations at least ten-fold lower.
The magnesium binding properties of some of
2 +the active compounds were studied, the pK^, (Mg )
values being obtained by the same gel-filtration and
2 +atomic absorption method as used for pK^, (Zn ) 
determinations. The compounds were indeed found to be 
poor chelators of magnesium ions compared to zinc 
ions. It is interesting to note that while (1) forms 
slightly stronger zinc complexes than PAA, its 
magnesium binding ability seems to be significantly 
lower. This is most likely to be due to the 
replacement of the oxygen ligand, a "hard" base
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(Pearson, 1968), in PAA by the "softer" heterocyclic 
nitrogen ligand of (1), reducing the tendency of 
(1) to form complexes with "hard" metal ions such as 
magnesium (this is discussed further in Section 5.5).
5-(Phosphonomethyl)-1(H)-tetrazole (1) was 
a more effective inhibitor of influenza A/X49 RNA 
transcriptase than PAA but a much less effective 
inhibitor of calf thymus DNA polymerase a (ID,-0 =
> 1000 yM) and therefore shows much greater selectivity 
in its enzyme inhibition, indeed PAA inhibits the RNA 
transcriptase at higher concentrations than required 
to inhibit DNA polymerase a; a property not 
exhibited by any of the heterocyclic compounds studied.
Little inhibition of influenza A/X49 replica­
tion in tissue culture plaque reduction tests was 
observed with most compounds, 5-(phosphonomethyl)-1(H)- 
tetrazole (1) was however, more active than PAA, 
inhibiting plaque formation by 25% at a concentration 
of 500 pM. The only other compound with comparable 
activity was the adenosine-5' ester (9) which inhibited 
plaque formation by 30% at 500 viN despite being inactive 
as an inhibitor of the viral RNA transcriptase. 
Nucleoside-5' esters of (1) showed similar patterns 
of inhibition in the herpesvirus assays, and is 
presumed to be due to hydrolysis to give free phosphonates 
in tissue culture systems.
None of the heterocyclic pyrophosphate 
analogues studied were toxic to MDCK cells after
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3-4 days at concentrations up to 4 mM, four times 
greater than the highest concentration of test 
compound used in tile plaque reduction assays. Both 
PAA and PFA were more toxic than the heterocyclic 
compounds at the higher concentrations, probably 
due to the greater susceptibility of cellular DNA 
polymerase a to these compounds and also the lower 
acidity of compounds (4) and (9).
Varying sensitivities of various strains 
of herpesviruses to pyrophosphate analogues has been 
noted in this study and in a number of other reports.
For example, strains of HSV-1 and HSV-2 have been 
isolated which show complete resistance to PAA and 
PFA, and this resistance has been correlated with 
changes in the DNA polymerases induced by these 
viruses (Eriksson and ¿Jberg, 1979; Hay and Subak-Sharpe, 
1976; Honess and Watson, 1977). Strains which are 
not resistant to these compounds can also show 
variation in susceptibility to these compounds, and 
the DNA polymerases of several strains of HSV-1, when 
inhibited with PFA, show a range of ID^q values from
0.4-3.5 yM (Eriksson and ttberg, 1979; Helgstrandet al. ,
1978) .
The sensitivities of various strains of 
influenza virus A to different concentrations of PFA 
and (1) revealed that the A/WS strain was the most 
sensitive and A/X49 the least sensitive strain tested. 
Variation in ID,-0 values obtained was not great
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amongst strains A/X31, A/RI5 and A/X49, however, the 
A/WS strain was significantly more sensitive to PFA 
in particular. The reason for the difference in 
sensitivity is not known, no studies have been 
reported on the differences in the sensitivities to 
pyrophosphate analogues of RNA transcriptase 
enzymes from influenza viruses, nor on influenza virus 
multiplication, although it has previously been observed 
that the effect of the antiviral drugs rimantadine and 
ribavirin in combination on influenza virus replication 
in cell culture is dependent on the strain of virus 
used (Hayden, et al. , 1980) . Previous studies have also 
shown that there is considerable strain variability in the 
amantadine susceptibility of influenza viruses, and 
this has been reported to decrease with increasing passage 
level in animals (Tisdale and Bauer, 1975). In the 
present study the more contemporary strain of influenza A 
used, influenza A/RI5 was no more sensitive to the 
pyrophosphate analogues than the other strains.
Amantadine resistance is a stable genetic 
characteristic that relates to the gene coding for the 
M (matrix) protein (Lubeck, et al. , 1978), and variation 
in the three polymerase protein genes PA, PBi, and PB2, 
may potentially play an important role in susceptibility 
to pyrophosphate analogues, as well as in host range 
and virulence, although the extent of this has not yet 
been determined.
The differences observed in tissue culture
systems may well be due to factors other than 
sensitivities of the various RNA transcriptases to 
these compounds, for example, cellular penetration 
in cells infected with different strains may vary 
due to different viruses affecting cell membranes and 
cellular functions differently. Studies on isolated 
RNA transcriptase systems are obviously required 
to clarify the events leading to variation in 
susceptibility to pyrophosphate analogues.
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CHAPTER 5 
THIOPHOSPHONATES
5.1 SYNTHETIC CHEMISTRY
5.1.1 Sources of Chemicals 
Monothiopyrophosphate (12) and bisthiopyro-
phosphate (13) were gifts from Dr. P. M. Cullis, 
Department of Chemistry, University of Leicester,
U.K. Thio-analogues of PAA, PFA and methylenebis- 
phosphonate were prepared as described in Section 5.2 
from the corresponding trimethylsilyl esters which 
were gifts from Dr. S. Masson, University of Caen, 
France. Trimethylsilyl esters of thiophosphonates were 
synthesised as described in Appendix IV. 0-Ethyl 
phosphonothioacetate (20) and ethyl phosphonodithio- 
acetate (21) were gifts from Dr. S. Masson, and were 
prepared as described in Appendix V. The thio-analogue 
of 5-(phosphonomethyl)-1(H)-tetrazole (1) was 
synthesised as described in Section 5.2.
5.1.2 Synthetic Routes
Diethyl esters of thiophosphonates can be 
prepared by Michaelis-Becker reaction of the 
corresponding chloroalkyl intermediates with diethyl- 
thiophosphite (Scheme II, Fig. 5.1.2(D). Diethylthio- 
phosphite is synthesised by reaction of commercially
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Fig. 5.1.2(i) The synthesis of thiophosphonates.
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available diethylchlorophosphite (diethylphosphoro- 
chloridite) with gaseous hydrogen sulphide in benzene 
according to Scheme I (Fig. 5.1.2(D). The final step 
in these synthetic routes involves dealkylation of 
diethyl thiophosphonates with ITMS, however more 
vigorous conditions are necessary for the dealkylation 
of thiophosphonates than required for dialkyl phosphonates, 
generally requiring temperatures of 100°C and longer 
reaction times (Scheme III, Fig. 5.1.2(D). Removal 
of the extremely hydrolytically labile trimethylsilyl 
groups requires stirring the compound in aqueous 
triethylammonium bicarbonate (pH 8.7-9.5) in order to 
avoid partial desulphuration which can occur at lower 
pH and in the presence of iodine and water. The 
presence of bromine and water has indeed been used to 
induce the desulphuration of bisthiopyrophosphate 
(Cullis, 1983) .
Triethylammonium salts of the thiophosphonates 
can then be purified by DEAE-Sephadex ion-exchange 
chromatography which satisfactorily separates the 
thiophosphonates from partially or fully desulphurised 
by-products.
5-(Thiophosphonomethyl)-1(H)-tetrazole (18) 
was thus prepared according to Fig. 5.1.2(ii) from the 
N-protected 5-(chloromethyl)-tetrazole also used in 
the synthesis of the tetrazole phosphonates as 
described in Section 2.
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Fig. 5.1.2(11) Route to 5- (thiophosphonomethyl)- 
1(H)-tetrazole (18).
Monothiopyrophosphate (12) and bisthiopyrophosphate 
(13) had been prepared as previously described 
(Cullis, 1983) as shown in Fig. 5.1.2(iii).
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Fig. 5.1.2(iii) Synthesis of thiopyrophosphates.
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5.2 EXPERIMENTAL
Diethylthiophosphite
Diethylthiophosphite was prepared according 
to the method of Krawiecki and Michalski (1960). A 
solution of diethylchlorophosphite (16 ml, 0.1 mol) 
and pyridine (8 ml, 0.1 mol) in benzene (75 ml) was 
stirred and hydrogen sulphide passed slowly through 
for 4 hours while the temperature was maintained at 
5°C. Pyridinium hydrochloride was filtered off and 
the filtrate washed with 2 x 25 ml ice-cold water, 
dried and evaporated in vacuo. The residue was 
distilled and diethylthiophosphite obtained (12.1 g,
78%) b.p. 90-92°C/l8 mm, 3lP n.m.r. (CDC13) 6 69.4 p.p.m.
5-(Thiophosphonomethyl)-1(H)-Tetrazole (18)
Sodium hydride (50% suspension in oil, 0.2 g,
4 mmol) was added to a solution of diethylthiophosphite 
(0.66 g, 4 mmol) in diethyl ether (20 ml) and the 
mixture heated under reflux for 30 minutes. The 
reaction was cooled to 0°C and 2-(benzyloxymethyl)-5- 
(chloromethyl)-tetrazole (1.2 g, 5 mmol) was added 
dropwise with stirring, which was continued for 
48 hours. The ether was then removed in vacuo and 
the residue purified by silica gel chromatography 
(solvent A) to give diethyl 2-(benzyloxymethyl)-5- 
(thiophosphonomethyl)-tetrazole (1.3 g, 73%), n.m.r. 
(CDC13) 6 1.3 (6H, t, J = 6 Hz), 3.75 (2H, d, 2Jp_H =
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18 Hz), 4.15 (4H, m, J = 7 Hz), 4.6 (2H, s), 5.9 (2H, s),
7.3 p.p.m. (5H, m), 31P n.m.r. (CDClj) 6 89 p.p.m.,
CIMS m/z 357 [M + H]+.
Diethyl 2-(benzyloxymethyl)-5(thiophosphono- 
methyl)-tetrazole (500 rag, 1.4 mmol) was then stirred 
for 3 hours in a solution of trifluoroacetic acid (43 g,
380 mmol) and thioanisole (8.7 g, 70 mmol) at room 
temperature. Evaporation of excess TFA and thioanisole 
in vacuo afforded diethyl 5-(thiophosphonomethyl)-1(H)- 
tetrazole after purification by silica gel column 
chromatography (solvent C) (215 mg, 65%), 1H n.m.r.
(CDC13) 6 1.25 (6H, t, J = 6 Hz), 3.77 (2H, d,
? 31Jp_H = 18 Hz), 4.1 p.p.m. (4H, m,J = 7 Hz), P n.m.r.
(CDC13) 5 86.8 p.p.m., CIMS m/z 237 [M + H]+, 254
[M + NH4]+.
Diethyl 5-(thiophosphonomethyl-1(H)-tetrazole 
(150 mg, 0.6m mol) was heated in a sealed tube at 
100°C for 72 hours with iodotrimethylsilane (400 mg,
1.7 m mol). The silane was removed in vacuo and the 
residue treated with 2 x 10 ml of 0.25 M triethyl- 
ammonium bicarbonate (pH 8.7), the sample being lyophilised 
between each treatment. The product was purified by 
ion-exchange chromatography on a DEAE-Sephadex A25 column 
(1.5 x 45 cm, Et3NH+ form) eluted with a gradient of 
0.25-0.75 M triethylammonium bicarbonate (1.5 L, pH 8.7) 
to give 5-(thiophosphonomethyl)-1 (H)-tetrazole as the 
bis(triethylammonium)salt (40 mg, 18%), *H n.m.r. (D30)
6 1.3 (18H, t, J = 6.5 Hz), 3.5 (2H, d, 2Jp_H = 18 Hz) ,
136
4.15 p.p.m. (12H, g, J = 7 Hz), 3lP n.m.r. (D20)
6 59.9 p.p.m. analysis C, 38.52; H, 9.31; N, 21.5;
C,. H,nN,0oPS.H-O requires C, 40.53; H, 9.31; N, 21.0.14 JJ b £ .
Thiophosphonomethyl Phosphonate (15)
The silyl ester (3, Appendix IV, 0.5 g,
1 mmol) was stirred with 2 x 10 ml 0.25 M aqueous 
triethylammonium bicarbonate (pH 8.7), the sample 
being lyophilised between each treatment. The 
residue was purified by chromatography on a DEAE- 
Sephadex A25 ion-exchange column eluted with a 
gradient of 0-1.0 M triethylammonium bicarbonate to 
afford the triethylammonium salt of thiophosphonomethyl 
phosphonate (240 mg, 60%), which was then converted 
into the sodium salt using a Dowex 50 (H+ form) ion- 
exchange column to give the sodium salt of thiophos­
phonomethyl phosphonate (130 mg, 55%), 1H n.m.r.
(D20) 6 2.6 p.p.m. (2H, dd, 2Jp_H (0) = 20 Hz, 2Jp_H (S)
18 Hz), 3lP n.m.r. (D20) 6 57.55 (d), 18.15 p.p.m. (d), 
Jp = 8 Hz, analysis C, 4.96; H, 3.63; P, 25.9; 
CH^0^P^Na2!sH20 requires C, 4.90; H, 2.1; P, 25.28.
Methylene Bis-thiophosphonate (16)
Methylene bis-thiophosphonate was prepared 
as above from the corresponding silyl ester (£, 
Appendix IV) to give the bisfcriethylammonium) salt
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in 65% yield. 3H n.m.r. (D2O) 6 1.3 (18H, t, J = 6.5 Hz),
2.7 (2H, t, 2Jp_H = 16 Hz), 4.15 p.p.m. (12H, q,
J = 7 Hz), 3lP n.m.r. (D20) 6 60.3 p.p.m., analysis 
C, 37.1; H, 9.37; N, 6.71; P, 16.23; gHggl^O^S^HjO 
requires C, 37.2; H, 9.13; N, 6.68; P, 14.76.
Thiophosphonoacetic Acid (17)
Thiophosphonoacetic acid triethylammonium 
salt was prepared as described above from the silyl 
ester (j>, Appendix IV) in 50% yield from the DEAE- 
Sephadex A25 column. 3H n.m.r. (D20) 6 1.3 (9H, t,
J = 6.5 Hz), 3.0 (2H, d, 2J„ u = 18 Hz), 4.2 p.p.m.xr “ri
(6H, q, J = 7 Hz), 3lP n.m.r. (D20) 6 57.8 p.p.m.,
analysis C, 37.73; H, 7.66; N, 5.64; CgH^NO^PS
requires C, 37.34; H, 7.83; N, 5.44.
Thiophosphonoformic Acid (19)
The trimethylsilyl ester of thiophosphonoformic 
acid (500 mg, 1.4 mmol) was stirred in 5 ml of 0.5 M 
triethylammonium bicarbonate (pH 9.5) and after stirring 
for 15 minutes was immediately applied to a DEAE-Sephadex 
A25 column (EtgNH+ form, 1.5 x 50 cm) which was eluted 
with a gradient of 0.25-1.0 M triethylammonium bicarbonate 
(pH 9.5) to afford thiophosphonoformic acid as the 
triethylammonium salt (163 mg, 46%), 3lP n.m.r. (D20)
6 45.99 p.p.m., analysis C, 30.93; H, 8.28; N, 5.74;
P, 12.43; C7Hl8N04PS!5H20 requires C, 33.3; H, 7.59;
N, 5.55; P, 12.3.
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h o ' 'oh
1 2 5 > 5 0 0 > 5 0 0 5 7
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HO OH
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HO OH
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H O ,?  ? ,O H  
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? ,O HHO'PCH^ P'OHh o n? > 5 0 0  > 5 0 0  > 5 0 0 > 6
HO
HO
i s s nu
3 5 0  > 5 0 0  > 5 0 0
PAA ho^ ^ ' oh
° Ns u,OH'C CHoP,
HO OH
3 5 0
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‘CHjP'« .O H  
OH
2 7 5  2 2 0  > 5 0 0 5 6
N— N e.OH
OH 1 3 0 9 0  > 5 0 0 > 6
PFA
O * « .O H  
H < rC P 'O H 3 0 50
19 HO" OH 45 150
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EtO
j. ? .O H
’ CCIfaP.
'  OH > 5 0 0  > 5 0 0 nd.
21 s. „ y.oHE.S^^OH 4 0 0  > 5 0 0 od. 5 5
Structures of thiophosphonates and 
I D values obtained.
Table 5.3
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5.3 ANTIVIRAL ACTIVITIES OF THIOPHOSPHONATESEXPERIMENTAL AND RESULTS
5.3.1 Effect of Thio-analoques of Inorganic Pyrophosphate on Influenza A/X49 RNA Transcriptase Activity and HSV-1 (HFEM)DNA Polymerase Activity
Influenza A/X49 RNA transcriptase activity 
was assayed as described in Section 4.1.3. Table 5.3 
shows the ID,-0 values determined for pyrophosphate 
(11, 125 yM) , monothiopyrophosphate (12, 60 yM)
and bisthiopyrophosphate (13, 33 yM), derived from
the dose-response curves obtained (Fig. 5.3.1) against 
influenza A/X49 RNA transcriptase.
The compounds show a progressive (approximately 
two-fold) increase in antiviral activity upon the 
substitution of each phosphoryl bond with a thiophosphoryl 
bond, bisthiopyrophosphate (13) being four times more 
active than pyrophosphate (11) as an inhibitor of the 
RNA transcriptase.
HSV-1 (HFEM) DNA polymerase activity, assayed 
as described in Section 3.1.5, was unaffected by 
compounds (11), (12) and (13), (all ID50's > 500 yM) .
5.3.2 Effect of Thio-analoques of Methylenebis- phosphonate on Influenza A/X49 RNA Transcriptase Activity and HSV-1 (KOS) DNA Polymerase Activity
Methylenebisphosphonate (14) is devoid of
antiherpes and anti-influenzal activity, however its
thio-analogues show increasing activity against
influenza RNA transcriptase and increasing zinc ion
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Fig. 5.3.1 Inhibition of RNA transcriptase of influenza virus (A/X49) by mono-(u) and bisthiopyrophosphate ( A ) .
binding (IDj0 (15) > 500 yM, pKd,  ^6; ID5Q (16) = 
350 yM, pK^, > 6). No improvement in activity against 
HSV-1 (KOS) DNA polymerase activity was observed 
((14), (15), (16) ID5Q's > 500 yM).
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5.3.3 Effect of Thlophosphonoacetic Acid on Influenza A/X49 RNA Transcriptase Activity and HSV-1 (KOS) DNA Polymerase Activity
As shown in Table 5.3, replacement of a
phosphoryl bond by a thiophosphoryl bond in PAA has
a marked effect on the zinc ion stability constant
obtained (PAA pK., = 5.5, (17) pK^, > 6) and an
improved activity against influenza RNA transcriptase
activity. Thiophosphonoacetic acid has comparable
antiherpes activity to PAA, inhibiting the HSV-1
(KOS) DNA polymerase by 50% at a concentration of
16 yM.
5.3.4 Effect of 5-(Thiophosphonomethyl)-1(H)- Tetrazole (18) on Influenza A/X49 RNA Transcriptase Activity and HSV-1 (KOS)DNA Polymerase Activity
5-(Thiophosphonomethyl)-1(H)-tetrazole (18) 
shows similar increases in activity and zinc-binding 
to those obtained for thiophosphonoacetic acid (17) 
over PAA, and inhibited influenza A/X49 RNA transcriptase 
activity by 50% at a concentration of 130 yM (Fig.
5.3.4). An increase in activity against HSV-1 (KOS)
DNA polymerase was also observed, inhibition of this 
enzyme activity by 50% was caused by 5-(thiophosphono­
methyl) -1 (H) -tetrazole at a concentration of 90 yM.
5.3.5 Effect of Thiophosphonoformic Acid (19) on Influenza A/X49 RNA Transcriptase Activity and HSV-1 (KOS) DNA Polymerase Activity
Despite the increased zinc ion stability
%
 
E
nz
ym
e 
ac
tiv
ity
142
Fig. 5.3.4 Inhibition of RNA transcriptase of influenza A/X49 by 5-(phosphonomethyl)-1(H)-tetrazole (o) and 5-(thiophosphonomethyl)-1(H)- 
tetrazole ( a ).
constant of (19) over PFA, anti-influenzal and 
antiherpes activity was little affected, a slight 
increase in activity against HSV-1 (KOS) DNA polymerase 
being observed (ID5Q (19) = 9 uM, ID5Q PFA = 12 uM).
143
5.3.6 Effect of Thioacetate Analogues of PAAon Influenza A/X49 RNA Transcriptase Activity and HSV-1 (KOS) DNA Polymerase 
Activity
Two PAA analogues - O-ethyl phosphonothio- 
acetate (20) and ethyl phosphonodithioacetate (21) - 
were tested for antiviral activity and found to be 
weak inhibitors of the influenza RNA transcriptase 
activity, but were devoid of antiherpes activity.
5.4 31P N.M.R. MEASUREMENTS OF PYROPHOSPHATEAND BISTHIOPYROPHOSPHATE IN THE PRESENCE OF DIFFERENT METAL IONS
3 l P n.m.r. measurements were carried out at 
308 K and 36.44 MHz on a Bruker WH90 spectrometer, 
chemical shifts are recorded relative to H^PO^ (0 p.p.m.) 
Solutions of tetrasodium pyrophosphate or tetra- 
(triethylammonium)bisthiopyrophosphate (15 mg/ml) were 
prepared in 0.1 M triethanolamine hydrochloride buffer 
(pH 8.2), the latter being made up in water which had 
previously been passed down a Chelex 100 (1 x 10 cm) 
chelating column (Na+ form, Biorad Inc.) to remove 
contaminating metal ions. To the pyrophosphate or 
bisthiopyrophosphate solution (1 ml, 1 equiv.) was 
added a solution in deuterium oxide (also treated with 
Chelex 100, 1 ml) which contained (0.8 equiv.) magnesium 
chloride, zinc chloride or cadmium bromide. The
31solutions were mixed, adjusted to pH 8.2 and the P 
n.m.r. spectra were recorded (Fig. 5.4). Chemical
144
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shifts are presented in Table 5.4.
Metal P2°7 P2°5S2
None -6.045 29.693
Mg2 + -5.254 32.418
Zn2 + -4.839 21.849
Cd2+ -5.643 20.714
Table 5.4 1P n.m.r. chemical shifts (p.p.m.) of solutions of pyrophosphate and bisthio- pyrophosphate at pH 8.2 after the addition 
of metal ions.
5.5 DISCUSSION
The apparent importance of zinc ion chelation 
in the antiviral activities of some pyrophosphate 
analogues prompted the investigation of compounds which 
might exhibit markedly different chelating properties 
without gross modifications in the structures of 
parent compounds. One way in which this can be 
achieved is by replacing the phosphoryl bond of 
phosphonates with the thiophosphoryl bond to give 
thiophosphonates. Replacement of an oxygen atom by 
the less electronegative and more polarisable sulphur 
atom has little effect on the molecular dimensions of 
the compound apart from the increased size of the 
sulphur atom and the PS bond being slightly lengthened 
and weaker than the PO bond (Saenger and Ekstein,
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1970; Moritani, et al. , 1971). The thiophosphonates 
synthesised and tested, however, show marked increases 
in antiviral activity over the phosphono-analogues 
and also large increases in zinc ion stability constants 
are observed.
The most potent compound tested was bisthio- 
pyrophosphate (13), containing two thiophosphoryl bonds, 
which inhibited influenza A/X49 RNA transcriptase 
activity by 50% at a concentration of 33 yM. The 
series of pyrophosphate (11), monothiopyrophosphate (12) 
and bisthiopyrophosphate (13) show a progressive and 
approximately two-fold increase in anti-influenzal 
activity for each thiophosphoryl bond substituted. 
Bisthiopyrophosphate was thus four times more active 
than inorganic pyrophosphate against this enzyme and 
has the greatest zinc ion stability constant of the 
series. Similar patterns are observed for the series 
of methylenebisphosphonates (14)-(16). Although 
methylenebisphosphonate has no antiviral activity, 
replacement of the phosphoryl group with a thiophosphoryl 
group results in some inhibition of influenza A/X49 
RNA transcriptase activity. Similar increases in 
antiviral activity and zinc binding are observed for 
thio-analogues of 5-(phosphonomethyl)-1(H)-tetrazole 
(1), PAA and PFA.
The fact that mono- and bisthiopyrophosphate 
show considerable antiviral activity in tissue culture 
against influenza A/X49 is also of importance (Hutchinson,
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et al., 1985). Pyrophosphate is involved in many 
enzymic reactions in host cells and some pyrophosphate 
analogues such as dichloromethylene bisphosphonate are 
cytotoxic (Cload and Hutchinson, unpublished observations, 
1983). It is therefore significant that the mono- 
and bisthiopyrophosphates do not appear to be cytotoxic 
to MDCK cells after 36 hours at concentrations at which 
they cause an appreciable reduction in the haemagglutinin 
titre of influenza virus A/X49. Mono- and bisthiopyro- 
phosphate also cause significant inhibition of plaque 
formation at 50 pM.
The Principle of Hard and Soft Acids and 
Bases (HSAB, Pearson, 1968) can be used to explain the 
differences in metal ion chelating properties of the 
phosphonates and their thio-analogues. The so-called 
'hard' bases (Table 5.5(D) are donor atoms of high 
electronegativity, of low polarisability and hard to 
oxidise. 'Soft' bases are larger, of low electronegativity, 
high polarisability and easy to oxidise.
Hard Soft
h 2o , OH", F- , Cl_ 
through 0- (P(0)-0-, 
RO-, RCOO-)
ROH, R20
n h 3, rnh2, n 2h4
CN-, RNC, CO 
through S (RS , R2S, 
r 3p , r 3a s , ( r o ) 3 p ,
I-, SCN-, S2032-
Intermediate
RSH)
Amines binding through N (ranging from primary to tertiary)
Table 5.5(i) Hard and soft bases (ligands) relevant to biological systems.
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The softness of a ligand can therefore be 
regarded as describing the looseness with which they 
hold their valence electrons. The classification of 
Lewis acids (Table 5.5(ii)) shows that the 'hard' acids 
are acceptor atoms of small size, high positive charge 
and lacking unshared electron pairs in their valence shell 
(not all these properties need to be possessed by any 
one acid). These properties lead to high electronega­
tivity and low polarisability.
Hard Soft
H+, Li+, Na+ , K+ Cu+, Ag+, Hg+
.. 2 + 2 + Mg , Ca , Mn2 + Pd2+, Cd2+, Pt2+,
A 1 3+ 3 + A1 , Fe , As3 +
Intermediate
_ 2 + Fe , Co2+, Cu2+, Zn2+
Table 5.5(ii) Hard and soft acids (metal ions) relevant to biological systems
'Soft' Lewis acids are generally larger acceptor atoms 
of low positive charge and containing unshared pairs 
of p or d electrons in their valence shell. The 
Pearson rule is that 'hard' acids (in this case metal 
ions) bind to hard bases (ligands) and 'soft1 acids 
prefer to bind 'soft* bases.
On the Pearson 'hard and soft' acid and base 
scale, zinc ions can be classified as 'intermediate- 
soft' and hence should form complexes with both hard
149
and soft ligands. Indeed, as shown by the complexing 
characteristics and in vivo roles of some essential 
metal ions (Table 5.5(iii)) nitrogen and sulphur 
ligands are preferred to oxygen as donor atoms 
(Ainscough and Brodie, 1976).
The thiopyrophosphates (12) and (13) contain 
a potential soft ligand (sulphur) and this can explain 
why these compounds are good chelators of zinc ions 
and therefore good inhibitors of the RNA transcriptase 
activity of influenza viruses. Further evidence in 
support of this type of zinc ion chelation through 
sulphur comes from the observed '^1P n.m.r. shifts of 
bisthiopyrophosphate in the presence of various metal 
ions. It was of interest to determine whether zinc ions
coordinated to the oxygen or sulphur ligands in bis-
31thiopyrophosphate. P n.m.r. measurements (Table 5.4 
and Fig. 5.4) show that when magnesium, zinc or cadmium 
ions were added to a solution of pyrophosphate in 
triethanolamine buffer at pH 8.2, the pH of the RNA 
transcriptase assay, only small shifts (^  1 p.p.m.) 
of the '^1P signal occurred, presumably due to the 
formation of complexes with the metal ions coordinated 
to the oxygen atoms of the pyrophosphate.
In the case of bisthiopyrophosphate at pH 8.2, 
addition of a 'hard1 metal ion such as magnesium 
produced a downfield shift of less than 2 p.p.m., 
addition of softer metal ions (cadmium or zinc) 
however, produced large shifts in the P n.m.r.
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signal of 8-9 p.p.m. Since cadmium ions have been shown 
to complex with sulphur in nucleoside thiophosphates 
(Jaffe and Cohn, 1978; Pillai, et al. , 1980) , the 
n.m.r. studies suggest that zinc ions coordinate to 
bisthiopyrophosphate through sulphur. Furthermore, 
magnesium ions are known to coordinate only to oxygen in 
phosphorothioates (as determined by x-ray structural 
analysis for diethyl 0,O-phosphorothioate (Schwalbe, 
et al. , 1973)) confirming that magnesium ion chelation 
is unlikely to be of importance in the antiviral action 
of these compounds.
Magnesium is therefore likely to form a chelate 
ring of structure I (Fig. 5.5(1)) and cadmium (and 
therefore zinc) likely to form the probably stronger 
chelate II.
o O
A - A / A Y / °
v . _ /  s
o O r!
\ d 2¡—  s /  o
[) (Zn2*)n (i d
.5 (i) Possible chelates of bisthiopyrophosphatiwith magnesium ion (I) or cadmium andzinc (II)
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If this method of coordination also occurs at the 
essential zinc ion in the transcriptase of influenza 
virus A, this may account for the difference in 
inhibitory activity between inorganic pyrophosphate 
and its thio-analogue.
Thiophosphonates in general do not, however, 
show any great improvement over the corresponding 
phosphonates in their antiherpesvirus activity, with 
similar ID,-q values being obtained for PAA, PFA, 
thiophosphonoacetic acid, and thiophosphonoformic acid. 
Only 5-(thiophosphonomethyl)-1(H)-tetrazole (18) shows 
improved activity against HSV-1 (KOS) DNA polymerase, 
inhibiting this enzyme by 50% at a concentration of 
90 yM.
The reason for the general increase in 
antiviral activity of the thiophosphonates against 
influenza viruses only is unknown. One possibility, 
however, is differing roles for zinc ions in viral 
DNA and RNA polymerases. The most likely function of 
enzyme bound zinc in polymerase enzymes is generally 
considered to be interaction with the 3'-hydroxyl 
of the growing end of the DNA and its activation 
for nucleophilic attack on the «-phosphate of the 
incoming nucleoside triphosphate (NTP) (Fig. 5.5(ii)) 
while magnesium ions coordinate via a bidentate 
S-y-Mg-NTP complex on the incoming triphosphate 
(Sigman, et al. , 1972; Springgate, et al. , 1973;
Mildvan and Leob, 1979; Eckstein, 1983).
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Fig. 5.5(ii) Active site of a polymerase enzyme showing possible role of zinc.
An enzyme bound zinc atom even if merely in 
close proximity to the pyrophosphate binding site of 
the polymerase, is likely to have an influence on 
pyrophosphate-like compounds, particularly those 
likely to bind strongly to zinc ions such as 
bisthiopyrophosphate coordinating via two 'soft' 
sulphur ligands. 5-(Thiophosphonomethyl)-1(H)-tetrazole 
contains a soft sulphur ligand and a heterocyclic 
nitrogen ligand, which is considered to be softer than 
oxygen on the HSAB scale. Indeed zinc in metallo- 
enzymes is often bound to the heterocyclic nitrogen
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atoms of histidine or cysteinyl sulphur atoms. It 
should be remembered, however, that the coordination 
of enzyme bound zinc to atoms of amino acids in the 
protein is likely to affect its overall hardness or 
softness (Hutchinson, 1985) and its chelating properties 
are therefore likely to be altered. Thus, a zinc ion 
coordinated to oxygen ligands is likely to behave 
differently towards chelating agents when compared to 
a zinc ion bound by nitrogen or sulphur. It could 
reasonably be expected that the stronger the 
a-electron donation from the ligand to the metal, the 
weaker the Lewis acidity of the metal centre. Ligands 
such as imidazole which are both a-donors and ir-acceptors 
may 'tailor' the metal ioris Lewis acid character by the 
degree of ir-acceptance. One reason for the differences 
in sensitivities of various strains of influenza A 
virus to pyrophosphate analogues (Chapter 4) could be 
differences in the amino acid residues holding zinc 
in the enzyme active site, creating zinc ions of 
slightly different degrees of softness, and therefore 
different degrees of sensitivity to such zinc chelating 
agents.
The presence of zinc ions in the pyrophosphate 
'well' of polymerase enzymes has not been established, 
however, it is interesting to note that unlike DNA 
polymerases, which appear in general to contain only 
one zinc atom per molecule (Mildvan and Leob, 1979) , many 
R’JA polymerases contain multiple zinc ions, despite
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single initiation and elongation sites. This suggests 
multiple roles for zinc ions, including purely 
structural ones, and could be a reason for the 
observed greater susceptibility of viral RNA 
polymerases to zinc chelating pyrophosphate analogues.
One drawback in the development of pyrophos­
phate analogues as antiviral agents with clinical 
potential has been the tendency of such compounds to 
accumulate in bones and teeth, despite the fact that 
such properties are not known to have any deleterious 
effects. This is probably due to the ability of 
pyrophosphate analogues to chelate 'hard' metal ions 
such as calcium. Since sulphur ligands to not appear 
to bind with any strength to hard metal ions like 
magnesium, it is likely that if the oxygen ligands in 
pyrophosphate analogues can be replaced by softer 
ligands such as nitrogen and sulphur then the 
accumulation of these compounds in bones and teeth 
could be eliminated.
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A P P E N D IX  I
S O U R C E S  OF M A T E R IA L S
A d e n o s i n e - ( 3 1- 5 ' ) - g u a n o s i n e S i g m a  ( L o n d o n )  C h e m i c a l  C o . ,  
P o o l e ,  D o r s e t ,  U . K .
B e n z y l c h l o r o m e t h y l  e t h e r F l u k a  A G ,  G . F . R .
B o v i n e  p a n c r e a t i c  D N a s e  I S i g m a  ( L o n d o n )  C h e m i c a l  C o . ,  
P o o l e ,  D o r s e t ,  U . K .
C a l f  t h y m u s  DNA p o l y m e r a s e  I P h a r m a c i a  F i n e  C h e m i c a l s ,  
U p p s a l a ,  S w e d e n
C e l l u l o s e  F 2 S 4  TL<-- P-*-a t e s E .  M e r c k ,  D a r m s t a d t ,  G . F . R .
C h r o m a t o g r a p h y  p a p e r  ( 3MM) W h a tm a n  L t d . ,  M a i d s t o n e ,  
K e n t ,  U . K .
DEAE C e l l u l o s e  DE52 W h atm an L t d . ,  U . K .
DEAE S e p h a d e x  A - 25 P h a r m a c i a  F i n e  C h e m i c a l s ,  
U p p s a l a , S w e d e n
DMEM (X 1 0 ) F l o w  L a b o r a t o r i e s  L t d . ,  
I r v i n e ,  A y r s h i r e ,  U . K .
Dowex 5 0 ,  W, 1 S i g m a  ( L o n d o n )  C h e m i c a l  C o . ,  
P o o l e ,  D o r s e t ,  U . K .
G F/C  d i s c s  ( 2 . 5  cm) W h a tm a n ,  L t d . ,  U . K .
L - G l u t a m i n e F l o w  L a b o r a t o r i e s  L t d . ,  U . K .
3h 2o A m e r s h a m  I n t e r n a t i o n a l  P L C  
A m e r s h a m ,  B u c k s . ,  U . K .
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MDCK c e l l s F l o w  L a b o r a t o r i e s  L t d . ,  U . K .
NCS F l o w  L a b o r a t o r i e s  L t d . ,  U . K .
NEAA F l o w  L a b o r a t o r i e s  L t d . ,  U . K .
P e n i c i l l i n / S t r e p t o m y c i n F l o w  L a b o r a t o r i e s  L t d . ,  U . K .
P h o s p h o n o a c e t i c  a c i d S i g m a  ( L o n d o n )  C h e m i c a l  C o . ,  
P o o l e ,  D o r s e t ,  U . K .
P h o s p h o n o f o r m i c  a c i d S i g m a  ( L o n d o n )  C h e m i c a l  C o . ,  
P o o l e ,  D o r s e t ,  U . K .
S e p h a d e x  G - 10 P h a r m a c i a  F i n e  C h e m i c a l s ,  
U p p s a l a , S w e d e n
S i l i c a  g e l  6 0  ( 2 3 0 - 4 0 0  m e s h ) E .  M e r c k ,  G . F . R .
[ M e t h y l - H 3 ] t h y m i d i n e  
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Determining the Stability Constant
of a Metal Complex by Gel Chromatography
Lei us consider the formation of s 1:1 metal complex, ML, 
between a metal ion. M, and a ligand, L, according to eqn. 
( 1)
M + L -= ML (1)
For the sake of simplicity the charge on each species is not 
presented. The concentration stability constant, K ,  of the 
metal complex to be determined is given by
_ |ML] ,0,* MfLl
in which | ) represents the molar concentrations of M . L, and
M L
Various physiochemical methods, such as spectropho­
tometry, potentiometry, ion exchange methods, solvent ex­
traction methods, solubility methods, etc., have usually been 
employed to determine the concentration or the activity of M, 
L, or ML (f, 2). If one of these activities or concentrations is 
experimentally determined, the other two can be calculated, 
which enables us to evaluate the stability constant of the metal 
complex. For example, if [ML] is determined spectropho- 
tometrically, [M] and [L] will then be calculated by
(M] - |M), - [ML] 
|L) - |L], - [ML]
(3)
«)
in which [M], and [L],, the respective total concentrations of 
metal and ligand, are known.
In this paper we describe the principle of a new technique 
that is based on a gel chromatographic method (3-7) and has 
been increasingly applied to the characterization o f metal- 
ligand binding in the fields of inorganic (3), bioinorganic 
(3-17), and environmental (18) chemistry. This chromato­
graphic method has an advantageous and unique character­
istic over the conventional static (batchwise) equilibrium 
methods, in that [M] can be kept at a desired and predeter­
mined value, [M]o, throughout the experiment In other words, 
the equilibrium solution being examined is “buffered” with 
respect to metal ion, as well as with respect to hydrogen ion, 
and [ML] and [L] are then dynamically adjusted to  be in 
equilibrium with (M]o through the process of their chroma­
tographic migration. Therefore, [M] is not required to  be an­
alyzed experimentally and one can evaluate the stability 
constant of the metal complex according to eqn., (5) by the 
measurement of [ML] that is in equilibrium with (M]o.
K -, |ML)
' [M]0 ( |L | ,  -  [ML]) <5)
in which (M]o and [L], are known. The only undetermined 
value, [ML], can be calculated by ’
[ML| - [M|, - [M|.-o (A.s- A mJ - o A.»-6 (6)
where i l j i i  the observed absorbance, that is the aum of the 
respective absorbances, A m,  and /  m l due to free metal ion 
and metal complex, a and b are constants. Equations (5) and 
(6) indicate that [ML] or K  can be easily determined by 
measuring without any complicated analysis o f the ob­
served results. The atomic absorption method has been ex­
tensively and successfully employed to obtain reproducible 
results (8,10,18). Spectrophotometric methods are powerful 
if the absorption due to free ligand is negligible. The terms A.S
and A m0 in eqn. (6) can also be translated into any kind of 
physicochemical responses of ML and M, such as are based 
on radioactivity measurement (18).
The most important point in practice of this approach is 
how to keep the concentration of free metal ion at a constant 
level during the equilibrium experiment. It seems very diffj. 
cull or almost impossible to maintain [M] constant by the 
conventional static methods in which [M] is usually allowed 
to be dependent on [M], and [L], as indicated in eqns. (3) and 
(4). As will be mentioned below, however, a simple way to 
answer this requirement is by use of a gel chromatographic 
method which was first applied by Hummel and Dreyer (J) 
to the binding of 2,-cytidilic acid with ribonuclease and has 
subsequently been employed for estimation of the stability 
constants of various metal complexes (8, 9), with some pro­
gressive modification in practical procedure (8, II). This 
technique enables us to observe directly the formation of ML 
complex that is in equilibrium with metal ion of the specified 
concentration, [M]o.
. G e l  C h r o m a t o g r a p h y  o l  M e la l  I o n s  a n d  L i g a n d s
Before we deal with the detailed discussion on the gel 
chromatographic determination of the stability constant of 
metal complex let us review briefly the gel chromatographic 
behavior of two constituents, a metal ion and a ligand (8, 
19}.
Cel chromatography is a form of liquid chromatography 
capable of separating solute molecules according to their size, 
and its basic principle has been explained in terms of sieving 
effect or steric exclusion (4-7). The separation of the com- 
ponents in a sample solution is usually carried out on a column 
packed with a gel or other porous material. It is a general 
elution pattern, though not always if there are side effects such 
as adsorption, that the solute molecules are eluted in the order 
of decreasing molecular size.
Although it was first applied mostly to the separation of 
very small molecules from very large ones, e.g., desalting from 
proteins, it has progressively been demonstrated to be widely 
applicable to the separation of not only a mixture of macro­
molecules but also a mixture of lower-molecular-weight 
species as small as hydrated metal ions. For example, the 
elution volumes of alkaline earth metal ions on a Sephadex 
G-15 column (Pharmacia Fine Chemicals AB) increased in the 
order. Mg < Ca «» Sr < Ba, which could be qualitatively cor­
related with the reverse sequence of the radii of these hydrated 
metal ions, i.e.. Mg (4.28 A) > Ca (4.12 A) ■ Sr (4.12 A )  > Ba 
(4.04 A ) (20).
A more pronounced effect of ateric exclusion has been 
shown for the elution behavior of inorganic polyphosphate 
anions with different degrees of polymerization (6, 21), For 
example, the elution volumes of orthophosphate (Pi), di­
phosphate (Pj), triphosphate (Pj), tetraphoephate (P<), and 
more high polymers (P.) decreased in the order Pi > Pj > Pj 
> P4 > P„. A mixture of Pi, Pj. and Pj. shown below for their 
acids, can be easily and completely separated from each 
other, 
oÍHO— P— OH
¿HiW
?
L
HO— P— O— P— OH
?f-
L
„J-o-Lo-L.
L L L
<rj (TJ
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F o r  t h e  q u a n t i t a t i v e  e x p r e s s i o n ,  t h e  e l u t i o n  v o l u m e  o f  a 
s o lu t e  m o le c u le ,  V , .  is r e p r e s e n t e d  in t e r m s  o f  s o m e  c o l u m n  
p a r a m e t e r s  (6 ) .  F o r  v e r y  la rg e  m o l e c u l e s  t h a t  a r e  c o m p l e t e l y  
d e l u d e d  f r o m  t h e  g e l  p o r e s ,  V'. is e q u a l  t o  t h e  i n t e r s t i t i a l  
v o lu m e  o f  t h e  c o l u m n .  V o  F o r  v e r y  s m a l l  m o l e c u l e s  t h a t  ca n  
p e n e t r a t e  in to  all p a r t s  o f  t h e  gel p o re s ,  V ,  is e q u a l  t o  t h e  to ta l 
l i q u id  v o lu m e  o f  t h e  c o l u m n ,  V\ +  Vo- F o r  m o l e c u l e s  o f  i n ­
t e r m e d i a t e  size , t h e  e l u t i o n  v o l u m e  is g i v e n  by
V .  -  V 0 + K d V, (7)
in which K i is a distribution coefficient tha t depends on the 
molecular size and lies in the range. 0 2 Ka 2 1.
Gel Chromatography of Melal Complex
In eqn. (8) a complexation reaction is shown schematically 
to illustrate the difference in size among a metal ion, a ligand, 
and a metal complex (6, 21)
(8)
in which the circles represent the sizes of the free metal ion, 
the free ligand, and the metal-ligand complex. It is assumed 
that if the size of the free metal ion is relatively very small 
compared with that of the free ligand, the size of the metal 
complex may be primarily determined by the contribution 
from the size of the ligand. In such a situation, the metal 
complex is expected to appear at or near the elution position 
of the free ligand. This speculation seems reasonable to a first 
approximation for polyatomic ligands such as inorganic po­
lyphosphates, EDTA, nucleotides, proteins, etc. The elution 
volumes of magnesium ion and magnesium polyphosphate 
complexes, for example, decrease in the order. Mg > MgPj > 
MgPj > MgP, > MgP„, which is in accord with the prediction 
from the increasing order in the ionic sizes, Pj < Pj < P< < P, 
or the decreasing order in the elution volumes, Pj > Pj > P4 
> P„. of the corresponding polyphosphate anions (8). The 
metal complex in some cases tends to be eluted later than the 
free ligand (5,22.  23 ) ,  for which no satisfactory explanation 
has been given. It is conceivable that the size reduction of the 
metal complex, in contrast to the expectation from the mo­
lecular weight basis, may be caused by such effects as the 
chelation and the reduction in charge of the hydration 
layer.
It should be noted that if the ML complex is eluted with an 
eluent containing neither M or L, it will dissociate successively 
into its constituents during the passage through the column 
to give a complicated elution profile of M, L, and ML, de­
pending on both the stability constant and kinetic factors (19). 
On the other hand, if an eluent contains a constant concen­
tration of M and the complexation equilibrium is established 
rapidly so as not to permit the separation of ML and L, a 
well-defined peak of ML accompanied by L is expected to 
appear at the elution position that corresponds to the 
weighted average of the elution volumes of ML and L.
Determination of Stability Constant
For the sake of clarity in expression, the formation of a 
magnesium complex, MgL, will be hereafter presented in in­
terpreting how one can determine the stability constant of a 
metal complex (6.8.19).
A gel chromatographic column packed with a tightly 
cross-linked gel, such as Sephadex G-10, G-15, and G-25 
(Pharmacia Fjne Chemicals AB) is pre-equilibrated with a 
buffered eluent containing a known concentration of mag­
nesium ion, |Mg]o. A known amount of a ligand, L, is dissolved 
in a solution of magnesium ion to prepara a sample aolution. 
It is an Important prerequisite that tha total magnesium 
concentration in the sample be exactly tha sama aa that in the 
eluent, if a Hummel and Dreyer pattern (Fig. 1) is to be ob­
tained. This means that tha concentration of free magnesium
F ig u re  1. A  sc ty y m a tk : r e p r e s e n ta t i o n  o f  H u m m e l a n d  D r e y e r  p a t te r n .  A c c o r d in g  
to  e g o .  <6) ( M g ) 0 »  a
ion in the sample solution is reduced to a l£vel lower than 
(Mg)o by an amount corresponding to the MgL complex 
formed.
An aliquot of tj»is sample solution is apphed to the pre­
equilibrated column and then eluted with the eluent used to 
preequilibrate the column. The MgL complex, along with L 
that is in a state'of dynamic equilibrium with ML, migrates 
down the column more rapidly than the free magnesium ion 
so as to come out from the zone of magnesium deficiency. L 
and ML continue their travel through the pre-equilibrated 
column to be in contact with fresh free magnesium ions in the 
subsequent plates to form more MgL until a steady state is 
reached in equilibrium with [Mg]o that is the concentration 
of free magnesium ion in the mobile phase of the pre-equili- 
brated column. The resulting elution profile is schematically 
shown in Figure 1. The absorbance, Acb. corresponding to the 
total magnesium concentration, (Mg)* » [Mg) + [MgL), is 
assumed to be monitored by atomic absorption methods and 
plotted against the elution volume (see eqn. (7)).
When MgL along with L emerges faster, the total concen­
tration of magnesium in the effluent rises above the base line 
level to form a positive peak of MgL. Behind the MgL peak, 
A0b continues to be constant and then decreases, at the elution 
position of free magnesium ion, to below the base line level to 
form a negative peak that corresponds to the amount of 
magnesium consumed to form MgL. The appearance of a pair 
of positive and negative peaks in the elution profile therefore 
provides a criterion of binding of M and L. It is evident that 
the height of the horizontal base line corresponds to (Mg)o. 
The concentration level of free magnesium in the zone of MgL 
complex has been interpreted to be equal to that in the hori­
zontal region, provided that the sample concentration is rea­
sonably low in comparison with the concentration of back­
ground electrolyte in the eluent (8, 11). In other words, the 
peak area of MgL above the base line, 5 m(Li *s a direct mea­
sure of the total amount of MgL complex that is in equilibrium 
with free magnesium whose concentration is [Mg)o. It is also 
noted that S m*l should be equal to the area of the negative 
peak. SMr Tb* peak area 5 miL or S Mg can be easily translated 
into the amount of MgL, Qm*L. on the basis of the standard­
ized area. So, that is regarded as an internal standard to be 
calibrated against the known amount of magnesium,
(Mg)o- Equation (5) thus can be rewritten as follows to simplify 
the calculation of the stability constant
K - 9m,l
[MgIo(Qu “ 9 m(l)
where Ql, represents the total amount of L applied.
The ratio of Qm«l to Qu “  designated as n and is correlated 
to K and (Mg)o by
TT ■ ^  [Mflo lint
K ~GZT i + * Im»K ‘ ,0’
The Hummel and Dreyer method in Figure 1 hat a great 
advantage that Qm. l can be estimated at well from SM. ever 
when 5 M|L can not be quantitatively determined by thr 
spectrophotometric method owing to the interference by I. 
that ia alao at the elution position of MgL. The exact mea­
surement of S m,. however, ia often difficult because the neg 
alive peak of free metal ions tends in general to broaden
(9)
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F ig u r e  2 . A  s c h e m a t i c  r e p r e s e n t a t i o n  o f a n  e lu t i o n  p r o f i l e  fo r  •  m i x e d  s o lu t io n  
o f  m a g n e s iu m  io n  a n d  fo u r  l i g a n d s .  I .e . ,  L , X , V , a n d  Z .
markedly if the metal ions are susceptible to adsorption. 
Another disadvantage of the S m.  measurement is that 5 m* 
can not be directly translated into QmiL if more than one li­
gand is contained in a sample to form various metal complexes 
(Fig. 2). To minimize the analytical error resulting from the 
peak area measurement it is recommended that the relatively 
well-defined peak of MgL complex be measured by employ­
ment of specific methods such as atomic absorption (8 ) and. 
for metals such as Zn-65, radioactivity measurement (18). In 
such instances the preparation of a sample solution becomes 
more convenient because magnesium concentration in the 
sample solution need not be the same as that in the eluent. It 
is in reasonable excess so as to obtain a positive peak at the 
elution position of free magnesium ion (Fig. 2), in contrast to 
the negative peak in Figure 1.
A schematic profile to be expected is shown in Figure 2 
when a mixed solution (1 ml) containing each 100 nmole of 
four ligands, i.e., L, X, Y, and Z that are different in size from 
each other, is assumed to be eluted with an eluent; (Mg)0 -  
10_1 M. The sample solution also contains 410 nmole of total 
magnesium that is 400 nmole in excess of that in 1 ml of the 
eluent. If the stability constants of four magnesium complexes 
are given as 1.0 X 105 for MgL, 1.0 X 104 for MgX, 1.0 X 10s 
for MgY, and 3.0 X 10s for MgZ, one can expect the amounts 
of the respective magnesium complexes, Q m i L ,  Q m j X .  Q m « y . 
and QmiZ, that are numerically (in nmole) shown in Figure 2 
for four peaks of magnesium complexes, as well as for a posi­
tive peak of free magnesium ion. In other words, one can easily 
calculate the stability constant, for example, of MgZ complex 
according to eqns. (9) and (11), if Q m , z  is given.
7 5
' 1 .0  X 1 0 -»  (1 0 0  - 7 5 )
-  3 .0  X  10» ( 11)
There is an example of the exercise in calculation of thisclass 
which is based on the peak area measurement on the chart of 
a magnesium diphosphate complex (8 ) whose log K  value 
obtained by other static methods (24) has been reported to 
be 5.42.
Numerical values in Figure 2 also indicate that the peaks 
for magnesium complexes increase at the expense of the peak 
of free magpesium ion. It should be noted, however, that the 
amount of each magnesium complex is dependent on [Mg]o 
but does not depend on both the amount of free magnesium 
ion in the sample or the peak area of free magnesium ion and 
the presence of other ligands. Therefore, Qm.l values obtained 
by both methods in Figures 1 and 2 should be,'in principle, 
equal to each other, so long as [Mg)o it the same.
According to eqn. (10) QmiL or n depends on (Mg)» If |Mg]o 
is lowered from-1.0 X 10”» M  to 1.0 X 10“‘ M, the values of 
Q m < u  Q  M f X ,  Q  m , v ,  and Q m i Z  will accordingly decrease from 
50,9.1,91, and 75 to 9.1,1.0,50, and 23, respectively, to result 
in the increase in the amount of free magnesium ion from 175 
to 317.
The ligand concentration is usually required to be very low, 
in comparison to the concentration of background electrolyte, 
to avoid the complexity caused by the Donnan effect 111.13. ;
2 5 ) .  In the accurate analysis of such a dilute sample solution 
it is important to know how to choose (Mgjo for sensitive de-; 
tection and how to minimize the analytical error. It is very 
convenient in practical use to remember that, if K |Mg)0 “  1,! 
50% of the total ligand can be detected as MgL and the relative ; 
error in estimating K can be predicted to be twice the relative 
error in the measurement of Q which is acceptable. On the 
other hand, at K[Mg)0 ”  10, the advantage that about 90% of 
the total ligand can be detected as MgL can not overcome the 
drawback of the unfavorable relative error in K that amounts 
to approximately ten times that in Q mjL-
Many investigations have been reported on the binding of 
more than one metal to a ligand (12-18), including the com­
petitive or cooperative binding of more than one kind of metal 
(11, 26). In order to avoid the complexity in the description 
of the principle, however, the information from these inter­
esting reports can not be presented in this paper.
The gel chromatographic method has application from the 
analytical viewpoint. It is evident from eqn. (10) that QmiL 
or S m , l  can be calibrated against Q t ,  to be determined. For 
example, gel chromatographic technqiue combined with an 
atomic absorption (low detector has been successfully applied) 
to the automatic and sensitive analysis of a mixture of various 
polyphosphates (8 ). This method will be in principle appli­
cable to the detection of any kinds of ligands which combine 
with a given metal ion that can be sensitively detected by 
atomic absorption or other selective methods.
Questions on the Mechanism
We have received many questions about this new technique 
from those who are familiar with the conventional static 
equilibrium methods in determining the stability constant. 
Most of these questions are based on a doubt as to whether or - 
not the equilibrium we can observe in such a dynamic trans­
port process can be regarded as the same as that in a static 
equilibrium system. One of the important questions is how one 
can realize that MgL and L are in equilibrium with [Mg)o- As « 
has been pointed out in the original paper of Hummel and 
Dreyer (3) the establishment of a steady state in equilibrium 
with [Mg]o is visually reflected on the appearance of a base line 
level corresponding to (Mg]0 between the peaks of MgL and 
Mg.
The second question is whether or not this technique is also 
applicable, as shown in Figure 2. to metal complexes that are 
not large enough to be completely excluded from the gel phase. 
This doubt may arise, unfortunately, from the confusing de­
scription in the literature by some gel chromatographers who 
stressed the preferable use of the gel type that permits the 
complete exclusion of MgL ai)d L. As has been noted by 
Determann and Brewer (5), it is not necessary for the ligand 
to be excluded completely from the gel phase. A prerequisite 
is that the degree of separation between the peaks of MgL and 
Mg be good so as to permit the appearance of a base line cor­
responding to [Mg]o between two peaks. This technique, for ; 
example, can be successfully applied to the relatively small '■ 
ligands such as EDTA and diphosphate anions whose K* 
values in eqn. (7) are not zero (8, 23).
The third question is about the effect of the atationary 
phase on the complexation equilibrium, which is related in a 
complicated manner to the above two questions. This question 
seems out of consideration for MgL and L, whose K 4 values 
are zero, and which is present only in the mobile phase. To be 
considered is the case for smaller MgL and L that are dis­
tributed not only in the mobile phase but also, in part, in the 
stationary phase. In order to make the answer as simple as 
possible, let us remember that, according to a random go- 
and-atop concept in chromatography (27), a solute molecule 
migrates down the column only when it is in the mobile phase, 
while its down-stream motion in the atationary phase is halted., 
This means that the effluent we can analyze contains only the 
equilibrium components in the mobile phase at the last plate 
of the column. The atationary gel phase plays an important
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role in  s e p a r a t i n g  M g L  a n d  M g  t o  rnAke a  s t e a d y  s t a t e  in 
e q u i l i b r i u m  b u t  d o c s  n o t  a f f e c t  t h e  c o m p l e x a t i o n  e q u i l i b r i u m  
in  t h e  m o b i l e  p h a s e  t h a t  w e  c a n  d e t e r m i n e .  T h e  i n t e r s t i t i a l  
m o b i l e  p h a s e  ( s p a c e )  b e t w e e n  gel p a r t i c l e s  m a y  b e  r e g a r d e d  
a s a vessel  in w h ic h  a s ta t i c  e q u i l i b r i u m  e x p e r i m e n t  is c a r r i e d  
o u t .
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APPENDIX III
DETERMINATION OF THE STRUCUTRE OF N-ALKYLATED 
TETRAZOLES BY THE MEASUREMENT OF 
NUCLEAR OVERHAUSER EFFECTS
N— N o
U \ n
N > C H 2 P(O H )2 1a 
CH2CH3
N=N O 
^ C H 2P(OH)2 1b
3 c H2CIXN
CH2OCH2Ph
2a PhCHpCHaN.
r =^CH£l 2b
3
CH3
Fig. A.III(i)
In order to determine whether alkylation 
of the tetrazole ring occurs at the N-l or N-2 
position, and therefore differentiate between structures 
(la)-(lb) and (2a)-(2b), nuclear Overhauser enhancement 
effects were studied.
Nuclear Overhauser enhancement measurements 
were carried out at 400 MHz of a D2O solution of (1) 
and CDClj solution of (2). When either the signals due 
to the protons of the methylene group attached to
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nitrogen ((1), 4.6 p.p.m.; (2), 5.9 p.p.m.), phosphorus
((1), 3.4 p.p.m.) or chlorine ((2), 4.65 p.p.m.) were 
irradiated for 1.5 s before accumulation of the 
n.m.r. spectrum, no n.O.e. enhancement of any signals 
was detected.
When the signal due to the protons of the 
N-methyl group (3.45 p.p.m.) of 1 -methyl-2-pyrroleaceto- 
nitrile (3) (400 MHz, d^-pyridine solution) was irradiated
under the same conditions, significant n.O.e. enhancement 
of the signals at 4.0 (-CH2CN) and 6.7 p.p.m. (ring 
proton alpha to the N-l nitrogen atom) occurred (Fig.
A.Ill (ii)) .
The n.O.e. results therefore suggest that 
structures (lb) and (2b) are correct, with ring alkylation 
occurring at the N-2 position of the tetrazole ring, 
since significant n.O.e. enhancement occurs only when 
an N-methyl substituent in the 1-position of (3) is
irradiated.

APPENDIX IV
EXPERIMENTAL
S 0
H U /P-CH2- P ^
OR
OR
RO S S .ORN II H /
P-CH 2-P/ \RO OR
R = Et 2 R= Et 2
R = Me3Si 3 R= Me3Si 4
R = NHEt3 7 to IOOH R= NHEt3 9
R = Na 8 p-c h 2-coor
/R0
R= Et 5 
R= Me3Si 6^ 
R= NHEt 3 10
'H NMR spectra were recorded with a 60 MHz varian spectrometer 
(EM 360). A Bruker UP 80 SY spectrometer was used for 13C NMR (internal TMS) 
and 31PNMR (H3PO4 as external standard). 6 are given in ppm and J in Hz.
Starting materials
Diethyl methanethiophosphonate was prepared by a Michaelis-Becker 
reaction (1) from diethylthiophosphite and iodomethane. Diethylthiophosphite 
was obtained by sulfuration (H2S in pyridine) of commercial diethylchlorophosphite 
according to (2).
Diethyl (0,0-diethyl thiophosphono)- methylphosphonate 1_
To a stirred solution of lithium diisopropylamide prepared from 
4.78 ml (33.9 mmol) of diisopropylamine and 25 ml of a solution (1.3 M in hexane) 
of BuLi (32.4 mmol) and 50 ml of THF maintained under N2 atmosphere and cooled 
to -78°C, is added dropwise 2.59 g (15.4 mmol) of diethyl methane thiophosphonate. 
Stirring is maintained fo 15 min. after the end of the addition and then 5.59 g 
(32.4 mmol) of diethyl chlorophosphite are added dropwise. The solution is 
allowed to warm to -20°C (3 h) and then poured in a saturated aqueous NH4CI 
solution, acidified with 5 % aqueous HC1 solution and extracted with ether.
The ether extracts are washed with brine, dried over sodium sulfate and 
concentrated under vacuo.
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The residue (4.51 g) is distilled under reduced pressure to yield 2.95 g (63 %) 
of a colourless liquid bp : 103-105° (0.01 mm)
‘h NMR (CCIO : 1.33 (t, J= 7, 12 H), 2.60 (dd, 2JHp(0) = 20.6, 2JHp (S)= 18,8 , 
2H) 4.10 (dq, JHH= 7, 3 JHp= 7,8 H).
13C NMR (CDC13) : 16.25 (2d, ÇH3-), 3.49 (dd, Jp(0)c = 135.94, Jp(s)_c = 107.23,
-ÇH 2-), 62.71 (2d, CH3-_CH2-0-).
31 P NMR (CDC13) : 83.16 [d, P(S)]; 17.75 [d, P(0)] ; Jpp= 7
Analysis : Calc, for C9 H 2 2O 5P 2S : C 35.52 H, 7.29 0, 26.29 S, 10.54 ;
P, 20.39. Found : C, 35.26 ; H, 7.35 ; 0, 26,21 ; S, 10.00.
O.O.O'O'-tetraethyl methylene bis-thiophosphonate 2
This compound is preparedby U.V. induced Michaelis Becker-reaction 
from diethylthiophosphite and dibromomethane according to the described 
method (3).
‘H NMR (CCU) : 1.32 (t, J= 7, 12 H) ; 2.84 (t, 2 JHP= 18, 2H) ; 4.1 (dq, JHH= 7, 
3JHp= 10, 8H).
13C NMR (CDC13)16.12 (quint. ÇH3-), 42.55 (t, Jp_c = 106.29, -CH2-), 62.91 (quint. 
CH 3-ÇH2-O).
31 P NMR (CDC1 3) : 82.29.
Bis- (trimethylsilyl) [o,0-bis-(trimethylsily1) thiophosphono]-methylphosphonate 3^
Bisphosphonate 1_ (2 mmol) is warmed at 100°C with (10 mmol) of iodo- 
trimethylsilane for 48 h. The dark brown mixture is distilled bp : 110-112°
(0.03 m ),0.645 g of 4 is obtained as a liquid (still coloured by some iodine).
'H NMR (CDC1 3) : 0.25 (s, 36H) ; 2.60 (dd, 2JHP(0 )= 21, 2JHP(S) = 10-5 . 2H)
31P NMR (CDC13 ) : 50.05 [p (S)] , 0.21 [P(0)].
0,0,0'0'-tetrakis-(triinethylsilyl) methylene bis-thiophosphonate 4
Bisphosphonate 2 (2 mmol) is warmed at 100° with 1,70 ml (12 mmol) 
of iodotrimethylsilane for 10 days. Distillation of the dark brown mixture give 
0,532 g of a liquid (containing traces of iodine) bp : 125.130°C (0.03 m ).
lH NMR (CDC13) : 0.25 (s, 36 H), 2.88 (t, 2JHp= 18.5, 2H)
31P NMR (CDC13 ) : 56.64.
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Ethyl (0,0-diethyl thiophosphono)-acetate 5 (4)
To a stirred suspension of sodium hydride (0.6 g, 0.015 mol) in 
ether (20ml) are added dropwise 2.04 ml (0.015 mol) of diethylthiophosphite 
(evolution of hydrogen is observed). The mixture is refluxed for 30 min. and 
Then cooled to 0°C. Ethyl chloroacetate (2.67 ml, 0.025 mol) is slowly added 
and the mixture is allowed to react at room temperature for 48 h. A minimum 
of water is added for the dissolution of the salts and after decantation the 
etheral layer is dried over sodium sulfate. After evaporation of the solvent 
the residue is distilled. 1.65 g (46 %) of a colourless liquid bp : 95°C 
(0.01 mm).
1 H NMR (CCIO 1.3 (~t, J= 7, 9H) ; 3.0 (d, Jh p= 20, 2H) ; 4.13 (m, 6H). 
31 P NMR (CDC13) « : 84.91.
Trimethylsilyl (0,0-trimethylsilyl thiophosphono)-acetate 6^
Thiophosphonoacetate 5^ (0.720 g, 3 mmol) is warmed at 100° with 
(1.70 ml, 12 mmol) of iodotrimethylsilane for 72 h. The brown solution is 
distilled under reduced pressure. 0.480 g of a liquid bp : 108-110 (0.03 mm) 
is recovered.
‘h NMR (CDC1 3) 4 : 0.28 (s, 27 H), 3.12 (d, J= 19.5, 2H)
31P NMR (CDC1 3) 4: 56.92.
References
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EXPERIMENTAL
RO 0 SN l| ||
p_CH2-C-XEt/RO
R= Et X= 0 l
R= Et X= S 2
R= H X= 0 3
R= H X= 5 4
O-Ethyl (diethylphosphono)thioacetate 1_
1_ was prepared according to (1)
Diethyl cyanomethylphosphonate (8.85 g, 0.05 mol) and ethanol (4.6 g, 
0.1 mol) are dissolved in 100 ml of benzene. The solution cooled to 5°C is 
saturated with gazeous chlorhydric acid and allowed to react 16 h. Benzene is 
evaporated and the residuetaken up by 80 ml of pyridine. The solution cooled to 
0°C is saturated by hydrogen sulfide (2 h) and allowed to react 16 h. The mixture 
is poured in 400 ml of an aqueous solution of chlorhydric acid (20 %) and 
extracted with ether. The extracts are washed several times with the chlorhydric 
acid solution, water and brine then dried over sodium sulfate. After evaporation 
of the solvent, the residu is distilled under reduced pressure. 9.37 g of a pale 
yellow liquid is obtained, bp : 90-91°C (0.08 mm), yield : 78 %.
1H NMR (CC14) : 1.2 to 1.6 (3 t, 9H) ; 3.42 (d, 2JpH = 23, 2H) ; 4.03 (dq,
3JHp= 7, J=HH= 6.5, 4H) ; 4.55 (q, J= 6.5, 2H).
Ethyl (diethylphosphono) dithioacetate 2^
Prepared in a 62 % yield by the method described above, ethanethiol 
being used instead of ethanol . |2 has been prepared recently by another way (2)1 
>H NMR (CC1J : 1.33 („t, J= 675, 9H) ; 3.23 (q, J= 6.5, 2H) ; 3.62 (d, 2JHP= 23, 
2H) ; 4.10 (dq, 3JHP= 7, JHH= 6.5, 4H).
0-Ethyl phosphono - thioacetate 3
lodotrimethylsilane (0.427 ml, 3 mmol) is added dropwise to a solution 
of thioacetate 1_ (0.256 g, 1 mmol) in 4 ml of methylene chloride cooled to 0°C. 
After 2 h at this temperature, 2 ml of water is added and the mixture is stirred 
for 20 mn. After decantation the aqueous phase is saturated with NaCl and 
extracted several times with ether. The etheral extracts are dried over sodium 
sulfate and after evaporation of the solvent the residu is cristallized in 
a carbon tetrachloride - ethyl acetate mixture. 0.118 g (64 %) of pale yellow 
needles, mp : 103°C, are oDtained.
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*H NMR (acetone d 6) : 1.38 (t, J= 7, 3H) ; 3.55 (d, 2 JHP = 23, 2H) ; 4.53
(q, JHP= 7, 2H).
Analysis (calc; for C4 H9O4PS) : C, 26.09 ; H, 4.92 ; S, 17.40 
Found : C, 28.88 ; H, 4.90 ; S, 16.83.
Ethyl phosphono - dithioacetate 4
Prepared as above. 155 mg (77 %) of yellow cristals mp : 122°C are
obtained
1 H NMR (acetone d5 ) : 1.3 (t, J= 7, 3H) ; 3.26 (q, 3JHp= 7, 2H) ; 3.83 (d,
2Jhp= 23, 2H) ;
Analysis(calc. for C4 H9O3 PS2 ) : C, 23.86 ; H, 4.51 ; S : 31.86. Found : C, 24.04 
H, 4.14 ; S, 30.85.
References
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THE AN TIV IR AL ACTIVITY OF TETR AZO LE PHO SPHO NIC ACIDS AND 
TH EIR  A N A LO G U E S
D . W . H U TC H IN S O N  AN D  M . NAYLO R
D EPAR TM EN T OF C H E M IS T R Y . U N IVER SITY OF W ARW ICK 
CO VNETRY. C V4 7AL
5 -(P h o s p h o n o m e th y l) - lH -te tra z o le  and a num ber of re la ted  
te trazo les have been prepared  and th e ir e ffec ts  on the re p lic a tio n  of H erpes 
S implex V iru s e s -! and - 2  have been investigated as well as th e ir  a b ilitie s  to  
Inh ib it the DNA po lym erases induced  by these v iruses a n d  the RNA
transcrip tase  activ ity  of in fluenza v iru s  A. C ontrary to  an e a r lie r  re p o rt, 
5 - (p h o s p h o n o m e th y l) - tH -  te trazo le  was not an e ffic ie n t in h ib ito r  of the  
rep lica tion  of HSV-1 and H SV -2 in tissue cu ltu re . A na lo g u e s  o f
5 - (p h o s p h o n o m e th y l) - lH -te tra z o le  w ere  a lso devoid of s ig n if ic a n t an tiv ira l 
activ ity. Only 5 - (  p h o s p h o n o m e th y l)- lH -te tra z o le  and
5 -( th lo p h o s p h o n o m e th y l) - lH -te tra z o le  inh ib ited  the in fluenza  v irus 
tra n sc rip ta se , and both w ere m ore e ffective  as in h ib ito rs  than
phosphonoace tlc  acid under the sam e co n d itio n s . The DNA po lym erases 
Induced by HSV-1 and H SV -2 were inh ib ited  s lig h tly  by
5 -(p h o s p h o n o m e th y l) - lH -te tra z o le  and to a lesser extent by its N -e th y l 
analogue and 3 - (  p h o s p h o n o m e th y l)-1 H -1 , 2 . 4 -tr ia z o le , a lth o u g h  none of 
these com pounds were as e ffective  as p h o sp h o n o a ce tic  a c id .
5 -(T h lo p h o s p h o n o m e th y l) - lH - te tra z o le  was a be tte r In h ib ito r of the DNA 
polym erase induced by HSV-1 than 5 -(p h o s p h o n o m e th y l) - lH - te tra z o le .
INTRODUCTION
A nalogues of in o rg a n ic  pyrophospha te , e . g . .  p h o s p h o n o a c e tlc 1 o r 
phosphono fo rm lc^  acids  are  se le c tive  Inh ib ito rs  of the DNA po lym erases  of 
several v iruses of the H erpes fam ily  and act d ire c tly  on the enzym es ra th e r 
than by being m etabolised to an active form  such as a nuc leos ide  
tr iphosphate  ana logue . The RNA tra n scrip ta se  activity of In fluenza v irus A 
can a lso be inh ib ited  by pyrophospha te  ana logues^ a n d . fo r exam ple. In 
the presence o f phosphono fo rm lc  ac id  In itia tion  of mRNA syn thes is  o ccu rs  
but cha in  e longa tion  does not take p lace4 . We be lieve  tha t the
effectiveness o f a pyrophosphate  ana logue  as an in h ib to r of in fluenza  RNA
3 5transcrip tase  Is re lated to its a b ility  to che la te  metal Ions, no tab ly  z inc ‘ 
as the la tte r is probably an im p o rta n t com ponent of the a c tive  site of the 
transcrip tase . We have recen tly  exam ined o ther pyrophosphate  ana logues.
e. g. . m o n o - and b is -th lo p y ro p h o s p h a te  as in h ib ito rs  of he rpes DNA 
polym erase and the re p lic a tio n  of in fluenza v irus  in MOCK c e ls 6 , and now  
wish to re p o rt o u r o b se rva tio n s  on the a n tiv ira l p ro p e rtie s  o f a n u m b e r o f 
h e te ro cyc lic  p h o s p h o n ic  ac ids  and th e ir a na logues.
It Is welt know n th a t lH -te tra z o le  can  be re g a rd ed  as an is o s te re  
o f the ca rboxy lic  a c id  g ro u p 7  and am ino  ac id  a n a logues  in w h ich  the  
ca rboxy lic  ac id  m o ie ty  has been rep la ce d  by a te tra zo le  ring  have s im ila r  
pKa values to th e ir p a re n t co m pounds. F u rth e rm o re , the te trazo le  m o ie ty  
can  form  stab le  co m p lexes  w ith m etal Ions. A recen t re p o rt8  th a t
5 -(p h o s p h o n o m e th y l) -1  H -te tra zo le  (1 ) was m o re  e ffec tive  th a n
phosphonoace tic  a c id  in  in h ib itin g  the re p lic a tio n  of H SV -2 prom pted  us to  
p repare  th is  co m p o u n d  and a num ber of re la ted  deriva tives and to 
investiga te  th e ir e ffe c ts  on the re p lica tio n  o f HSV-1 and H SV-2 in t is s u e  
cu ltu re  and on the in h ib itio n  of the DNA po lym erases  induced  by th e s e  
v iruses. The e ffe c t of these  com pounds on the RNA tra n s c rip ta s e  o f
in fluenza v irus A was a lso  investiga ted .
MATERIALS AND METHODS 
V irus and Enzyme A ssays
The HSV-1 s tra in  used w as KOS and the H S V -2  s tra in  was 3 3 4 5 . 
The inh ib ition  of th e  DNA po lym erases Induced  by these  v iruses in HeLa 
ce lls  was c a rr ie d  o u t by the m ethod of Powell and P u rifro y9 . The e ffe c ts  
o f h e te rocyc lic  p h o sp h o n ic  a c id s  and th e ir ana logues on the re p lic a tio n  o f 
HSV-1 and H SV-2 w e re  de te rm in e d  by p laque re d u c tio n  assays. Vero c e lls  
( 2  x 1 0 ® ce lls  per w e ll)  w ere grow n to c o n flu e n ce  In m a in tenance  m e d iu m  
[D u lb e cco 's  m od ified  E ag le 's  m e d iu m , 10% foeta l c a lf se ru m , g lu ta m in e  
( 4 .5  g /D ]  in 24 w e ll p la tes and each w ell was in fec ted  w ith v irus (5 0  
p . f .u .  in 0 .2  m l) .  A fte r v irus  abso rp tio n  had taken p lace (1 h o u r, 4 ° ) ,  
the CMC overlay (0 .  7 m l) was added to g e th e r w ith the test co m p o u n d  In 
m ain tenance  m edium  (0 . 1 m l) . The p la tes  were then incuba ted  fo r 3 -4  
days at 3 7 °  in a h u m id ifie d  a tm osphere  o f C 0 2  (5% ) In a ir . The n u m b e r 
o f p laques In each w e ll w ere then d e te rm ined  a fte r fix ing  and s ta in in g  w ith 
Q iem sa s ta in . C o n tro l w ells w ithou t test com pound  showed on a ve rage  50 
p laques per w e ll.
The in flu e n za  v irus s tra in  used was A /X 4 9 . a c ro ss  be tw een 
A /E n g  la n d /8 6 4 / 75 a n d  A /P R /8 /3 4  with the H3N2 su rfa ce  an tigens o f the 
A /E n g la n d  s tra in . RNA tra n sc rip ta se  assays and the e ffec t of test
com pounds on v irus rep lica tion  in MOCK ce lls  was ca rr ie d  out as p rev ious ly  
d e s c rib e d 6 .
C hem ica l P rocedures
^  N. m . r. spec tra  w ere reco rded  at 220 MHz and ch e m ica l sh ifts  
a re  g iven in p .p .m .  w ith e ithe r te tram e thy ls ilane  ( fo r  COCI3  and dg-D M S O ) 
o r sod ium  3 -( tr im e th y ls ily l) -1 -p ro p a n e  su iphonate  ( fo r  D2 0 )  as s ta n d a rd s . 
61P N .m . r .  sp e c tra  w ere re co rd e d  at 3 6 .4 4  MHz and chem ica l s h ifts  are  
re co rd e d  re la tive  to  85% H3 PO4  (e x te rn a l, dow nfie ld sh ifts  p o s it iv e ) . 
C hem ica l ion isa tio n  mass s p e c tra  were determ ined using am m on ia  as 
re a g e n t gas as previously  d e s c r ib e d 16. T riazo les, te trazo les and th e ir 
phosphona te  este rs  w ere p u rifie d  by s ilica  gel ch rom atog raphy  by the  
m ethod of S t i l l 1 1  using the fo llo w in g  solvent system s; A . a c e to n e /6 0 -8 0 o 
pe tro leum  e th e r ( 3 /7 ,  v /v )  ; B . CHCI3 .' C . m e thano l/C H C l3  ( 1 / 9 .  v / v ) . 
The de te rm in a tio n  o f pKd . values re la ted  to the strength  of b ind ing  o f z incO
ions to phosphonates was by get fi lt ra t io n ''.
P repa ra tion  of T e trazole P hosohon lc  Acids
5 -(P h o s p h o n o m e th v l) - lH - te tra z o le  ( 1 ) . -  5 - (C h lo ro m e th y l) - lH - te tra z o le  was 
p repa red  by hea ting  c h lo ro a c e to n itr ile  ( 6 .4  m l, 0 .1  m ol) w ith dry sod ium  
azide (2 9 .5  g , 0 .4 4  m ol) and anhydrous a lum inium  ch lo ride  (1 3 .3  g . 0 .1  
m ol) In dry THF (200  m l) u n d e r reflux in a n itrogen  a tm osphere  fo r  14 
ho u rs . The re a c tio n  m ixture was co o le d , ac id ified  w ith 5 M HCI and then 
extracted  w ith e thyl ace ta te  (3  x 100 m l) .  The com bined extracts  w ere
d rie d  (N a 2 S 0 4 ) and the  so lven t rem oved in vacuo. The res idue  was 
re c rys ta llise d  from  CHCI3  to g ive th e  ch lo rom ethy l. te trazole ( 9 . 6  g . 8 1 % ).
m .p .  8 5 ° . lit. 1 2  8 5 ° . ^  n . m . r .  (d 6  DMSO) 6  5 .1  p . p . m . .  CIMS m /z
119 (M *■ H] + , 136 tM + NH4)+ .
N - ( B enzvloxvm ethv l)- 5 - ( c h io ro m e th v l)- te tra z o le . -  To the ch lo ro m e th y l 
te trazo le  ob ta ined  above ( 5 .0  g ,  1 e q u tv .) in dry dioxan (6 0  m l) was
added g ra d u a ly . w ith s tir r in g , so d iu m  hydride (50%  suspension In o il .  2 .2 5  
g . 1 .1  e q u iv . ) .  A fter 30 m in u te s , benzyl ch lo rom ethyl e the r ( 6 . 0  g . 1 
e q u iv .)  was added and the m ix tu re  s tired  fo r 16 hours at 2 5 ° . The
re a c tio n  was then filte re d , the so lven t rem oved from  the filtra te  in vacuo
and the res idue  purified  by s il ic a  ch rom atography (so lven t A) to g ive  N- 
( benzyloxym ethyl) -5 - (c h to ro m e th y l)  -te tra zo le  ( 8 . 6  g . 8 5 % ). 1H n . m . r .
(C O C I3 ) 6  4 .6 5  ( 2H s) . 4 .8  (2 H  s) . 5 .9  (2H  s) and 7 .3  p .p .m .  (5H
m ) . CIMS m /z  239 [M + H l+ , 256 (M + NH4 1+ . N-l B enzyioxym ethyl) 
- (c h lo ro m e th y l)  - te tra z o le  ( 2 . 4  g , 0 .0 1  m ol) was s tirre d  a t 120 fo r 14
hours in  tr ie thy i phosph ite  ( 5 . 0  g . 0 .0 3 3  m o l) . A fte r th is  tim e , excess 
trie thy l phosph ite  was rem oved  in vacuo and the res idue  p u rifie d  by s ilic a  
ch rom atog raphy  (s o lv e n t B) to  give the diethyl e s te r of N-l benzyioxym ethyl) 
-5 - (p h o s p h o n o m e th y l) - te tra z o le  ( 2 .2  g . 6 5 % ). H n . m . r .  (C D C Ig) 6  1 .3  
( 6 H t.  J = 6  Hz) . 3 .5 5  (2 H  d . J = 20 H z ). 4 .2  (4H  m) . 4 .6 5  (2 H  s) .
5 .9  ( 2H s) . and 7 .3  p . p . m .  (5H  m) , CIMS m /z  341 (M + H I. 358 [M + 
NH41 .
This d ie thyl e s te r w as s tirred  in tr if lu o ro a ce tic  a c id  ( 8  m l) fo r 72 
hours a t room  te m p e ra tu re . Rem oval of the so lvent in vacuo a ffo rd e d  d ie thy l 
5 - (p h o s p h o n o m e th y l) - lH - te tra z o le  ( 1 . 3  g . 90%) a fte r p u rific a tio n  by s ilic a  
ch rom atog raphy  (s o lv e n t C) . ' h  n . m . r .  (CDCIg) 6  1 .3 5  ( 6 H t. J = 6  
H z), 3 .7 5  ( 2H d . J = 20 H z) and 4 .2 5 6  (4H  m . J = 7 H z ), CIMS m /z
221 (M H I4-. 238 [M + NH4 1 + .
D iethyl 5 -p h o s p h o n o m e th y l)-1  H -te tra zo le  (1 .1  g ) w as s tirre d  fo r 2 
hours a t room  te m p e ra tu re  w ith  b rom otrlm e thy ls ilane  (1 .5 2  g )  . E vaporation 
of the  s ilane  gave a re s id u e  to w hich excess w ater was a d d e d , the  la tte r 
was rem oved by ly o p h ills a tio n  and the add ition  of w ater a n d  lyoph ilisa tlon
was repeated severa l tim e s . The p ro d u c t was purified  by ch ro m a to g ra p h y
on D EAE-Sephadex A25 ( E tgN H + fo rm  1 .5  x 45 cm ) and e lu tion  w ith a 
g ra d ie n t of 0 .5 - 1 .0  M EtgNHHCOg (pH  8 .4 )  to give the tr ie th y la m m o n iu m  
salt o f 5 - (  p h o s p h o n o m e th y l)-1  H -te tra zo le  w hich was co n ve rte d  us ing  a 
Dowex 50 (H + fo rm ) c o lu m n  Into the  free  acid (615 m g. 75% . m. p. 170°
( d e c . ) .  *H  n .m . r .  (D 2 0> 6  3 .5  p .p .m  (d .  J = 20 H z ) . 31P n . m . r .  8
1 6 .9  p . p . m . .  A na lys is  C 1 4 .6 0 . H 3 .3 3 . N 3 3 .1 2 .  P 1 8 .4 2 % , 
C2H5N4 ° 3 P requ ires  C 1 4 .6 4 . H 3 .0 7 ,  N 3 4 .1 5 . P 18 .8 8 % . 
5 -(2 '-P h o s D h o n o e th v l) - lH - te tra z o le  (2 ) . -  This was p re p a red  as d e scrib e d  
above from  5 - ( 2 '- c h lo r o e th y l) -1  H -te tra zo le  and was Iso la ted  as the 
d lsod ium  sa lt a fte r ch ro m a to g ra p h y  on a Dowex 50 (N a 4  fo rm ) co lu m n . ^H
n .m . r .  (D gO ) 8  2 .1  (2 H  m ) . 3 .2  p .p .m .  (2H  m) . 3 1 P n .m . r .  (D 2 0 )
6  2 4 .7  p . p . m . .  A na lys is  C 1 5 .9 7 , H 3 .1 1 . N 2 6 .2 1 .  P 1 3 .8 8 % . 
c 3H5N4 ° 3 PNa2 re q u ire s  C 1 6 .2 0 . H 2 .3 0 . N 2 5 .2 0 . P 1 3 .9 5 % .
5 - ( ThlophosD honom ethvI) -1  H -te tra z o le ___ i l l . -  Sodium hydride  (50%
suspension in o il. 0 .2  g , 1 equiv. ) was added to a so lu tion  of O .O -d le th y l 
th iophosph ite  ( 0 . 6 6  g , 1  e q u iv .)  in d ie thyl e ther ( 2 0  m l) a nd  the m ixture  
heated under reflux fo r 30 m inutes. The reaction  was c o o le d  to 0 °  and
/V - (b e n z y lo x y m e th y l) -5 -(c h lo ro m e th y l) - te tra z o le  ( 1 . 2  g , 1 e q u lv .) was 
added d ropw lse  w ith  s tirr in g  w h ich  was con tin u e d  fo r  48 hours. The e th e r 
was then rem oved  In vacuo and the  re s id u e  purified  by s il ic a  
ch ro m atog raphy  (s o lv e n t A) to  give d ie thy l A /-(b e n z y lo x y m e th y l) -5 -th lo p h o s - 
p h o n o m e th y l)- te tra z o le  ( 1 .3  g . 7 3 % ). ^H n . m . r .  (C DC I3 ) 6  1 .3  ( 6 H t.
J = 6  Hz) 3 .7 5  (2 H  d . J = 18 H z ), 4 .1 5  (4H  m , J = 7 Hz) . 4 .6  (2H  
s) . 5 .9  (2  H s) . 7 .3  p. p. m . (5H  m , CIMS m /z  357 [M + H I* .
This d ie th y l es te r ( 1 . 3  g) was s tirre d  fo r 84 hours in so lu tio n  in 
tr lf iu o ro a ce tic  a c id  at room  te m p e ra tu re . E vaporation of excess TFA 
afforded d ie thy l 5 -( th lo p h o s p h o n o m e th y l) - lH - te tra z o le  (350 m g. 40% ) a fte r 
pu rifica tion  by s il ic a  ch ro m a to g ra p h y  (s o lv e n t C ) . 1H n .m . r .  (C D C Ig) s
1 .25  ( 6 H t.  J = 6  Hz) . 3 .7 7  (2H  d , J = 18 H z ). 4 .1  p. p. m . (4H  m . J 
= 7 Hz) . CIMS m /z  237 IM ♦  HI'*’ . 254 CM + NH41 + .
D ie thyl 5 -( th lo p h o s p h o n o m e th y l) - lH - te tra z o le  (150 m g. 1 eq u iv . ) 
was heated in  a sea led tube at 100° fo r  72 hours  w ith io d o trim e th y ls ila n e  
(40  m g, 2 e q u iv . ) .  The excess s ila n e  was rem oved In vacuo and the 
residue tre a te d  w ith  2 x 10 ml of 0 .2 5  M EtgNHHCOg (pH  8 . 7 ) .  the 
sam ple be ing  lyo p h ilise d  betw een each tre a tm e n t. The p roduct was p u rifie d  
by c h ro m a to g ra p h y  on a D EA E -S ephadex A -2 5  co lu m n  (E tgN H * fo rm . 1 .5  x 
45 cm ) w ith e lu tio n  w ith a g ra d ie n t o f 0 .2 5 - 0 .7 5  M EtgNHHCOg (pH  8 .7 )  
to give 5 -( th io p h o s p h o n o m e th y l) - lH - te tra z o le  as th e  b ls -trle th y la m m o n lu m  
salt (4 0  m g . 1 8 % ). ’ h  n . m . r .  (D gO ) 1 .3  (18H  t .  J = 6 .5  H z ). 3 .5  (2H  
d . J = 18 H z ) .  4 .1 5  p .p .m  (12H  q . J = 7 Hz) . Analysis C 3 8 .5 2 , H 
9 .3 1 , N 2 1 .5 .  C 1 4 H3 5 N6 0 2 PS. H20  re q u ire s  C 4 0 .5 3 . H 9 .3 1 . N 2 1 .0 .
/V -E th v l-5 -(p h o s o h o n o m e th v l)- te tra z o le ___ i l l . -  5 - (C h lo ro m e th y l) - lH - te t ra -
zole ( 1 .2  g , 1 e q u iv .)  was heated in  tr le th y l phosph ite  ( 5 .0  g . 3 e q u iv .)  
at 120° fo r 14 h o u rs . Excess tr le thy l phosph ite  w as then rem oved In vacuo 
and the re s id u e  p u rifie d  by s ilic a  ch ro m a to g ra p h y  (s o lv e n t A) to  give d ie thy l 
A /-e th y l-5 -(p h o s p h o n o m e th y l) te trazo ie  ( 1 . 9  g . 8 0 % ), ' 'h  n .m . r .  (C D C Ig)
6  1 .2  ( 6 H t .  J = 6  Hz) . 1 .5  ( 3H t .  J = 6  Hz) . 3 .4  (2H  d . J = 20 H z ).
4 .1  ( 4H m . J = 7 H z ). 4 .5 5  p .p .m .  (2H  q . J = 7 Hz) . CIMS m /z  249
(M + H I* . 266 IM  + NH41 + .
Th is  d ie th y l ester ( 1 .0  g ) was s tirred  fo r 2 hours at room
tem pera tu re  w ith  b ro m o trlm e th y ls ila n e  ( 1 . 5  g ) . Evaporation of excess 
silane  In vacuo gave a re s idue  to w h ich  excess w ater was added. The 
la tte r was rem oved  by repeated  lyo p h llisa tlo n  to leave a p roduct w hich was 
purified  by ch ro m a to g ra p h y  on a D EA E -S ephadex A25 co lum n (E tgN H +
fo rm . 1 .5  x 45  cm ) and e lu tion  w ith a g ra d ie n t of 0 - 0 .5  M EtgNHHCOg 
(pH  8 .4 )  to give the  tr ie thy lam m on ium  sa lt o f
fV -e th y l-5 -(  p hosphonom ethy l) - te tra z o le  w hich was converted  In to  the free  
ac id  using a Oowex 50 (H + fo rm ) co lu m n , yield (3 2 0  m g . 41% . 1H
n . m . r .  ( 0 2 O) 6  1 .4 5  (3 H  t .  J = 6  H z ). 3 .4  (2H  d . J = 20 H z ). 4 .6  
p. p. m. (2H  q . J = 7 H z ), 3 1 P n . m . r .  (D 2 0 )  1 8 .8  p . p . m . .  Analysis C 
2 3 .6 ,  H 5 .0 2 , N 2 6 .7 . P 1 4 .7 9 %  C4 H9 N4 OgP. H20  re q u ire s  C 2 2 .8 6 . H 
5. 2 0 . N 26. 6 7 . P 14. 76%.
N u c le a r O verhauser e n h a n ce m e n t m easurem ents  were c a rr ie d  out at 
400 MHz on a pyrid ine  so lu tion  of ( 4 ) .  W hen e ithe r the s ig n a ls  due to the 
pro tons of the  m ethylene g ro u p  alpha to the phosphorus atom ( 3 .4  
p . p . m . )  o r th e  pro tons of the m e thy lene  g ro u p  attached to n itro g e n  ( 4 .6  
p . p . m . )  w ere Irrad ia ted  fo r 1 .5  s before accum u la tion  of th e  ^H n .m . r .  
sp e c tru m , no e n h a n ce m e n t of a n y  s igna ls  cou ld  be d e te c te d . When the 
s ig n a l due to th e  protons of the N -e th y l g roup  (3 .4 5  p . p . m . )  of 1 -m ethyl
2 -  p y rro le a c e to n ltr ile  was ir ra d ia te d  under s im ila r c o n d it io n s . s ig n ifica n t 
enhancem en t o f the  s igna ls  at 4 .0  ( -C H 2 CN) and 6 .7  p .p .m .  (r in g  proton 
a lpha to n itro g e n  atom ) o c c u rre d .
3 -  ( P h o s o h o n o m e th v l-1 H -1 . 2 . 4 - tr ia z o le  (5 ) . -  3 -(C h lo ro m e th y l-1  H - 1 ,2 ,4 -
tr iazo le  ( 3 .0  g . 1 equiv. ) w hich had been prepared as d e s c r ib e d 13, was 
heated with tr ie th y l phosph ite  ( 1 2 . 5  g . 3 e q u iv .)  at 120° fo r  12 hours. 
Excess tr ie thy l phosph ite  was rem oved  in vacuo and the  re s id u e  purified  by 
s ilic a  ch ro m a to g ra p h y  (so lve n t C) to afford  d ie thyl 3 - (  p h o s p h o n o m e th y l)-1 H  
- 1 . 2 . 4 -tr ia z o le  (2 .1  g . 3 5 % ). ’ h  n .m . r .  (CDCIg) 6 1 .3  ( 6 H t. J = 6  
H z ). 3 .5 5  ( 2H d . J = 20 H z ). 4 . 2  (4H  m . J = 7 H z ). 8 .3  p .p .m .  (1H  
s) , CIMS m /z  220 (M + H I*. T h e  diethyl es te r ( 1 .5  g) was heated under 
re flux In co n ce n tra te d  HCI (1 0  m l) fo r 12 h o u rs , the excess HCI was then 
rem oved In vacuo and the re s id u e  purified  by ch ro m a to g ra p h y  on DEAE 
ce llu lo se  (E tgN H + fo rm ) with e lu tio n  by a g ra d ie n t of 0 - 0 .5  M EtgNHHCOg 
(pH  8 .4 )  to g ive  tr ie thy lam m on ium  3 - ( phosphonom ethyl) - 1 H - 1 . 2 . 4 -tr la zo le . 
U sing a Dowex 50 (N a + fo rm ) c o lu m n  th is  was converted  In to  the d lsod lum  
sa lt (700  m g. 4 4 % ). ] H n .m . r .  (D 2 0> 6  3. 3 (2H  d . J = 20 H z ), 8 .3
p .p .m .  (1H  s) . 31 P n .m . r .  ( D2 0 )  6  1 7 .4  p . p . m . .  A na lys is  C 1 5 .3 7 , H 
4 .2 .  N 1 9 .6 . P 13 .5% . CgHgNgOgPNagHgO requ ires  C 1 6 .0 . H 2 .6 7 . N 
18. 6 7 . P 13. 8 %.
A d e n o s ln e -5 ' Ester of 5 - (  P hosphonom ethv l) - lH - te tr a z o le — L S I -  To a 
so lu tion  of the  anhydrous py rid im um  salt o f 5 - (  phosphonom ethy l) -1 H - te tra -
zole (150 m g . 1 equ lv. ) and 2 ',  3 '-0 - is o p ro p y lid e n e  adenos ine  (1 8 4  m g. 1 
equlv. ) In DMF ( 4  m l) was added a so lu tion  o f d icyc lohexy l ca rb o d iim id e  
(6 0 0  m g) in  DMF (3  m l) .  The m ixture was s tirre d  a t 2 0 °  fo r 96 ho u rs ,
w ater (5  m l) w as added and the s tirr in g  con tinued  fo r  a fu rth e r 24 hours .
The re a c tio n  m ix tu re  was then filte red  and the filtra te  evapora ted  to dryness 
in vacuo. The re s id u e  was pu rified  by ch ro m a to g ra p h y  on a DEAE ce llu lo se  
(E t3 NH+ fo rm . 3 . 5 x 40 cm ) co lum n w ith e lu tion  by a g ra d ie n t o f 0 - 0 .5  M 
Et3 N H H C 0 3  (p H  8 .2 ) .  2 ',  3 '-0 - ls o p ro p y lid e n e  adenosine  5 '- ( 5 -
( p h o s p h o n o m e th y l) - lH -te tra z o le l was iso la ted as the  tr ie th y la m m o n iu im  salt 
(9 0  m g. 2 5 % ). 1H n. m . r. (D gO ) . 6  1 .3  (18H  t .  J = 6 .5  H z ). 1 .6  (3H  
s) . 1 .8  ( 3H s) . 3 .2 5  (12H  q , J = 7 Hz) . 3 .4 5  (2 H  d . J = 20 H z ). 4 .1 5  
( 2H m) . 4 .7  (1 H  m) . 5 .1 5  (1H  m) . 5 .3  (1H  m ) . 6 .3  (1H  d . J = 4
H z ). 8 .3  (1 H  s) . 8 .4 5  p. p. m . (1H  s) .
Rem oval o f the isopropy lldene  g roup  and iso la tio n  of the fre e  acid  
o f ( 6 ) was a ch ie ve d  by passing the trie thy lam m on ium  sa lt down a Dowex 50 
(H + fo rm ) c o lu m n  to give (5 2  m g, 18%) p ro d u c t. ^H n .m . r .  (D 2 0 ) ,  6
3 .5  ( 2H d) . J = 2 H z ). 4 .3  (2H  m) . 4 .5  (1H  m) . 4 .6  (1H  m) , 5 .1  (1H
m ) . 6 .3  (1 H  d . J = 4 H z ). 8 .5  (1H  s) . 8 . 6  p .p . m .  (1H  s) . A na lys is  C
3 4 .9 ,  H 4 .6 3 .  N 2 7 .0 .  P 6 . 8 % . C 1 2 H 1 6 N9 OgP. 4HgO requ ires  C 3 2 .0 .  H 
5. 7. N 27. 8 . P 6 . 2%.
T h v m ld ln e -5 ' E s te r o f 5 - (P h o s p h o n o m e th v l) - IH -te tra z o le __ ill- ~ The
3 '-0 -a o e ty l th y m id in e -5 ' es te r of 5 - (  p h o s p h o n o m e th y l) - lH -te tra z o le  was 
prepared  in  50%  yie ld as the tr ie thy lam m on ium  sa lt from  S '-O -a c e ty l 
thym id ine  and ( 1 )  as described  above. The acety l g ro u p  was rem oved by 
trea ting  th is  sa lt (3 4 0  m g) w ith m ethanol (1 0  m l) w h ich  had been satura ted  
w ith gaseous a m m o n ia . The p roduct of th is  re a c tio n  after rem oval o f 
excess m e th a n o l was pu rified  by ch ro m a to g ra p h y  on a DEAE ce llu lose  
co lum n (E t3 NH+ form  2. 5 cm  x 45 cm ) with e lu tio n  by a g ra d ie n t of 0 - 0 .5  
M Et3 N H H C 0 3  pH  8 .4  and fina lly  converted  Into th e  free  acid (1 4 0  m g. 
54% ) w ith the a id  of a Dowex 50 (H + fo rm ) c o lu m n . ’ h  n . m . r .  (D 2 0>
1 .7  ( 3H s) . 2 . 3  ( 2H m) . 3 .3 4 5  (2H  d . J = 20 H z ) . 4 .1  (3H  m) . 4 .5  
(1 H  m) . 6 .2 5  <1H m) . 7 .5  p .p .m .  (1H  s) . A na lys is  C 3 5 .1 0 , H 4 .4 5 . 
N 2 0 .6 5 . P 8 .1 9 % . C 1 2 H 1 7 N6 0 7 P. HgO re q u ire s  C 3 5 .4 7 . H 4 .4 6 . N 
2 0 .6 8 . P 7 .6 2 % .
P repara tion  of B is -T e tra zo le s  and Tetrazo ie  C arboxylic  A cids 
5 . 5 '-M e th v le n e b ls - lH -te tra zo le  ( 8 ) ■ -  To a so lu tion  of m a lo n o n ltrile  ( 2 .2  g .
0 .0 3  m ol) In d ry  THF (1 5 0  m l) was added d ry  sod ium  azide (2 0 .0  g ,  0 .3  
m l) w ith s tir r in g  fo llow ed by d ry . pow dered a lu m in lu lm  tr ic h lo rid e  ( 9 . 0  g , 
0 .0 3  m o l) .  T he m ixture was heated fo r 14 h o u rs  under re flux  in  a 
n itro g e n  a tm o s p h e re , then  coo led  and a c id ifie d  w ith  5 M HCI. The so lu tio n  
was extracted  w ith  ethyl ace ta te  (3  x 100 m l) ,  the  com bined e x tra c ts  d ried  
(N a 2 S 0 4 ) and the so lvent rem oved In vacuo. The re s id u e  was 
re c rys ta llise d  fro m  a ce to n itr ile  to  g ive 5 . 5 '-m e th y le n e b ls - lH - te tra z o le  ( 2 .3  
g . 50% ) m .p . 2 0 8 ° . lit. 1 4  2 1 5 ° , 1H n. m . r. (D 2 0 )  4 .7  p. p. m . ( s ) .  
A na lys is  C 2 3 .8 4 . H 2 .3 3 . N 7 3 .7 9 % , C3 H4 N 8  re q u ire s  C 2 3 .7 0 . H 2 .6 5 . 
N 7 3 .6 6 % . CIMS m /z  153 (M + H ]+ 170 CM + NH4 1+ .
5 . 5 '-E th v le n e b is — lH -te tra z o le  (9 )  . -  This was p repa red  In an a n a lo g o u s  
m anner from  s u c c in o n itr lle . m .p . 2 3 4 ° , l i t . 1® 2 3 0 ° . 1H n . m . r .  (D 2 0 )
3 .5  p. p. m . ( s )  . Analysis C 2 8 .9 0 . H 3 .2 2 ,  N 6 4 .1 % , C4 HgNg re q u ire s  
C 2 8 .9 0 . H 3 .6 4 .  N 6 4 .1 % . CIMS m /z  167 IM + H I* .  184 [M + NH 4 1+ .
1 H -T e tra z o le -5 -e th a n o lc  Acid  ( 1 0 ) . -  A so lu tion  in  DMF (1 0 0  m l) o f ethyl 
cya n o a ce ta te  ( 1 1 .5  g . 0 .1  m o l) ,  am m on ium  c h lo r id e  ( 5 .9  g . 0 .1 2  m ol) 
and dry sod ium  azide ( 7 .1 5  g . 0 .1 1  m ol) was heated  at 100° fo r 16 hours 
u n d e r n itro g e n . Excess DMF was rem oved in vacuo the res idue  d isso lved  
In w ater (5 0  m l) and then a c id ifie d  to pH 2 .0  w ith  HCI. This m ix tu re  was 
co o le d  to 5 °  when crys ta ls  sepa ra ted  ou t w h ich  were filte re d  o ff and 
w ashed w ith  Ice  w ater. R ecrys ta llisa tio n  from  p ro p a n -2 -o l gave  ethyl 
1 H -te tra z o le -5 -e th a n o a te  ( 7 .6  g . 5 0 % ). m .p .  1 2 8 ° . lit. 1 4  1 2 8 -1 3 0 ° .
The e thy l es te r (500  m g) was heated un d e r re flux in 3M NaOH 
so lu tion  (2 0  m l) fo r 4 hours . This so lu tio n  was neutra lised  w ith 5M HCI 
and then evapora ted  to  d ryness In vacuo. The res idue  was e x tra c te d  with 
ho t a c e to n itr ile  ( 1 0  m l) ,  f i lte re d , and the a ce to n itr ile  evapora ted  to 
d ryness . The 1 H -te tra z o le -5 -e th a n o lc  ac id  ob ta ined  was re c ry s ta llis e d  from  
a c e to n itr ile , y ie ld  360 mg (93% ) m .p . 1 7 0 °. 1H n .m . r .  ( 0 2 O) 6  4 .1
p .p .m .  ( s ) .  CIMS m /z  129 (M + H l+ . 146 [M + NH4 1+ . A nalysis C 2 8 .1 7 . 
H 3 .1 0 . N 4 3 .8 3 % . CgH 4 N 4 0 2  re q u ire s  C 2 8 .1 3 . H 3 .1 5 , N 4 3 .7 4 % . 
lH -T e tra z o le -5 - (3 '-D ro o lo n lc  A c id ) (1 1 ) . -  5 - ( 2 -C ya n o e th y l) -1  H - te tra z o le .
a b y -p ro d u c t form ed in the syn thes is  of ( 9 ) ,  was p u rifie d  by s ilica  
ch ro m a to g ra p h y  (so lve n t C) . m .p . 1 4 0 -1 4 2 ° , "*H n .m . r .  (d® -D M S O ) 6
3 .5 5  ( 2H t .  J = 6  Hz) 3 .8  p .p .m .  (2H  t. J = 6  Hz) . CIMS m /z  124 (M + 
H )* .
The cyanoethyl te trazo le  (5 0  m g) was heated under re flux  in 
so lu tion  In 20%  H C I/g la c ia l a ce tic  ac id  ( 2 . 5  m l. 1/1 v /v )  fo r 12 hours.
excess a c id was rem oved In vacuo and the res idue crys ta llised from
p ro a p n -2 -o l to g ive 1 H -te tra z o le -5 -- (3 '-p ro p io n ic ac id ) (3 6 m g. 62%)
m .p . 2 1 8 -2 2 0 °  (d e c . ) , 1H n .m . r . (D gO ) 6 2 .8 ( 2H t.  J = 6 .5 Hz) .
3 .2 2  p .p . m . (2H  t . J = 6. 5 Hz) . CIMS m /z  143 CM + H l+ , A na lys is . C
3 3 .8 .  H 4 .2 0 .  N 3 8 .9 1 %  C4 HgN4 0 2 re q u ire s  C 3 3 .8 .  H 4 .2 5 . N 
39. 42% .
DISCUSSION
In our hands, the  m ost e ffec tive  rou te  fo r the p repa ra tion  of 
5 - (p h o s p h o n o m e th y l) - lH - te tra z o le  (1 ) was by A rbusov reac tion  between 
tr le th y l pho sp h ite  and an N -p ro te c te d  5 -(c h lo ro m e th y l) - te tra z o le . If th is 
reac tion  is c a rr ie d  ou t w ith o u t p ro tec tion  of the  rin g  n itro g e n , a fu rthe r 
re a c tio n  o c c u rs  d u rin g  the  A rb u so v  reac tion  re su ltin g  in the fo rm a tio n  o f the 
d ie thy l e s te r o f N -e th y l 5 -(p h o s p h o n o m e th y l) - te tra z o le . The N -e th y l bond 
c a n n o t e a s ily  be broken and hence  the  lH - te tra z o ie  ca n n o t be prepared  by 
th is  m e th o d . The ethyl g ro u p  is p robab ly a ttached  to N -2  o f the te trazo le  
ring  as no n u c le a r O ve rhause r enhancem ent of s ig n a ls  in the 400 MHz *H 
n . m . r .  sp e c tru m  o f (4 )  c o u ld  be observed w hen the s igna ls  due to the 
pro tons o f e ith e r the  m e th y le n e  g roup  a ttached  to phosphorus or the 
m ethylene g ro u p  a ttached  to  n itro g e n  w ere ir ra d ia te d  be fore  a ccum u la tion  of 
the s p e c tru m . On the  o th e r hand , a s ig n ific a n t n u c le a r O verhauser
e n h a n ce m e n t of the  s igna ls  d u e  to the  pro tons o f both the m ethylene group 
attached to  ca rb o n  and th e  proton a lpha to the  ring  n itro g e n  atom  in 
N -m e th y l 2 -p y ro le a c e to n itr ile  (1 2 ) o cu rre d  when the s igna l due to the 
pro tons o f the  N -m e th y l g ro u p  was irra d ia te d  b e fo re  accum u la tion  of the 
sp e c tru m .
W e find tha t the  benzyloxym ethyl g ro u p 16 Is exce llen t fo r the 
p ro te c tio n  o f the ring  n itro g e n  atom  as it is easily  a ttached to the te trazo le
r in g , is s ta b le  unde r the  co n d itio n s  of the A rbusov reaction  and is readily
rem oved by tre a tm e n t w ith  tr if lu o ro a c e tic  ac id  at room  tem pera tu re . In 
co n tra s t to  the  re p o rt by Yaouanc et a l . 8 . we found that the  1 .3 -d ip o la r  
add ition  o f azide ion to d ie th y l p h o sp h o n o a ce to n itrile  gave n e g lig ib le  yie lds 
of the d ie th y l es te r o f ( 1 ) .  O ther te trazo le  ana logues used in our
in ve s tig a tio n s  were e ith e r m ade  by an adaptation of our synthesis  of (1 ) o r 
w ere m ade  by prev ious ly  pub lished  p ro ce d u re s . It is of in te re s t that the 
A rbusov re a c tio n  betw een tr le th y l phosph ite  and 3 - ( c h lo ro m e th y l) - 1 . 2 . 4 - t r i -  
azo le  d id n o t resu lt in a lky la tio n  of the ring  to a s ig n ifica n t extent and the
m ajor p ro d u c t of th is  reaction  was d ie th y l 3 - (p h o s p h o n o m e th y l) - l , 2 , 4 - t r i -  
azole. T he reason fo r this d iffe re n ce  in behaviour o f the ch lo ro m e th y l 
triazole and  te trazo le  Is not c le a r but It Is possib le  th a t the d iffe re n ce  in 
n u c le o p h lllc ity  between the ring  n itro g e n  atom s of the  two ring  system s may 
resu lt in  th is  d iffe re n t behaviour.
C o n tra ry  to  the previous report**, we did not find  tha t com pound 
(1 ) was an  e ffec tive  Inh ib ito r of the re p lic a tio n  o f e ith e r HSV-1 o r H SV-2 
when th e se  viruses were tested in tissu e  cu ltu re  (T a b le  2 ) .  C om pound 
(1 ) was a weak Inh ib ito r of ce ll free  DNA po lym erases Induced by e ith e r 
v irus s tra in  but the  conce n tra tio n s  p ro d u c in g  50% in h ib itio n  of the enzym e 
activity fo r e ithe r po lym erase were co n s id e ra b ly  g re a te r than th a t fo r 
phosphonoace tlc  a c id  (T ab le  2 ) .  C om pound  (1 ) was a m oderate  In h ib ito r 
o f the RNA transcrip tase  of In fluenza v iru s  A . the co n ce n tra tio n  p roduc ing  
50% in h ib itio n  of th is  enzyme was approx im a te ly  the sam e as th a t fo r 
p hosphonoace tic  ac id  (T ab le  1 ).
Both  phosphonoace tic  acid and  (1 )  have s im ila r a ffin ities  fo r z inc 
Ion un d e r the cond itions  of the tra n s c rip ta s e  assay (p K d < 5 .5  and 5 .6  
re s p e c tiv e ly ). A lte ra tion  in the  s tru c tu re  of (1 )  such as ring  a lky la tion  
( 4 ) .  In se rtio n  of an add itiona l m e thy lene  group between the te trazo le  ring 
and the phosphon lc  ac id  res idue ( 2 ) o r  re p la ce m e n t of the  phosphon ic  acid 
by a ca rboxy lic  ac id  res idue ( 1 0 ) gave com pounds w hich were poor 
ch e la to rs  o f z inc ion (pK d < < 4) and w h ich  were devoid o f an tiv ira l activ ity . 
R ep lacem ent of the phosphory l oxygen in (1 ) by su lphur g ives
5 -( th lo p h o s p h o n o m e th y l) - lH -te tra z o le  (3 )  and we prepared  th is  com pound 
by a M lchae lls  Becker reac tion  be tw een the an ion  of O -O -d ie th y l 
th lo p h o sp h lte  and N -p ro te c te d  ( 5 -c h lo ro m e th y l)- te tra z o le . The
th lo -a n a lo g u e  ( 3 ) was a good c h e la to r of z inc ions (p K ^ . > 6 ) and was a 
m ore e ffe c tive  Inh ib ito r of HSV-1 DNA polym erase and Influenza RNA 
tra n sc rip ta se  than the parent com pound  5 - (  p h o s p h o n o m e th y l)- lH -te tra z o le . 
The on ly  o the r com pound w hich had a p p re c ia b le  activ ity  as an In h ib ito r of
the DNA polym erases of HSV-1 or H S V -2  and the RNA tra n sc rip ta se  of
Influenza v irus was 3 -(p h o s p h o n o m e th y l) - 1 ,2 ,4 - t r ia z o le  (5 ) w hich was a 
m odera te  ch e la to r of z inc Ion (p K ^. 4 .7 )  (T ab le  1 ).
In an a ttem pt to Im prove the uptake of (1 )  In to  ce lls  and In view
of the reported  an tiv ira l activ ity  of nuc le o s id e  este rs  of phosphonoace tic
a c ld * ^ , we prepared the a d e n o s ln e -5 ' and th y m ld ln e -5 ' es te rs  of ( 1 ) .  Both 
of these  nucleos ide  esters were w eak in h ib ito rs  of HSV-1 and H SV-2
re p lica tio n  in Vero ce lls  a lthough  n e ith e r co m pound  showed a p p re c ia b le  
In h ib ito ry  a c tiv ity  a g a in s t the  ONA po lym erases in d u ce d  by these v iru se s  or 
ag a in s t In fluenza  v irus  RNA tra n s c rip ta s e .
T h u s , de sp ite  the  previous re p o rt8 , and desp ite  the s im ila r ity  in 
p ro p e rtie s  be tw een the  te trazo le  and carboxy lic  a c id  m o ie tie s , we do  not 
be lieve th a t 5 - (p h o s p h o n o m e th y l) - lH - te tra z o le  (1 )  shows p ro m ise  as a 
po ten tia l a n tiv ira l age n t.
ACKNOWLEDGEMENT
F in a n c ia l a ss is ta n ce  from  R oche P roducts  Ltd. . Welwyn G arden 
C ity . U. K. is g ra te fu lly  acknow ledged .
REFERENCES
1. B o e z l. J. A . Pharm. Thar.. 4. 231 (1 9 7 9 )
2. O b e rg , B. . Pharm. Thar. . 19. 387 (1 9 8 3 )
3 . C lo a d . P. A . and H u tch in so n , D. W. Nucleic Acids Has. . 11. 
5621 (1 9 8 3 )
4 . S tr id h . S. and D a tem a. R. Virology. 135. 293 (1984 )
5. H u tc h in s o n . D. 
in  p ress  (1 9 8 5 )
W. . N aylo r. M. and S e m p le . G . . Chem. Scripta.
6 . H u tc h in s o n . D. W. . N aylo r. M. and C u llls . P. M. Antiviral Res. .
5 . 67 (1 9 8 5 )
7. B u tle r. R. N. . Adv. Heterocyclic Cham.. 21. 323 (1 9 7 7 )
8 . Y aouanc. J. J. , S tartz . G. K raus. J . L. . C haste l. C . . and
C o lin . J. . Tetrahedron Letters. 21. 2689 (1980)
9. P ow e ll. K. L. and P urlfoy . D. J. M. . J. Virol. . 24. 618 (1 9 7 7 )
1 0 .
1 1 .
1 2 .
C lo a d . P. A. 
57 (1 9 8 3 )
S till.  W. C. J. 
B e h rin g e r. H.
and H u tch in so n , D. W. Org. Mass Spectrom. .
Org. Chem.. 43. 2923 (1978) 
and  Kohl. K. . Chem. Bar.. 89. 2648 (1 9 5 6 )
18.
13. J o n e s . R. G. 
1538 (1 9 7 7 )
and  A in sw o rth . C. . J. Amer. Chem. Soc. , 77.
14. F in n e g a n . W. G . H enry. R. A. 
Chem. Soc.. 80. 3908 (1 9 5 8 )
and Lofqu is t. R. . J. Amer.
15. W ille m s. J. F and H eugebaert. F. C. Belg. Patent. 722. 025
(1 9 6 9 ) :  Chem. Abs. . 72 . 66949 (1 9 7 0 )
16. A n d e rs o n . H. J . and G roves . J. K. . Tetrahedron Letters. 3165
(1 9 7 1 )
17. H e lm e r. E. P. and N ussbaum , A. L. . U .S . Patent 4 .0 5 6 ,6 7 3
(1 9 7 7 )
TABLE 1
E ffec t o f Tetrazo le  P hosphon ic  A c id s  and Analogues on 
RNA T ra n scrip ta se  of In fluenza  Virus A and th e ir A b ility  to Bind Z inc Ions
C om pound I 50 (pM ) pKd . (Z n 2+)
HOgCGHgPOgHg 350 5. 5
<i> 275 5. 6
( 2 ) 550 4. 6
(3 ) 130 > 6
(4 ) > 1 0 0 0 < 4
(5 ) 580 4. 7
( 6 ) > 1 0 0 0 n. d.
( 7) > 1 0 0 0 n. d.
( 8 ) > 1 0 0 0 < 4
(9 ) > 1 0 0 0 < 4
( 1 0 ) > 1 0 0 0 < 4
( 1 1 ) > 1 0 0 0 < 4
C oncen tra tion  p roduc ing  50%  in h ib itio n  of enzyme activity.
TABLE 2
E ffect of 
HSV-1 or
Tetrazoles 
H SV-2 and
on DNA 
on V irus
Polym erases
R eplica tion
in duced  by 
In Vero C ells
DNA P o lym erase I ^ q (pM ) HSV Plaque 
A ssay I 5 0
R eduction 
( m g /m l)
C om pound HSV-1 H S V -2 a HSV-1 H SV-1
h 2 o 3 p c h 2c o o h 1 0 1 0 40 0 . 0 2 2 0. 025
( 1 ) 2 2 0 275 > 1 0 0 0 0. 4 0. 35
( 2 ) > 1 0 0 0 > 1 0 0 0 > 1 0 0 0 > 1 > 1
(3 ) 90 n. d . > 500 n. d. n. d.
(4 ) 870 > 1 0 0 0 > 1 0 0 0 > i > 1
(5 ) 380 520 > 1 0 0 0 0. 7 0 . 82
( 6 ) 850 900 > 1 0 0 0 0. 7 0. 72
(7 ) > 1 0 0 0 > 1 0 0 0 > 1 0 0 0 0. 85 0. 9
C om pounds (8 -1 1 )  w ere Ina c tive  at < 1000 jxM (ONA po lym erase
assay o r « 1 m g /m l p laque  re d u c tio n  assay. No com pounds were 
cyto toxic  at conce n tra tio n  < 1 m g /m l In the p laque reduction  assay.
CHjCHjPO^Hj c h 2p <s ) ( o h )2
(3 )
°2  «5
(4> (6) (6 ) R m aduM M lm  -  S '
(7 ) R -  daoxythym kSn* -  f i '
N -------- N N----------N
K A
H CMî-C H j H
(0>
CHjCO OH
N -------N
H
CHjCHjCOOH
(10) (11) ( 12)
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The effect of pyrophosphate analogues on the replication of different strains of 
influenza virus A in tissue culture
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Pyrophosphate analogues such as phosphonoform ate (foscarnet), thiopyrophosphates, and substituted m ethylene 
bisphosphonates, inhibit the replication o f  influenza virus A/X49 in tissue culture (1 —3) by inhibiting the RN A  
transcriptase activity o f this virus. Pyrophosphate analogues, in particular, phosphonoform ate and phosphonoacetate (4), 
also inhibit the D N A  polymerase induced by herpes viruses and it has been observed that different strains o f herpes 
viruses exhibit different sensitivities to the inhibitors. For example, strains o f  HSV-1 and HSV-2 have been isolated which 
show complete resistance to phosphonoacetate or phosphonoform ate and this resistance has been correlated with changes 
in the DNA polymerases induced by these viruses (5 — 7). No reports have been published so far on  the sensitivities o f 
different strains o f  influenza virus A to  inhibition by pyrophosphate analogues, although it has been  observed that the 
effect o f rim antadine and ribavirin in com bination  on influenza virus replication in cell culture is dependent on the strain 
o f  virus used (8). W e are studying (9) the  effect o f pyrophosphate analogues such as phosphonoform ate and 5-phosphono- 
m ethyl-lH -tetrazole on the replication o f  influenza virus A in Madin-Darby canine kidney (M D C K ) cells and wish to 
report our observations on the variation o f inhibition with the virus strain used.
M ateria ls  and methods: A /X491H3N2, Recombinant: A/England/864/75 X A /PR /8/34] was a gift from  
D r N.J. Dim m ock, D epartm ent o f Biological Sciences, University o f Warwick. A/X31 [H3N2, Recom binant A /P R /8 /34  
(H1N1) X A /H ong Kong/1/68 (H 3N 2)], A /R 15  [A/R1/5*57(H2N2)1, A/WS [A/W S/33 (H IN D I were gifts from  D r K. 
Katrak, Roche Products Ltd, Welwyn, UK.
Inhibitor concentration (>iM)
Figure 1 (¡eft): Inh ib ition  o f  p laque fo rm a tio n  b y  s tra in s  o f  influenza  virus A  in M D C K  cells by phosphonoform ate, A /X 4 9  (is ) , A /X 3 1  (X )  
A /  R I 5  (9 )  a n d  A /  W S  ( o ) .  Figure 2  (right): In h ib itio n  o f  p laque fo rm a tio n  b y  strains o f  influenza  virus A  by 5-phosphonom ethyl-1 H -te tra zo le
A / X 4 9  (£s) A /X 3 1  (X ). A / R I 5  ( • ) ,  a n d  A /  W S  (o ) .
For the plaque reduction assay M DCK cells were seeded onto 5 cm plastic dishes at 3.0 x  10® cells/plate and the cells 
were grown at 37°C until confluent in m aintenance m edium . The confluent monolayers were washed with PBS and 
aspirated to dryness. Virus suspension (100 ¿¿1, 60 PFU) was added to the cell sheets and left for 15 min at room  
tem perature. The test com pound at the appropriate concentration (400 /ul) was then added and left for 45 m in before 
addition o f the overlay which consisted o f  an agar m edium  containing 0.1% BSA, 2.5 /¿g/ml crystalline trypsin and 0.1% 
D EAE Dextran. T he plates were incubated at 33°C for 4 — 6 days, stained with neutral red and the plaques counted.
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Results and discussion: The results are presented in Figures 1 and 2. The sensitivities o f  our strains o f influenza virus A 
to different concentrations o f phosphonoform ate (Figure 1) and 5-phosphonom ethyl-lH -tetrazole (Figure 2) are shown. It 
may be seen that the A/W S strain was the m ost and A/X49 was the least sensitive. T he reason for this difference in 
sensitivity is not known and we are studying the  effect of pyrophosphate analogues on the  RNA transcriptase activities o f 
these viruses. However, we present these data at this time as we wish to draw to the atten tion  of others that the strain o f 
influenza virus A used may well affect results on the inhibition o f  virus replication by various compounds.
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INHIBITION OF VIRAL NUCLEIC ACID SYNTHESIS BY ANALOGUES OF INORGANIC PYROPHOSPHATE
D. W. Hutchinson, . Naylor and G Semple
Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
2ABSTRACT
Analogues of Inorganic pyrophosphate can Inhibit the DNA 
polymerase of herpes simplex virus 1, or the RNA transcriptase 
activity of influenza virus A. Stuctural features of the 
pyrophosphate analogues which are essential for their 
inhibitory activity are discussed and these are related to the 
ability of the analogues to bind zinc ion.
INTRODUCTION
A number of nucleoside analogues such as acyclovir [1] 
and (E )-5-bromoviny1-2'-deoxyuridine (BVDU) [2] have recently 
been shown to possess antiviral activity and much effort has 
been spent recently on the synthesis of nucleoside analogues 
which might have better therapeutic properties than these two 
compounds. Both acyclovir and BVDU inhibit the synthesis of 
DNA in herpes-infected cells. Initially these two compounds 
are phosphorylated by virus-induced enzymes to give their 
5'-monophosphates, these are then converted into the 
5'-triphosphates which inhibit DNA synthesis in the 
virus-infected cells. Thus, the analogues must be metabolised 
before they can exhibit their antiviral properties and they are 
only active against a narrow range of viruses of the herpes 
family.
Compounds which inhibit nucleic acid synthesis in 
virus - infected cells without the necessity of a metabolic step 
might be expected to be active against a wider range of viruses 
than acyclovir or BVDU and might have clinical value so long as 
toxicity problems can be overcome. One such class of
3inhibitors are analogues of inorganic pyrophosphate which can 
inhibit the reaction:
pppX < - * (pX)n + PPi
Phosphonoacet ic acid (1) [3] was the first member of this
family to be shown to possess antiviral activity and the 
related compound phosphonoformic acid (2) [4] is also an active 
antiviral agent. Both (1) and (2) inhibit DNA synthesis in 
cells which have been infected by herpes viruses and these 
compounds inhibit the DNA polymerases induced by these viruses.
(HO)2P(0)CH2COOH (H0)2P(0)C00H (HO)2P(0)CH2C00Me
(1) (2) (3)
Me0(H0)P(0)CH2C00H ( HO )2P (O )CH?CH?COOH (HO)?P (O )CR1R2P (O ) (OH)2
(4) (5) (6)
The antiviral properties of a number of analogues of (1) 
and (2) have been examined and it has been observed that 
esterification of either the phosphoryl or the carboxyl groups 
to give for example (3) or (4) leads to a marked reduction in 
the antiviral activity [5]. Moreover, insertion of extra 
methylene groups between the phosphoryl and carboxyl groups as 
in (5) also reduces the antiviral activity. Enzyme kinetic [6 ] 
and other data [7] indicate that these compounds inhibit the 
herpes-induced DNA polymerases by acting directly on the 
enzymes without prior conversion into an active compound and 
that (1) and (2) probably act by chelating with an essential 
metal ion in the DNA polymerases induced by herpes viruses. 
Pyrophosphate analogues can also be effective inhibitors of the
4RNA transcriptase activity of influenza virus A. Initiation of 
mRNA synthesis does take place in the presence of 
phosphonoformate (2) but elongation of the RNA chain does not 
occur [8].
We have studied a variety of pyrophosphate analogues and 
believe that their ability to inhibit nucleic acid synthesis in 
cells which have been infected with either herpes or influenza 
viruses is related to their ability to form stable chelates 
with a metal ion (probably zinc) at the active centres of the 
enzyme systems [9]. We have shown that there is a good 
relationship between the ability of the analogue to bind zinc 
ion at pH 8 and its effectiveness as an inhibitor of influenza 
mRNA synthesis [7]. We determine the binding constant of the 
analogue to zinc ion by a simple gel-filtration method at the 
pH optimum of the transcriptase reaction and from this derive 
the term pK^ j. which we define as -log10 (dissociation constant 
of zinc ion - pyrophosphate analogue complex). The ionic 
species of the analogue which binds to the zinc ion is not 
defined in our term pK^ ■ as this merely refers to the ability of 
all ionic species present to bind zinc ion under given 
conditions, i.e., the conditions of the transcriptase assay. We 
find that if a pyrophosphate analogue has a pK^, * 6 under these 
conditions then the compound is a good inhibitor of the 
transcriptase, on the other hand compounds with a pKçj. < 5 are 
in general poor inhibitors of the transcriptase (Table 1). The 
exact nature of the metal ion at the active centre of the 
transcriptase system has not been determined unegulvocal J y. 
Addition of excess magnesium or manganese ion to the 
transcriptase assay system fails to affect RNA synthesis a n d
5hence it is unlikely that these are the essential metal ions. 
It has been proposed [10] that most polymerase enzymes require 
zinc for activity and it has been shown the influenza viruses 
do contain zinc [11]. Addition of zinc ions to the 
transcriptase assay which has been partially inhibited by a 
pyrophosphate analogue restores the enzymic activity to a 
limited extent. However, zinc ion is toxic to the enzyme at 
high concentrations [12] and when excess zinc ion is added to 
the system full enzymic activity is not restored.
The results of our studies on pyrophosphate analogues 
can best be summarised by considering phosphonoacetic acid as 
the archetype pyrophosphate analogue and considering in turn 
the changes in biological activity which are brought about by 
varying the carboxyl, methylene and phosphoryl groups.
(a) Variation of the Carboxyl Group
As mentioned earlier, esterification of the carboxyl 
group in (1) leads to a loss of antiviral activity in cell free 
systems and a similar loss in activity is observed when the 
carboxyl group is replaced by an amide group. In animals, 
however, some carboxylic esters do have anti-herpes activty 
presumably because these esters are hydrolysed in vivo to 
liberate the free acid [5]. Replacement of the carboxyl group 
by a phosphoryl group gives rise to methylene bisphosphonic 
acid (6, R1-R2«H). While the parent compound is devoid of 
antiviral activity, as will be discussed later, replacement of 
hydrogen by an electron withdrawing group leads to compounds, 
e.g. (6, R^-R2-C1) which are good inhibitors of the RNA 
transcriptase of influenza virus but which have little or no
6anti-herpes activity.
Analogues of amino acids in which the carboxylic acid 
residue has been replaced by a lH-tetrazole residue have pKa 
values which are close to those of the parent amino acids and 
the tetrazole moiety has been used as an isostere for the 
carboxylic acid group in many pharmaceutically active compounds 
[13]. The recent report that 5-phosphonomethyl tetrazole (7) 
has anti-herpes activity [14] prompted us to synthesise a range 
of heterocyclic analogues of phosphonoacetic acid [15]. 
Treatment of 5-(chloromethyl)-lH-tetrazole with triethyl
phosphite gave the diethyl ester of /V-ethyl-5-(phosphono- 
methyl)-tetrazole presumably due to intramolecular attack by 
the tetrazole ring on the intermediate formed in the Arbusov 
reaction. The esterifying groups of the phosphonic acid
residue could be removed by acid but A/-ethy 1-5-(phosphono- 
methylj-tetrazole (10) was a very poor chelator of zinc ion and 
had no effect on the transcriptase of influenza virus. The 
ethyl group could not readily be removed from the tetrazole 
ring in this synthetic route, so we protected this ring with 
the benzyloxymethyl group before the Arbusov reaction. The 
diethyl groups and the benzyloxymethyl residue were readily 
removed from the Arbusov product with acid and 
5-(phosphonomethyl)-lH-tetrazole (7) was obtained in high 
yield. The 5-(phosphonoethyl) analogue (9) was obtained in a 
similar fashion. It is interesting that the Arbusov reaction 
between 3-(chloromethyl)-1H-1,2,4-triazole proceeded smoothly 
without any intramolecular alkylation of the triazole ring. The 
bistetrazole (12) and the carboxylic acid (30) were prepared by
standard methods.
We find that compound (7) and its triazole analogue (8) 
are weak inhibitors of the DNA polymerase induced by HSV-1. 
The 5-phosphonoethyl tetrazole (9) and the N-alkylated analogue 
(10) show no inhibitory activity against this enzyme. Of the 
four compounds, only (7) has significant inhibitory activity 
against the RNA transcriptase of influenza. The carboxylic 
acid (11) and the bis-tetrazole (12) do not inhibit either the 
DNA polymerase of HSV-1 or influenza RNA transcriptase. Only 
compound (7) binds zinc to an appreciable extent (pKd . - 5.6) 
and hence this parameter again is a pointer to the antiviral 
activity of these compounds (Table 2).
(b) Variation of the Methylene Group
The homologue of phosphonoacetic acid without a 
methylene group is phosphonoformic acid (2), a compound which 
is in general a more active antiviral agent than (1). The 
homologue of (1) with two methylene groups is 
3-phosphonopropionic acid (3) a compound with litle antivral 
activity. The effectiveness of these compounds as inhibitors of 
influenza transcriptase is again reflected by their ability to 
bind zinc ion (Table 1). One reason for the gradation in pl^ , 
values is that compound (2) forms a chelate with a 
f ive-membered ring, (1) forms a chelate with a six-membered 
ring and (3) forms a chelate with a seven-membered ring. It is 
well known that the order of stability of cyclic metal chelates 
is 5 > 6 > 7 [16]. Substitution of the methylene group with an 
alkyl or aryl group can lead to a loss of activity as a 
transcriptase inhibitor in cell-free systems. However, an 
increase in activity can be observed in tissue culture probably 
because these compounds are more lipophilic than the parent and
8are taken up more readily by cells [17]. Replacement of the two 
hydrogen atoms of the methylene group in (1) by two chlorine 
atoms has a marked effect on the properties of the carboxyl 
group. The ability of dichlorophosphonoacetic acid to bind 
zinc ion is low (pK<ji < 4) and the compound does not inhibit the 
RNA transcriptase of influenza virus..
As mentioned above, methylene bisphosphonate (6, R1 = R^ 
* H) has little or no antiviral activity. Replacement of the 
bridge hydrogen atoms in (6) by electron withdrawing groups 
such as halogen increases the ability of these compounds to 
bind zinc ion and markedly increases their antiviral activity 
[7]. Replacement of the bridging methylene group by a carbonyl 
group (13) also leads to a good chelator of metal ions with both 
anti-herpes [18] and anti-influenza activity [7]. The 
presence of at least one electron withdrawing group on the 
bridging carbon atom in (6) and the observation that lipophilic 
pyrophosphate analogues are often more effective as inhibitors 
of viral replication in tissue culture than the polar parent 
compounds has led us to prepare [19] a number of C-alkyl 
monochloromethylene bisphosphonates. As may be seen in Table 3,
these compounds are inhibitors of the RN transcr iptase of
influenza virus A in cell free systems and are inhibitors of
viral replication in MDCK cells (Table 3). While the ability 
of these compounds to inhibit the transcriptase appears to be 
independent of chain length, the hexyl- and benzyl-substituted 
bisphosphonates are the most effective inhibitors of viral 
replication in cell culture. All are more effective than 
phosphonoacetic acid in both inhibitory systems.
9(c) Variation in the Phosphoryl Group
Inorganic pyrophosphate at a sufficiently high 
concentration will inhibit RNA synthesis by the influenza 
transcr iptase system (Table 1) [7]. Replacement of one or both 
phosphoryl groups by a thiophosphoryl group leads to mono-(14) 
and bis-(15)thiopyrophosphate. Both these compounds are 
considerably more effective than the parent pyrophosphate in 
inhibiting the replication of influenza virus A in MDCK cells 
and the synthesis of RNA by the transcr iptase system [20]. 
Sulphur is a "soft" centre and oxygen is a "hard" centre on the 
Pearson "hard and soft" acid and base scale [9]. Both (14) and 
(15) are good chelators of zinc ion and it is possible that the 
increased antiviral activity shown by the thiopyrophosphates is 
related to the formation of stronger metal chelates in the 
transcriptase system of influenza virus than with 
pyrophosphate.
Removal of the oxygen between the phosphoryl groups of 
pyrophosphate gives rise to hypophosphate (16). While this has 
been shown to be an inhibitor of the DNA polymerase of 
herpes-infected cells [18], we have shown it to have little or 
no effect on the transcriptase of influenza virus. Similarly 
peroxyd iphosphonate (17) is inactive against the transcriptase 
and the inactivity of (16) and (17) can be correlated with the 
abilities of these compounds to bind zinc ions (Table 2). In 
these latter two compounds, the change in distance between the 
two chelating phosphoryl groups may also be important.
Replacement of the phosphoryl group in (1) by the 
arsonate group to give arsonacetate (18) leads to a compound 
with anti-herpes activity [21] and with some anti-influenza
I O
activity. Methylene biaarsonate (19) also shows little 
antiviral activity. Furthermore, toxicity problems
associated with these arsenicale and with hypophosphate make 
them unattractive for clinical use.
(H0)2P(0)C0P(0)(0H)2 (H0)2P(0)0P(S)(0H)2 (HO)2P(S)OP(S)(OH)2
(13) (14) (15)
(H0)2P(0)P(0)(0H)2 (H0)2P(0)00P(0)(0H)2 h 2o 3a s c h 2c o o h  CH2(AS03H2 )2
(16) (17) (18) (19)
DISCUSSION
We believe that the evidence presented above strongly 
supports the sugestión that nucleic acid synthesis in cells 
which have been infected by either herpes or influenza viruses 
can be inhibited by pyrophosphate anlogues which act by forming 
a very stable chelate with an essential metal ion in the 
polymerase/transcriptase enzyme systems induced by the viruses. 
Before pyrophosphate analogues are adopted for clinical use, 
however, there are obvious toxicity problems to be overcome as 
many processes in the host cells involve the
liberation of pyrophosphate and these may be affected by the 
presence of pyrophosphate analogues. One such problem is the 
accumulation of certain pyrophosphate analogues in bones and 
teeth [22]. This problem may be obviated by using these
compounds topically to treat, for example, herpes infections. 
Another way in which this accumulation in bone might be 
overcome is to incorporate bulky groups into the analogues as 
this should make them less compatible with the hydroxy apatite
11
lattice of bones [23] and hence make them less likely to be 
incorporated into this lattice.
It is encouraging that many of the pyrophosphate 
analogues which inhibit virus-induced processes do not seem to 
be highly toxic to cells. For example, the thiopyrophosphates 
(14) and (15) inhibit the replication of influenza A virus in 
MDCK cells at concentrations which do not appear to affect the 
viability of the cells after 48 hours [19]. Furthermore, 
substituted methylene bisphosphonates inhibit the
transcriptase of influenza virus A at concentrations at which 
they have little or no effect on the DNA polymerases of HSV-1 or 
-2, the DNA polymerase a [17] of mammalian cells (Table 1) and 
the DNA and RNA polymerases of Escherichia coli [7],
Recently, the effect has been studied of a large number 
of derivatives of phosphonoacetic acid on the DNA polymerase 
induced by HSV-2 and on the replication of HSV-2 in tissue 
culture [24]. The results of these investigations broadly 
agree with those outlined above except that it was observed 
that carboxylic esters of low molecular weight alcohols 
inhibited the DNA polymerase. This result is in contract with 
observations with HSV-1 [25] and our observations with the RNA 
transcriptase of influenza. The reason for this difference 
is not clear and deserves further investigation.
The hypothesis that pyrophosphate analogues inhibit 
virus replication by virtue of their chelating with an 
essential metal ion should lead to the design of compounds with 
significant biological activity but which incorporate features 
which reduce their toxicity or which lead to an increase in the 
uptake of the analogue into a particular region of the host.
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EXPERIMENTAL
Materials
Arsonoacetate and methylene bisarsonate were gifts from 
Dr.H.B.F.Dixon, Cambridge University, U.K., hypophosphate was a 
gift from Dr. B. V. L. Potter, Leicester University, U.K., and 
peroxydiphosphonate was a gift from Professor N. J. Leonard, 
University of Illinois at Urbana-Champaign, U.S.A. C-Alkyl 
monochlor omethylene bisphosphonates [19] and heterocyclic 
methylene monophosphonates [15] were prepared as described. 
Biological Assays
The influenza virus strain used in these experiments was 
A/X49, a cross between A/England/864/75 and A/PR/8/34 with the 
H3N2 surface antigens of the A/England strain. RNA
transcriptase assays and the determination of the antiviral 
activity of compounds in Madin Darby Canine Kidney (MDCK) cells 
were carried out as previously described [20]. The herpes 
simplex-1 virus strain used was KOS. The inhibition by 
pyrophosphate analogues of the DNA polymerase induced by this 
virus was carried by the method of Powell and Purifroy [26] and 
the DNA polymerase a assays were carried out by the method of 
Sabourin ot at. [27]. The determination of pKd . values related to 
the strength of the binding of zinc ion to the pyrophosphate 
analogues were determined by a gel-filtration method [7].
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TABLE 1
INHIBITORY EFFECT OF PHOSPHONOACETIC ACID ANALOGUES AND METHYLENE BISPHOSPHONATES OF THE RNA TRANSCRIPTASE OF INFLUENZA VIRUS A AND CALF THYMUS DNA POLYMERASE a [7]
Compound
PKdl
(Z n 2 * )
Concn. (jiM )
In fluenza RNA 
T ranscriptase
Producing 50% Inh ib ition
DNA Polym erase a
rch2cooh 5.5 275 45
RCOOH 5.6 35 35
RCH2CH2COOH < 4 > 500 > 500
RCHMeCOOH ~ 5 500 > 500
rconh2 < 4 > 500 > 500
(EtO)2P (O )CH2COOH < 4 > 500 > 500
ROR 5.7 125 > 500
RNHR 5.7 50 > 500
rch2r 5.3 > 500 > 500
RCHC1R > 6 85 > 500
rcci2r > 6 75 > 500
RCBr 2R > 6 10 350
RCOR 5 . 4 20 100
Where R - (HO)2P(0)
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TABLE 2
INHIBITORY EFFECT OF PYROPHOSPHATE ANALOGUES AND HETEROCYCLIC METHYLENE PHOSPHONATES ON THE RNA TRANSCRIPTASE OF INFLUENZA VIRUS A AND THE DNA POLYMERASE OF HSV-1
Co n o n . (¿lM) Producing 5 0 *  Inhibition
p*d -
(Zn2 * )
Influenza A HSV-1
Compound "RNA transcriptase DNA polymerase
Heterocyclic Analogues
5 -  ( Phosphonom ethyl )- te tra z o le  ( 7 ) 5.6 275 220
3 -  ( Phosphonom ethyl ) - 1 ,2 ,  4 -tria zo le  (8  ) 4. 7 580 385
5 -  ( Phosphonoethyl ) - te tra z o le  (9  ) 4.6 550 > 1000
N -e th y l-5 - ( phosphonom ethyl )- te tra z o le < 4 > 1000 870
(1 0 )
T e tra zo le -5 -e th a n o ic  acid (1 1 ) < 4 > 1000 > 1000
St S '-M ethy le ne  b is te trazo le ( 12 ) < 4 > 1000 > 1000
Others
M onoth iopyrophosphate (1 4 ) 5.4 60 > 500
B isth iopyrophosphate( 15 ) > 6 33 > 500
Hypophosphate ( 16 ) 5.1 > 500 150
Peroxydiphosphonate (17) 4.8 - 500 n.d.
Arsonoacetate (1 8 ) 4.7 > 500 n.d.
M ethylenebisarsenate  ( 19 ) ~ 5 > 500 n.d.
n.d. not determined
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TABLE 3
INHIBITORY EFFECT OF C-ALKYL MONOCHLOROMETHYLENE BISPHOSPHONATES RCC1(P03H2)2 ON THE RNA TRANSCRIPTASE OF INFLUENZA VIRUS A AND ON THE REPLICATION OF INFLUENZA VIRUS A IN MDCK CELLS
R
pKd- 
( Zrr+) I250 (%) PR500<%)
H > 6 97 22
Me n.d. 54 n.d.
Et n.d. 61 n.d.
n-Pr n.d. 55 34
n-Bu > 6 64 37
n-Hex > 6 59 83
CH2Ph > 6 58 60
PAA(l) 5.5 35 0
n.d. not determined
^SO " % inhibition of tion of 250 iM transcriptase at
phosphonate concentra-
pr500 ■= % reduction of phosphate at a PFU (Virus Control - 7.7 x 10 concentration of 500 ßM
®) caused by
18
(15) 2.10 4.2
19
FIGURE 1 PHOSPHONOACETIC A C ID
H O  ||
/
HO CH
COOH
Phosphonoacetic Acid
20
FIGURE 2 HETEROCYCLIC ANAIXXJUES OF PHOSPHONOACETIC ACID
Et
(10) (11) (12)
\ 21
FIGURE 3 METAL CHELATES OF (A) PHOSPHONOFORMIC, (B)PHOSPHONOACETIC, AND (C) 3-PHOSPHONOPROPIONIC 
ACIDS.
(a) (b) (c)
Metal chelates of (a ) phosphonoformic (b )  phosphonoacetic 
and (c )  3-phosphonopropionic acids.
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1 6 -2 8
Joseph, S. K ., V erhoeven, A. J . & Meijer, A. J . (1 9 8 1 )  B io ch im . 
B io p h y s . A c t a  6 7 7 , 5 0 6 -5 1 1
O chs, R. S. &  L a rd y , H. A. (1 9 8 3 )7 . B io l. C h em . 2 5 8 , 9 9 5 6 -9 9 6 2
S taddon , J . M .&  MeGivan, J . D . (1984) B io c h e m . J . 2 1 7 ,4 7 7 - 4 8 3  
T aylor, W. M., R einhart, P. H . & Bygrave, F . L. (1983 ) B io c h e m . J. 
2 1 2 ,5 5 5 -5 6 5
W illiamson, D. H ., L und, P. & K rebs, H. A. (1 9 6 7 ) B io c h e m . J . 103, 
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S tr e s s  p r o t e in s  a re  in d u c e d  b y  h y p e r o s m o la r i t y  in  c h ic k  e m b r y o  f ib r o b la s t s
PIER G IO R G IO  PETRO N IN I, MARIA ROSARI A 
TRAM A CERE, GIUSEPPE PIEDIMONTE and 
ANGELO F. BORGHETTI
Istitu to  d i Patologia Generale, Università d i Parma, 43100  
Parma, Ita ly
A wide range o f  environm ental stim uli includ ing  heat, 
oxygen deprivation , teratogens, heavy m etals, e th y l  alcohol, 
am ino acid analogues e tc ., is known to  induce th e  synthesis 
o f a family o f  stress p roteins in p rokaryotic and  eukaryotic  
cells (A shbum er & Bonner, 1979). The fun c tio n s o f  these 
inducible stress proteins are poorly understood . Schlesinger 
e t al. (1982) have hypothesized  tha t the in d u c tio n  o f  these 
proteins cou ld  defend the cell exposed to  an environm ental 
insult from  fu rth er damage by m odifying the nuclear and 
the cy toplasm ic cy toskeleton  so to  p ro tec t th e  m etabolic 
apparatus from  the stim ulus persistance and  to  adapt 
consequently . In addition, the process o f  cell ad ap ta tio n  to 
adverse environm ental factors is know n to  involve the cell’s 
ability to  m odify  the chemical com plexion o f  the m em brane 
and to  alter tile  activity o f  m em brane-associated enzymes 
including tran sp o rt processes (Q uinn, 1983).
We have recently  show n that the exposure o f  chick 
em bryo fibroblasts to  a hyperosm olar m edium  resu lts in an 
increase o f  am ino  acid-transport activity. T h is  change 
appears to  be restricted to  the A system o f  m ed ia tion  for 
neutral am ino  acids, to  be dependent on bo th  active tran­
scription and  translation, and to  require a con tinuous 
exposure o f  the cells to  the hyperosm olar stim ulus 
(Tram acere e t  al., 1984a,b).
In pursuing a correlation betw een the p robab le  increase 
in the num ber o f  transport m olecules and the a ltera tion  o f  
gene expression in cells exposed to  a h yperosm olar environ­
m ent, we s tu d ied  the p a tte rn  o f  polypeptides synthesized 
during the ad ap ta tio n  process to  a hyperosm olar stress.
Secondary cultures o f  chick em bryo fib rob lasts were 
exposed to  0 .5  o s m  in com plete culture m edium . Labelling 
was perform ed  betw een 0 .5  and 3 or 18.5 and 21 h o f  the 
hyperosm olar treatm ent. Cells were then solubilized  in 
SDS/sample b u ffe r and the labelled proteins were separated 
on 10% (w /v ) SD S/polyacrylam ide slab gel (Lacm m li, 
1970) and de tec ted  by fiuorography as described b y  Bonner 
& Laskey (1974).
The effect o f  cell exposure for 3 o r 21 h to  a  0.5 osM 
m edium  on th e  pattern  o f  pro tein  synthesis was exam ined. 
When the p a tte rn  o f  polypeptides synthesized du ring  the 
treatm ent was com pared with those syn thesized  by un­
treated  cells, the  synthesis o f  certain pro teins appeared 
reduced w hereas for others there was a clear enhancem ent. 
As shown in Fig. 1, after 3 h o f  hyperosm olar trea tm en t 
four proteins w ith  apparent M r o f  76 000, 59 0 0 0 , 5 1 0 0 0  
and 38 000 w ere synthesized in sm aller am o u n ts  than in 
con tro l cells, m eanwhile o thers (Mr 63 000 and 36 000) 
were synthesized  in greater am ounts. When cells were 
labelled betw een  18.5 and 21 h o f  hyperosm olar trea tm en t, 
the synthesis o f  those polypeptides th a t a t 3 h o f  hyper­
osm olar exposure  appeared reduced or increased, returned
A bbreviation used : SDS, sodium  dodccy l sulphate.
Fig. 1. Pattern o f  proteins sy n th es ized  in hyperosm olarity- 
treated chick e m b ry o  fibroblasts
Cells were exposed to 0.5 o s m  in com plete culture m edium . 
The labelling procedure w as perform ed with lO^iCi of 
( 14Clglycine/ml between 0 .5 and 3 o r 18.5 and 21 h o f the 
hyperosm olar treatm ent. Show n is a fluorograph o f  th e  gel. 
Lancs (a) and (6): co n tro ls  at 3 o r  21 h o f  incubation , 
respectively. Lanes (c) and (d ):  cells exposed to  0.5 o s m  for 
3 or 21 h, respectively.
to  contro l values. M oreover, the synthesis o f  M t 57 000 
polypeptide was m arkedly increased. These prelim inary 
data suggest th a t the expression  o f  some specific p ro teins 
changes at specific times during  the cell adap ta tion  to 
hyperosm olarity. At early tim es there is a change in the
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synthesis o f  several po lypep tides, whereas at la ter times the 
protein pattern  appears to  be similar to control.
Our unpublished observations on the behaviour o f such 
param eters as po lyribosom e profile, cation co n ten t and 
am ino acid transport have shown a strong pertu rbation  o f 
these param eters in tile  first few hours o f  hyperosm olar 
treatm ent followed by  a slow but persistent re tu rn  to  the 
values o f  the control. These results are an indication o f  the 
capacity o f  the cells to  cope w ith an osm otically altered 
environm ent and arc com patib le  w ith the above described 
m odulation o f p ro te in  synthesis. O f course, the possibility 
that the change in the  expression o f  specific p ro teins might 
be referred to  the a lte ra tio n  o f  some functions in hyper- 
osm olarity-treated cells deserves fu rther study.
This work was suppo rted  by grants from  the Consiglio Nazionale 
deile Ricerche (p rogetto  finalizzato Oncologia n. 8 4 .00466 .44 ) and 
by the  Associazione Italiana per la Ricerca sul Cancro.
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P y r o p h o s p h a t e  a n a lo g u e s  as in h ib ito r s  o f  v ira l p o ly m e r a s e s
DAVID VV. HUTCHINSON, MATTHEW NAYLOR, 
GRAEME SEMPLE a n d  PAUL A. CLOAD 
D epartm ent o f  C hem istry , University o f  Warwick, Coventry  
C V4 7AL, U.K.
Analogues o f  pyrophosphoric  acid, e.g. phosphonoacetic 
(I), phosphonoform ic ( II )  and C -substituted m ethylene 
bisphosphonic acids ( I I I )  and the related te trazoie (IV) 
can act as product inh ib ito rs o f  viral polym erases. For 
exam ple, the replication  o f  herpes viruses can be inhibited 
by (I) (Boezi, 1979) o r (II)(O b erg , 1983), both  com pounds 
inhibiting the DNA polym erases induced by these viruses. 
In addition, (I), (II), ( I I I ,  X =  Y =  Cl) and (IV ) can inhibit 
the RNA transcriptase activ ity  o f  influenza virus A (Cload 
& H utchinson, 1983; S tr id h  & Datem a, 1984).
(H 0 )2P (0)C H 2C 0 2H
(1)
(H 0 )2P (0 )C X Y P (0)(O H )2
(III)
(H 0 )2P (S )0 1 \0 )(0 H )2
(V)
(1 I0 )2P (0 )C 0 21I
(II)
N ------ N
H 1n-n ^
II
CH 2P(O XOH)2
(IV )
(lIO )2P(S)O P(SX O II)2
(VI)
The inhibition o f  th e  RNA transcriptase activity of 
influenza vim s by these com pounds appears to  be related 
to  their abilities to form  com plexes with an essential metal 
ion (probably zinc) in the  transcriptase (Cload & H utchinson, 
1983; Hutchinson 1985). Thus (III, X =  Y =  H) forms 
only weak complexes w ith  zinc ions at physiological pH 
while (III, X =  Y =  Cl) fo n n s  considerably stronger com­
plexes. This behaviour is  paralleled in their inhibitory 
activities and (111, X =  Y  =  Cl) is a good inh ib ito r o f  the 
RNA transcriptase activ ity  while (III, X =  Y =  H ) is a poor 
inhibitor.
The metal chelating p roperties o f  inorganic pyrophos­
phate are affected if ox y g en  atom s are replaced by sulphur. 
Oxygen is a ‘hard’ c en tre  o f  the Pearson Hard and Soft 
Acid and Base Scale w hile sulphur is a ‘so ft’ centre (Pearson, 
1968). Thus, th iopyrop liosphates m ight be expected  to 
bind to Z n2* ions in a m an n er d ifferent to tha t observed 
w ith pyrophosphate. We have shown by 3IP n.m .r. that 
bisthiopyrophosphate (V I)  appears to  bind to  Z n2* through
sulphur while it  b inds to  Mg2* through oxygen (Hutchinson 
et al., 1985). Mono- (V) and bis-thiopyrophosphate (VI) 
form  strong com plexes w ith Z n2* ions under physiological 
conditions. They are as good inhibitors o f  tire RNA tran­
scriptase activity o f  influenza virus A as com pounds ( I)—(IV) 
and are better inh ib ito rs o f  the transcriptase than inorganic 
pyrophosphate. M ono-and bis-thiopyrophosphate inhibit 
the replication o f  influenza vims A in MDCK cells and do 
n o t appear to  be cy to tox ic  to these cells after 3 days at 
concentrations w hich cause m arked inhibition o f  virus 
replication.
Lipid-soluble pyrophosphate analogues should be taken 
up by cells m ore readily than highly polar com pounds, 
e.g. (I)—(III). The presence o f  an electron-w ithdrawing 
group on the bridge carbon atom  o f  m ethylene bisphos­
phonates is necessary if  these bisphosphonates are to  be 
good inhibitors o f  the RNA transcriptase o f  influenza 
virus A (Cload & H utchinson, 1983). We have developed 
a m ethod  for the synthesis o f  C-alkylated m onochloro- 
bisphosphonates (V ll)  in high yield:
(R 10 ) 2P (0)C H C 1P (0X 0R ' )2
(h o ) 2p ( o x : r 2c ip (0 ) ( o h )2
The key steps in o u r synthetic route are the use of 
thallium (l) e thoxide as base to form  the anion from a 
tetra-alkyl ester o f  m onochlorom ethylene bisphosphonate 
follow ed by reaction w ith an alkyl iodide and de­
esterification with trim ethylsilyl brom ide (Hutchinson 
& Semple, 1985). In this way (V ll) can be prepared in 
over 80%  yield overall. If the sodio- or lithio-salts o f 
the m onoanion o f  the te tra  ester o f  m onochlorotncthylcne 
bisphosphonate are used in the alkylation step or if dc- 
estcrification is carried o u t by hydrolysis w ith concen­
trated  acid, m arked reductions in the yield o f  (V II) occur. 
In prelim inary experim ents, we have shown that (V II, 
R — Me, n-Pr, n-Bu, n -llcx) arc effective inhibitors o f
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th e  RNA transcrip tase activity o f  influenza virus A as 
th is activity is inhib ited  by m ore th an  50% when the 
analogues are presen t a t a concen tration  o f  250/iM-
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Several acid-soluble nucleotides act as specific signals in the 
regulation o f  m etabolic reactions (Tom kins, 1975). The 
p as t decade has seen a considerable grow th in interest in 
the novel purine nucleotide P l ,P4-bis-(5’-adcnosyl)-tetra- 
phosphate  (A p4A). This apparently  ubiqu itous com ponent 
o f  living cells has been shown to  alter its  intracellular con­
cen tra tio n  up to  1000-fold during the G t to  S progression 
o f  a synchronized cell cycle (W cinmann-Dorsch et al., 
1984). It may be involved in a num ber o f  m etabolic processes 
in the cell including the initiation o f  DNA replication 
(W einm ann-Dorsch e t  al., 1984) and stim ulation  o f  pro­
cessing o f  ADP-ribosylated proteins (Surow y & Berger, 
1983). It is synthesized by the am inoacyl-tRN A  synthetases 
in th e  presence o f  Z n 2* ions(G oerlichef a/., 1982). Evidence 
to  date  suggests a role as a messenger m olecule in cellular 
p ro liferation .
As part o f  our investigations in to  the  function o f  Ap4A 
we have previously exam ined the levels o f  this nucleotide 
during  developm ent o f  the brine shrim p Artem ia. When 
am etabolic encysted gastrulae o f  A rtem ia  resume develop­
m en t they do so in th e  total absence o f  DNA replication 
and cell division until the point o f  ha tch ing  (16 h )  although 
p ro te in  and RNA synthesis proceed unhindered . Upon re­
in itia tion  o f  developm ent, a 125-fold rise in the intracellular 
concen tra tion  o f  Ap4A was observed, th e  m axim um  level 
coinciding with hatch ing  and the onset o f  DNA synthesis 
(M cLennan & P resco tt, 1984).
In o rder to  clarify the relationship betw een Ap4A, DNA 
synthesis and cellular grow th and division we have sought 
to iden tify  the intracellular target p ro teins o f this nucleo­
tide. We report here th a t the m ajor p ro te in  isolated from 
newly hatched larvae which is capable o f  binding Ap4A is 
a p ro te in  kinase.
When extracts o f  larvae are analysed b y  sucrose density 
gradient sedim entation  analysis and the binding o f 
[31 1 ]A p4A determ ined in each fraction b y  a nitrocellulose 
filter binding assay, a m ajor binding p ro tein  o f M t 93 000 
(4 .8S) is observed w hich co-sedim ents w ith  an enzymic 
activity capable o f  incorporating [“ P jorthophosphate  
in to  histone 112B using [7 -32P]ATP as substra te.
By contrast, no  evidence has been ob ta ined  to  suggest 
that this binding pro tein  may be associated with the DNA 
polym erase—a-holoenzym e com plex in th is organism, as 
has been reported  previously for Ap4A-binding proteins 
from calf thym us (G rum m t, 1978) and HcLa cells (Rapa- 
port c t  al., 1981).
T he A rtem ia  b inding protein has been partially purified 
from newly hatched larvae by am m onium  sulphate pre-
A bbrcviation used: A p ,  A, P 1, P '-h is-(5 '-a de nosy  !)■ tetr.jp lim p hate
c ip ita tio n , Matrex Blue and DEAE-cetlulose chrom atography 
and AcA 34 gel filtration . This schem e was designed to 
rem ove phosphodiesterases and all o th e r  enzym e activities 
capable o f  degrading the ligand, thus allowing a m ore 
detailed  study o f  the  pro tein . The purified Ap4A-binding 
p ro te in  still possesses protein  kinase activity.
Using histone H2B (th e  p refe rred  substrate) and [7 - 
32P]ATE o f  m edium  specific activ ity  ( 1.4 Ci/m m ol), stim u­
lation o f  the kinase activity was observed in the presence 
o f  lpM -cyclic AMP and 1 mM-cyclie GMP (2.1 and 2.0- 
fold respectively). However, a t sim ilar concentrations, 
Ap4A had no detectable effect on kinase activity. 
C alm odulin and C a:* were also w ith o u t effect.
The preparation was found to  possess endogenous 
accep to r polypeptides when [7 -32P]ATP o f  high spécifié 
activ ity  was used ( >  5 0 0 0 C i/m m ol). A fter separation 
on a 1 0 % (w/v) polyacrylam ide gel, four m ajor acceptor 
species o f  A/r 35 00 0 , 40  000, 42  0 0 0  and 72 000 were 
observed. These polypeptides all appear to  be part o f  a 
single pro tein  com plex, as shown by their co-sedim entation 
on a 5—20% sucrose gradient. Since m ost pro tein  kinases 
undergo autophosphorylation  in v itro  when incubated 
w ith [7 -32P]ATP o f  high specific activity (de Jonge & 
Rosen, 1977), such a mechanism m ay be responsible for 
the incorporation  observed here. The precise subunit 
com position  o f  the native kinase is a t present unclear, but 
our observations m ay be the result o f  partial proteolysis 
o f  a larger precursor. Such an observation has been made 
by several investigators (K uo & Shoji, 1982).
The polypeptides o f  A/r 35 000  and 4 0 0 0 0  or 42 000 
may represent the pro teo ly tic  p ro d u c ts  o f  the M r 72 000 
polypep tide w hich, when associated with the third poly­
pep tide o f  low m olecular w eight, y ields the native kinase 
o f  M r 93  000.
This in terpretation  is supported  by  the fact that auto- 
phosphory lation  o f  crude ex trac ts in the presence o f  
sodium  fluoride, an ATPase and protein phosphatase 
inh ib ito r, yields on ly  the p o lypep tide  o f  M , 72 000  on 
sodium  dodecyl su lphate /polyacrylam ide gel. This poly­
pep tide co-sedim ents w ith  the native A p4A-binding protein 
o fA /r 93 000 on sucrose gradients.
Cyclic AMP ( lp M )  or cyclic GMP (lp M ) com pletely 
suppress the phosphorylation  o f  the bands o f M , 42 000 
and 4 0  0 0 0  while cyclic GMP also reduces phosphorylation 
o f  the polypeptides o f  M t 72 000  and 35 000. The possible 
role o f  this kinase in growth regulation and developm ent 
in A rtem ia  and the significance o f  Ap4A binding are 
curren tly  under investigation.
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A 2.4 kilobase H in d  III fragm ent o f  hum an genome DNA 
w hich hybrid ized  tRNA was isolated from a larger fragment 
cloned in X C haron  4A and  subcloned in to  tire plasmid 
pA T153. This recom binan t w as found to  be o f  remarkably 
high transcriptional activity  when m icroinjected in to  
X enopus  oocy te  nuclei, p roducing m ore tRN A  than a 
com parable cloned  cluster o f  seven active X enopus  tRNA 
genes (Clarkson e t a!., 1978). Southern b lo t analysis 
(Southern , 1975) o f  restric tion  fragments and determ ination 
o f  the sequence (Sanger e t  al., 1980) o f  1250 residues 
w ithin the 2.4 kilobase fragm ent revealed the presence o f  a 
single tRN A clu  gene (residues 356—427 inclusive o f the 
sequenced fragm ent) in the middle o f  the 2.4 kilobasc 
fragm ent. Im m ediately preceding this gene there is a 
sequence w hich can be fo lded in to  a tRNA-like structure 
(G oddard  et al., 1983).
The separation o f  the intragenic p rom oter elem ents o f 
eukaryotic tR N A  genes is variable. This variability would 
be elim inated, to  allow com m o n  recognition and binding 
o f  RNA polym erase III a n d /o r  transcription factors, if 
die gene itself ad o p ted  a higher-order tRNA-like structure 
(Hall e t al., 1982^. These observations, together with the 
finding that the 5 -flanking, o r  upstream, sequence o f  some 
tR N A  genes inh ib its transcrip tion  (see, e.g., Dingermann 
e t  al., 1982; H ipskind & C larkson, 1983), led  us to  ask 
w hether tire po ten tia l for a tRNA-like structu re  within the 
upstream  sequence o f  this very  active hum an tRN A clu 
gene serves to enhance transcrip tion  o f  the gene. We there­
fore constructed  a series o f  recom binants in w hich parts o f  
the  upstream  sequence w ere deleted and present below 
o u r initial results and ten tative conclusions on the tran­
scriptional activity o f  some o f  these.
The tRN A Glu gene, cloned  as a 937 base-pair fragment 
in M13mp9 for sequence analyses, was subcloned further 
as a 489 base-pair B co R l—N a e l  fragment in the same 
vector. There w ere no suitably  positioned restriction sites 
to  allow simple deletion o f  on ly  the tRNA-like upstream 
sequence (residues 285—3 5 5 ). However, a unique S s t I 
site (297—302) in the recom binan t allowed access to this 
region for sequential rem oval o f  nucleotides by partial 
digestion with B a t31 exonuclease. Subsequent cleavage by 
S tu l  at another unique site a f te r  nucleotide 151 upstream 
from  the Ss/I s ite , resulted in deletions w hich contained 
a com m on sequence (residues 1 — 151) o f  hum an genomic 
DNA before the deletion. W ith no hydrolysis by S tu l,  
deletions were confined  largely to  the tRNA-like flanking 
sequence.
T he e x te n t o f deletion in each o f  the generated m utants 
was estim ated  from the size o f  the fragments released on 
digestion o f  the DNA w ith S m a I ( <  259 base-pairs or 
<  4 0 4  base-pairs in the absence o f  digestion by S tu l) . A 
su itab le  range o f  deletions were selected and characterized 
by sequence analysis. Supercoiled replicative form  RNA, 
free o f  con tam inating  host DNA, was prepared from  these 
recom binan ts and quantified spectrophorom ctrically .
DN A  (10 ng per oocy te) was co-injected w ith [or-32PJ- 
G T P (4 1 0  C i/nm ol;0 .5  pCi per o o cy te ) into X enopus  oocyte 
nuclei (1 0  oocytes per recom binant) and incubated over­
night (B ienz & G urdon, 1982). T ota l RNA was extracted 
from  tlie ten pooled oocytes and separated on 10% poly­
acrylam ide gels containing 4 M-urea (Kressman et al., 1978). 
The new ly synthesized RNA was detec ted  by autoradio­
graphy o f  the gel. The am ounts o f  RNA transcribed from 
three d ifferen t recom binants was quantified  by m easure­
m en ts o f  the radioactivity o f  die tR N A  and pre-tRNA in 
tiie gel bands. These recom binants were Glu6, containing 
tiie in ta c t sequence, D5 from w hich residues 152—305 
inclusive had been deleted to  remove the first arm o f the 
po ten tia l tRNA-like upstream  sequence, and D7 where tiie 
p o ten tia l for tiie first tw o arms o f  th a t structure had been 
d estroyed  by removal o f  residues 152—311 inclusive. The 
decrease in RNA produced from  100% (Glu6) to 42% 
(D 5) to  19% (D7) indicates that deletion o f increasingly 
large p o rtio n s o f die tRNA-like structu re  in the upstream 
sequence o f  diis hum an tRN A Glu gene gradually decreases 
die transcrip tional activity o f  Uiat gene. Since dicse pre­
lim inary  results support the hypodiesis d iat transcription 
o f  d ie  gene is enhanced by diis unique upstream sequence, 
we are pursuing furdier studies on die transcriptional 
activ ity  o f  a wider range o f  die characterized deletion 
m utan ts.
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Th io -ana logues  o f  in o rg an ic  py rophosphate  in h ib it 
the rep lica tion  o f  in fluenza  v irus A  in  v itro
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S u m m a ry
M o n o -  a n d  b i s th io p y ro p h o sp h a te  can  inhibit  th e  replication  o f  influenza virus 
A / X 4 9  in M a d i n - D a r b y  can ine  k id n ey  (M D C K )  cells at  co n cen t ra t io n s  a t  which no 
cy to tox ic  effect is observed a f te r  3 days .  The th io p y ro p h o s p h a te  a n a lo g u es  inhibit  the 
R N A  tran sc r ip ta se  ac tivity o f  this v irus  possibly by chela t ing  with an  essential metal  
ion  in the t ran sc r ip ta se  com plex .  ( " P J N M R  spectroscopy  indicates th a t  b is th io p y ro ­
p h o s p h a te  co o rd in a te s  to  zinc t h ro u g h  su lp h u r  a n d  m agnes ium  th ro u g h  oxygen 
w h ich  m ay  influence the inh ib i to ry  p ropert ies  o f  this c o m p o u n d  with m e ta l-con ta in ­
ing  enzym es.
in f luenza ;  inhib i t ion ;  m o n o th io p y ro p h o s p h a te ;  b i s th io p y ro p h o sp h a te ;  t ranscr ip tase
Introduction
T h e  an t iv ira l  activity o f  p y ro p h o s p h a te  ana logues  such as p h o sp h o n o a c e t ic  (1) (1], 
p h o s p h o n o f o r m ic  (2) [2] a n d  su bs t i tu ted  methylene b isphosphon ic  (3) [3] acids is 
well  k n o w n .  W e have recently  o bse rved  that  the inh ib i to ry  activity  o f  these c o m ­
p o u n d s  on  th e  R N A  transcr ip tase  activi ty  o f  influenza virus A /X 4 9  appea rs  to  be 
re la ted  to t h e i r  metal-chelat ing  p roper t ies ,  an d ,  in par t icu la r ,  to  th e i r  abili ty to 
c o m p le x  w ith  zinc ions. O n  the  P ea r so n  'h a rd  an d  so f t ’ acid a n d  base scale, zinc ions 
a rc  classified as  ‘in te rm ed ia te ’ a n d  hence  should fo rm  com plexes with b o th  hard  and  
sof t  l igands [4], We now  report  on  th e  effect o f  th io p y ro p h o s p h a te s  (4) a n d  (5) which 
c o n ta in  a po ten t ia l  soft l igand ( su lp h u r )  on  the replication  o f  influenza virus A /X 4 9  
a n d  o n  its R N A  transcrip tase.
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( H 0 ) 2P ( 0 ) C H 2C 0 0 H
( 1 )
(H O )2P(C>)COOH
(2)
( H 0 ) 2P (0 )C C 1 2P ( 0 ) ( 0 H ) ;
(3)
(H O )2 P ( S ) 0 P ( 0 ) ( 0 H ) 2
(4)
( H O )2P(S)O P(S)(O H )2
(5)
M ater ia ls  and Methods
M o n o th io p y r o p h o s p h a te  (4) a n d  b is th io p y ro p h o s p h a te  (5) were p r ep a red  as d e ­
sc ribed  previously [5,6] a n d  the d e te rm in a t io n  o f  zinc ion stabil i ty  c ons tan ts  (K d.) were 
carr ied  ou t  as described  [3].
Virus type and  preparation
T h e  influenza virus A /X 4 9  was a  c ro s s  between A / E n g la n d /8 6 4 / 7 5  an d  
A / P R / 8 / 3 4  with the H 3 N 2  surface an t igens  o f  th e  A /E n g la n d  strain . The virus was 
g ro w n  in the a l lan to ic  sac  o f  fertile h e n s ’ eggs a n d  was isolated essential ly as described  
[7], E leven-day-old e m b ry o n a te d  h en s’ eggs w ere  inocu la ted  with infected a l lan to ic  
fluid (0.1 ml o f  a I0"J d i lu t io n  in p h o sp h a te -b u f fe re d  saline (PBS)),  the  eggs were 
in cu b a ted  (3 3 °C /4 8  h)  a n d  then  chilled ( - 2 0 ° C / 2  h). The  a l lan to ic  fluid was collected 
a n d  centr ifuged (3000 r .p .m . /2 0  min) to  r em o v e  u n w an ted  egg m em branes;  from this 
p o in t  o n w ard s  all p ro c e d u re s  were ca r r ied  o u t  a t  0 -4°C .  T h e  s u p e rn a ta n t  w as rem o v ­
ed  a n d  the virus was pelleted by cen t r i fu g a t io n  (21000  r .p .m . /9 0  min, 6 X 250 ml 
ro to r ) .  T he  su p e rn a ta n t  w as d iscarded  a n d  th e  virus pel let was al lowed to  soak  
overn igh t  in PBS. T he  pel let was then  re su s p e n d e d  in PBS a n d  layered o n to  a velocity 
g rad ien t  o f  10-40% ( w /v )  sucrose in buffer  (30  ml, 10 m M  Tris -H C l,  p H  7.4) a n d  
centr ifuged (22000  r . p . m . / l  h, 3 X 65 ml sw in g -o u t  rotor) .  T h e  diffuse virus b and  was 
collected by b o t to m  p u n c tu r e  and  the  suc rose  w as  dilu ted  o u t  with PBS to a final 
v o lu m e  o f  30 ml. T he  v irus  suspens ion  was layered  o n to  a n  equ il ib rium  gradient  o f  
3 0 -7 0 %  ( w /v )  sucrose in bu f fe r  (30 ml, 10 m M  Tris -H C l,  p H  7.4) a n d  centr ifuged 
(2 0 0 0 0  r .p .m . /o v e rn ig h t ,  3 X  65 ml sw ing-ou t  ro to r ) .  The  virus b and  was collected,  
d i lu ted  with PBS a n d  the  v irus pelleted by cen t r i fu g a t io n  (30 000 r .p .m . /2  h, 8 X 50 ml 
ro to r ) .  T he  s u p e rn a ta n t  w a s  discarded a n d  th e  pellet was a l lowed to  soak overnight  in 
PBS. T he  virus was then  resuspended  in bu f fe r  (3  ml, 400 p M  Tris -H C l,  p H  8.0) an d  
f rozen  as a l iquo ts  at  - 7 0 ° C  a n d  thaw ed  once  p r io r  to use.
R N A  transcriptase assay
T he  s ta n d a rd  reac t ion  m ix tu re  co n ta in ed  in 200 pi: 50 m M  T ris -H C l,  p H  8.0; 5 m M  
m agnes ium  aceta te ;  150 m M  potass ium  ch lo r ide ;  5 m M  dith io th re i to l ;  0.4 m M  A p G ;  
0 .25%  (v /v )  N on id e t  P-40; 0 .4  m M  each o f  A T P ,  C T P ,  G T P a n d  [>H]UTP(5 p C i ) a n d  
pur if ied  virus (10 pi, 2000 H A U ).  M ix tures  w ere  kept a t  4 °C  until  zero time of
reac t ion ,  polym erisa t ion  being initiated by a d d i t io n  o f  virus.  T h e  mixture was kept  a t  
30°C  fo r  12 h during  which t ime the in c o rp o ra t io n  o f  t r i t ium  in to  acid-precip itable  
m ater ia l  increased  in a linear  fashion. After  1 h . c o ld  sa tu ra te d  so d iu m  p y ro p h o sp h a te  
so lu t io n  (200 pi)  followed by cold T C A  (2 ml, 10% w /v )  w as a d d e d  an d  the m ix tu re  kept 
on  ice f o r  15 min a f te r  th o ro u g h  ag ita t ion .  P rec ip i ta ted  m a te r ia l  was collected on 
W h a t m a n  G F / C  discs which were washed severa l  t imes with 10% T C A ,  once  with 
e th an o l  a n d  dried. T h e  radioactiv i ty  o f  m a te r ia l  p rec ip i ta ted  o n  the discs w as then  
d e te rm in e d  by scinti l lat ion c o u n t in g  using a to luene -based  m ed iu m .  P y ro p h o s p h a te  
an a lo g u e s  were added  to  the reac t ion  m ix tu res  before ad d i t io n  o f  virus. T h e  concen ­
t r a t io n  o f  analogue which  inhibited by 50%  the  in c o rp o ra t io n  o f  [’HJurid ine into 
a c id - in so lub le  material was derived from th e  d o se - re sp o n s e  curve  fo r  each c o m ­
p o u n d .
A ntiv ira l a c tiv ity  in vitro
T h e  haem agg lu t in in  titre o f  the virus g ro w n  a t  low multiplic ity  o n M D C K  cells was 
d e te rm in e d  with an d  w ithou t  added  p y ro p h o s p h a te  an a lo g u e  in the following m a n ­
ner.  G la s s  vials (1 cm diam .)  w ere seeded w i th  2 X 10s M D C K  cells a n d  1 ml o f  
m a in te n a n c e  medium (D u lb e c c o ’s m odified  E a g le ’s m ed iu m ;  D M E M )  co n ta in ing  
g lu ta m in e  (200 pM), 5%  foetal ca lf  se rum  a n d  pen ic i l l in /s t rep tom yc in  (50 u n i t s /m l)  
was a d d e d .  The cells were incuba ted  ove rn ig h t  a t  37°C in a  C 0 2 incuba to r ,  then  the 
m a in te n a n c e  medium  was rem oved  an d  the cell  sheet washed tw ice with a  so lu tion  o f  
0 .1% B SA  in PBS. The vials were inocu la ted  w i th  influenza v irus A /X 4 9  at a m.o.i . o f  
0.01 in fec t io u s  virus part ic les/cell  in 100 pi v o lu m e .  After  the  v irus had  been al lowed to 
a b s o rb  o n t o  the cells fo r  1 h at  r o o m  te m p e r a tu re ,  the inocu lum  w as rem oved an d  500 
pi o f  m a in te n a n c e  m edium  ( D M E M  +  g lu ta m in e  +  0.1% BSA +  pen ic i l l in /s t rep to ­
mycin -I- 25 p g t r y p s in /m l )  which con ta ined  0, 10 ,50  o r  100 pM  o f  test  c o m p o u n d  were 
ad d e d .  T h e  cells were incubated  a t  33°C for  3 d a y s  in a gassed  in c u b a to r  a f te r  which 
t ime the m ed iu m  was rem oved  a n d  the h aem ag g lu t in in  assay  carr ied  ou t  (Tab le  1).
A p la q u e  assay was a lso  carr ied  ou t  in th e  fo llow ing m a n n e r .  M D C K  cells were 
seeded o n t o  5 cm plastic dishes a t  3.0 X 106 ce l l s /p la te .  T hese  were grow n a t  37°C until 
con f luen t  in m ain tenance  medium . T he  c o n f lu e n t  m onolayers  w ere washed with PBS 
a n d  a s p i ra te d  to  dryness . Virus suspension  (100 p i)  was a d d e d  to  th e  cell sheets an d  left 
for  1 h a t  r o o m  tem pera tu re .  T he  inoculum  w a s  rem oved  a n d  th e  cells were overlaid 
with an  a g a r  m edium  which co n ta ined  0 .1%  B S A , 2.5 p g /m l  crystalline t rypsin  an d  
0 .1%  D E A E  Dextran .  T h e  plates were in c u b a te d  a t  33°C fo r  4 - 6  days, s ta ined  with 
n eu tra l  red  a n d  the p laques  coun ted .  The re su l t s  a re  p resen ted  in Table 2. Sam ples 
f rom  the las t  wash o f  the cell m ono layers  a f t e r  a b s o rp t io n  o f  the  virus were retained  
a n d  p la q u e s  to show th a t  haem agglu t in in  a n d  infectious virus y ields were no t  due  to 
residual  n o n -a b so rb e d  virus.
N o  cy to to x ic  effects cou ld  be observed w ith  e i ther  t h io p y ro p h o s p h a te  a t  100 pM  
af te r  3 days .
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TA BLE 1
Effect o f m ono- and bisthiopyrophosphates on hacm agglutinin titre  o f  influenza virus A /X 49  grow n on 
M DCK  cells (m ean o f  two assays)
C om pound C oncentration 
(M M)
HAU
(log,0 un its/m l)
Cell control < 2 .0
Virus control 0 3.65
M onothiopyrophosphate 100 2.64
50 3.10
10 3.45
B isthiopyrophosphate 100 2.10
50 2.70
10 3.60
TA BLE 2
Yield reduction assay by m easurem ent o f infectious influenza A /X 49  virus grown on M DCK cells (m ean of 
two assays)
Com pound C oncentration
(pM)
P FU /m l
Cell control < 1 0
Virus control 0 4.77 X I07
M onothiopyrophosphatc 100 1.05 X 106
50 1.5 X 107
10 4.25 X 107
B isthiopyrophosphatc 100 4.2 X I0J
50 9.7 X I0‘
10 5.0 X 107
[ixP \N M R  m easurem ents
These  were ca r r ie d  o u t  a t  308 K a n d  36.44 M H z  o n  a  B ruker  W H 9 0  spec trom ete r ,  
chem ical  shifts a r e  reco rded  relative to H 3P 0 4 (0 p p m ) .  So lu tions  o f  te t r a so d iu m  
p y r o p h o sp h a te  o r  t e t r a ( t r i e th y la m m o n iu m )b is th io p y ro p h o sp h a te  (15 m g /m l )  were 
p r ep a red  in 0.1 M tr ie th a n o la m in e  hyd ro ch lo r id e  buffer ,  p H  8.2, the  la tter  be ing  m a d e  
u p  in w ate r  which  h a d  previously been  passed d o w n  a  small  Chelex 100 chela t ing  
co lu m n  (Na* fo rm .  B iorad  Inc.). T o  the p y ro p h o s p h a te  o r  b is th io p y ro p h o sp h a te  
so lu t ion  (1 ml, 1 m o l )  w as ad d ed  a  solu tion  in d e u te r iu m  oxide  (also t rea ted  with 
Chelex 100, 1 ml)  w hich  co n ta ined  0 .8  mol o f  m a g n e s iu m  ch lor ide ,  zinc ch lo r ide  o r  
c a d m iu m  b ro m id e .  A f te r  mixing the  [JIP ]N M R  spec tra  were recorded  (Tab le  3).
Results
B oth  m o n o -  a n d  b i s th io p y ro p h o sp h a tc  inhibit  the rep l ica t ion  o f  influenza virus
[ JIP]NMR chemical shifts (ppm ) o f  solutions o f  pyrophosphate or b isth iopyrophosphate at pH 8.2 after 
the addition of metal ions
M etal p,o, P ; 0 (S,
None -6.045 29.693
M g" -5.254 32.418
Z n2* -4.839 21.849
C d 2* -5.643 20.714
Fig. I. Inhibition o f RN A  transcriptase o f influenza virus A /X 49 by m ono- and bisthiopyrophosphate.
A /X 4 9  in M D C K  cells (Table 1). T h e  haem agg lu t in in  t i t re  o f  3.65 log ,0 un i ts /m l  for 
th e  contro l  in the absence  o f  t h io p y ro p h o s p h a te  was r e d u c e d  to  2.64 log,0 un i t s /m l  for 
m o n o -  a n d  2.10 lo g ,0 u n i t s /m l  for b is th io p y ro p h o sp h a te  a t  100 pM. Similarly a virus 
yield o f  4.77 X I07 P F U / m l  in the virus co n t ro l  was reduced  to  1.05 X 10* P F U /m l  for 
m o n o -  and  4.2 X 10s P F U / m l  for  b is th io p y ro p h o sp h a te  a t  100 pM . N o  cytotoxic 
effect was observed w ith  ei ther  c o m p o u n d  a f te r  3 days in o u r  assays.  The co m p o u n d s  
inhibit  the RN A  t ranscr ip tase  activity o f  the  virus (Fig. 1) p ro d u c in g  a 50% inhibition 
o f  the transcr ip tase  a t  60 p M  (m o n o th io p y ro p h o sp h a te )  a n d  33 pM (b is th iopyrophos­
phate) . Both c o m p o u n d s  were good ch e la to rs  o f  zinc ions  a n d  the pK d. a t  p H  8.2(3] 
w as 5.4 ( m o n o th io p y ro p h o sp h a te )  a n d  6.3 (b is th io p y ro p h o s p h a tc ) ;  un d e r  similar 
condit ions inorgan ic  p y ro p h o sp h a te  had  a p K d. o f  5.7. F r o m  t h e [ l lP ]N M R  spectra  o f  
solutions o f  b is th io p y ro p h o sp h a te  a f te r  a d d i t io n s  o f  m e ta l  ions it a p p ea r s  that  zinc 
ions bind th rough  s u lp h u r  and  m agnes ium  ions bind th r o u g h  oxygen (Table 3).
Discussion
P yrophospha te  an a lo g u e s  are o f  interest as  antiv ira l  c o m p o u n d s  as they  arc  p roduc t
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inhib i to rs  o f  p o ly m e ra s e / t r a n s c r ip ta s e  enzym es  a n d  hence  cou ld  inhib it  viral nucleic 
ac id  synthesis w ithou t  b e in g  m etabo l ised .  H o w ev er ,  p y ro p h o s p h a te  is involved in 
m a n y  enzymic reac t ions  in the host  cells a n d  hence  p y ro p h o s p h a te  a n a lo g u e s  m ay  be 
cytotoxic as  is the case w i th  d ich lo ro m e th y le n e  b i s p h o s p h o n a te  (3) (C lo a d ,  P .A. and  
H u tch in so n ,  D .W . ,  u n p u b l i s h e d  o b se rv a t io n s ,  1983). T h u s ,  it is s ignif icant  th a t  the 
m o n o -  an d  b i s th io p y ro p h o s p h a te s  do  n o t  a p p e a r  to  be cy to tox ic  to  M D C K  cells a f te r  
36 h a t  concen t ra t io n s  a t  which  they  cause  a n  app rec iab le  r ed u c t io n  in the  haem agg lu -  
tinin  titre  o f  influenza v i ru s  A /X 4 9 .  T h e  th io p y ro p h o s p h a te s  cause  a 50%  inhib i t ion  
o f  the R N A  tra n sc r ip ta se  o f  this virus a t  c o n c e n t ra t io n s  s im ila r  to  th a t  fo r  p h o s p h o n o -  
fo rm a te  (35 p M ) an d  lo w e r  th a n  tha t  f o r  ino rgan ic  p y ro p h o s p h a te  (125 pM).
We have suggested t h a t  th e  inh ib i to ry  effect  o n  the R N A  tran sc r ip ta se  o f  influenza 
v irus A caused by p y r o p h o s p h a t e  a n a lo g u es  is r e la ted  to  th e i r  abil i ty  to  chela te  zinc 
ions  [3], a n d  we bel ieve t h a t  it is s ignif icant  th a t  b o th  th io p y ro p h o s p h a t e s  are  goo d  
che la to rs  o f  zinc ions. T h e  in t ro d u c t io n  o f  the  ‘so f t ’ s u lp h u r  a to m  (on  the  H S A B  scale) 
in to  the p y ro p h o s p h a te  res idue  m igh t  well a l te r  the c he la t ing  p ro p e r t ie s  o f  the 
molecule. It was , t h e r e fo r e ,  o f  interest to  d e te rm in e  w h e th e r  zinc ions c o o rd in a t e d  to 
oxygen o r  su lp h u r  in b i s th io p y ro p h o s p h a te .  (“ P JN M R  m eas u re m e n ts  (T a b le  3) show  
th a t  when m agnes ium , z in c  o r  c a d m iu m  ions were a d d e d  to  a  so lu t ion  o f  p y r o p h o s ­
p h a te  in t r ie th a n o la m in e  bu f fe r  a t  p H  8.2, the  p H  o f  the  t ran sc r ip ta se  as say ,  only small 
shifts  (ca. 1 ppm )  o f  t h e  31P signal o c c u r re d ,  p re su m a b ly  d u e  to  the f o rm a t io n  o f  
com plexes with the m e ta l  ions  c o o rd in a te d  to  the  oxygen o f  the p y ro p h o s p h a te .
In the case o f  b i s th io p y ro p h o s p h a te  a t  p H  8.2, ad d i t io n  o f  a ‘h a r d ’ meta l  ion 
(m agnes ium )  p ro d u c e d  a  dow nf ie ld  sh if t  o f  less th a n  2 p .p .m .  O n  the o th e r  h an d ,  
add i t io n  o f  soft metal io n s  (zinc o r  c a d m iu m )  p ro d u c e d  a  large upfield shift  o f  8 -9  
p p m  o f  the [3IP JN M R  s igna l .  Since c a d m iu m  ions  have been show n  to  c o m p le x  with 
s u lp h u r  in nucleoside t h i o p h o s p h a t e s  [8], the  ( ’'P J N M R  results  suggest  th a t  zinc ions 
p ro b a b ly  co o rd in a te  to  b i s th io p y ro p h o s p h a te  t h ro u g h  s u lp h u r .  If  th is m e th o d  o f  
coo rd in a t io n  a lso  occu rs  a t  the  essential  meta l  ion (p ro b a b ly  zinc) in the  t ran sc r ip ta se  
com plex  o f  influenza v i ru s  A ,  this m ay  a c c o u n t  fo r  the  d ifference in in h ib i to ry  activity 
be tween inorgan ic  p y r o p h o s p h a t e  a n d  its th io -a na logue .
Acknowledgements
W e thank  Miss L. M c L a i n  for  the d e te rm in a t io n  o f  th e  an tiv ira l  act ivi ty  o f  the 
th io -ana logues  in v i t ro ,  a n d  M r.  R .C .K .  Je n n in g s  fo r  the  l 3lP ]N M R  m easu rem en ts .
References
1 Boczi, J.A . (1979) The an tiherpes  action o f phosphono-acclate . Pharm acol. Thcr. 4 , 231-243.
2 Obcrg, 13. (1983) A ntiviral effects of ph o sphono fo rm atc(P F A , foscarnet sodium ). Pharm acol. Thcr. 
19, 387-415.
3 C load. P.A. and H u tch in son . D. W. (1983) The inhibition o f the RNA polym erase activity of influenza 
virus A by pyrophosphate analogues. Nucleic Acids Res. I I ,  5621-5628.
Pearson. R.G . (1968) H a rd  and soft acids and  bases HSAB Part I. J . Chem. Ed. 45. 581-587.4
73
5 Reynolds, M .A., O ppenheim er, N .J. an d  Kenyon, G .L . (1983) Enzyme-catalysed positional isotope 
exchange by phosphorus-31 nuclear magnetic resonance spectroscopy using either '"O- or l70-p ,y- 
bridge-labelled adenosine 5 '-triphosphate. J. Am. Chem. Soc. 105, 6663-6667.
6 C ullis, P.M. (1983) Facile synthesis o f  bridge-oxygen-labelled pyrophosphates: the preparation of 
adenosine 5 '-[p,y-l80 ]triphospha te. J . Am. Chem. Soc. 105. 7783-7784.
7 Kelly, D .C . and D im m ock, N .J. (1974) Virology 61. 210-222.
8 Pillai, R .P ., Raushel, F.M . and V illafranca, J .J . (1980) Stereochemistry o f binding o f  thiophosphatc 
analogues o f A TP and A D P to  ca rbam ate kinase, glutam ine synthetase and carbam oyl-phosphate 
synthetase. Arch. Biochem. Biophys. 199, 7-15.
